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1. INTRODUCTION 
1.1 Genetic engineering 
Genomic sequencing efforts have mapped the entire code of the human and murine genome 
(Venter et al. 2001; Waterston et al. 2002). Data comparison allows for the identification of 
homology regions and conserved domains. But what is the benefit of the knowledge about 
the technical design of a musical instrument when you do not know how to play it? In the 
case of the human and murine genome, we still need to gather information on gene 
regulation and gene function. To analyze the function of a gene, the corresponding protein 
must be analyzed by biochemical methods. Naturally occurring genetic mutations in 
organisms were the first opportunity to identify a disrupted protein and ascertain its genetic 
cause. Using the “clinical picture”/phenotype as a starting point, functionality was ascribed 
to the gene and its protein. In order to accelerate the acquisition of knowledge, scientists 
started to deliberately expose flies and worms to mutagens (Auerbach 1947; Auerbach and 
Robson 1947; Muller 1955). Still, changes in the genetic code were induced at random. 
Genetic engineering is the term used for technologies that are able to specifically alter the 
genetic makeup of an organism. DNA is either inserted or removed from the genome. 
Genetic engineering started with the genetic modification of a plasmid that was transformed 
into an E. coli bacterium (Cohen et al. 1973). Soon, mice were the targets of genetic 
engineering (Jaenisch and Mintz 1974). Due to their similarity to humans with regard to 
genetics, physiology, biochemistry and disease they are the ideal experimental animal. In 
addition, mice are small and easy to breed. Of capital importance however is the feasibility 
to efficiently induce specific genetic modifications. Gain of function/overexpression models 
and gene disruption/”knockout” models are powerful tools for the scientist. The impact on 
cells, tissues and the organism can be investigated. Furthermore, genetically altered mice 
allow evaluating the therapeutic value of a gene and its protein in a pathophysiological 
context. 
 
1.1.1 Transgenic mice 
The transgene technology comprises the transfer of a foreign DNA strand into the genome of 
an organism (Gordon and Ruddle 1981). Classically, an artificially constructed expression 
cassette is inserted into the host genome to produce a particular protein. Molecular cloning 
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techniques allow for the exogenous assembly of genetic elements. By DNA manipulation 
promoter-, coding- and terminator- sequences can be arranged in a bacterial plasmid. In the 
mouse model, the DNA construct is injected into the pronucleus of a fertilized ovum. The 
embryo is then transferred into the uterus of a surrogate mother (Gordon et al. 1980). 
Expression cassettes randomly integrate into the murine genome. The offspring of the foster 
mother can then be analyzed for the presence of the expression cassette. Heritage of the 
genetic modification follows the Mendelian distribution pattern (Gordon and Ruddle 1981). 
Accordingly, the genetic modification is present in all cells of the organism. Transcription of 
the transgene is subjected to the epigenetic regulations of the integration site (Allen et al. 
1988). Further determinants of expression levels are the deployed promoter and the total 
number of transgene integrants. Consequentially, the protein synthesis of a trangene is 
unpredictable – this is the major drawback of transgene engineering. 
 
1.1.2 Gene targeted mice 
Gene targeting is a technique that allows to change the DNA sequence of a specific 
endogenous gene by homologous recombination with a targeting/replacement vector 
(Doetschman et al. 1987; Thomas and Capecchi 1987). The targeting vector is comprised of 
DNA sequences identical to the gene of interest with modifications that were introduced via 
standard recombinant DNA technology. By electroporation, the targeting vector is 
introduced into pluripotent embryonic stem (ES-) cells. The two DNA entities, genomic DNA 
and targeting vector DNA, interact, recombine and exchange DNA sequences. By this 
method, genes can be disrupted to “knockout” an allele and generate “null mutants”. 
Alternatively, DNA material can be introduced, a so-called “knock-in”, to modify gene 
expression. Next, the ES cells are selected and screened, often by Polymerase Chain 
Reactions (PCRs) and/or Southern blots, for the desired modifications at the defined gene 
locus. “Positive” ES cell clones are injected into blastocysts. The blastocysts are reimplanted 
into pseudopregnant females. In the case that the modified ES cells contribute to the 
germline of chimeric offspring, the targeted allele becomes inherent part of the genome 
effective from the next generation.  
The conventional knockout strategy affects every cell of an organism at any time. As a 
consequence, genetic modifications may be lethal at an early embryonic stage (Farese et al. 
1995; Fassler and Meyer 1995; Accili et al. 1996). Furthermore, the function of an enzyme 
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can never be analyzed in a single cell type, tissue or at a defined time point of development 
or disease. In order to have temporal and spatial control of the genetic knockout approach, 
the conditional knockout technology was developed (Gu et al. 1994; Rajewsky et al. 1996). 
The main requirement for this adaption is a system that is able to disrupt a gene in an 
inducible way. This is accomplished by site-specific recombinases, Cre- and FLP-recombinase, 
which recognize specific recombination sites and rearrange the DNA in-between (Orban et 
al. 1992; Vooijs et al. 1998). A recombination site is a 34 bp DNA sequence. An asymmetric 8 
bp center is flanked by 13 bp palindromes (see figure 1.1 A) (Hoess et al. 1982). The 
asymmetric center of the recombination sites confers directionality and determines whether 
two recombination sites are in the same or opposite orientation. Cre- and FLP recombinase 
recognize loxP- (locus of cross-over in bacteriophage P1) or FRT (FLP recombination target) 
sites, respectively. Two recombination sites are cloned into non-coding DNA of the targeting 
vector and frame a DNA sequence that is essential for the function of the targeted gene. Just 
like in the conventional knockout approach, the modifications are transferred into the 
murine genome by homologous recombination within ES cells. Following germline 
transmission of the “floxed” (flanked by loxP sites) allele, flox-mice are bred with mice 
transgenic for the Cre-recombinase. The cells of the offspring will hold a disrupted targeted 
allele under the “condition” that the Cre-recombinase is expressed. In the case that the 
recombination sites were arranged with the same orientation, the recombinase disrupts the 
gene via excision of the floxed segment (see figure 1.1 B). Opposite orientation causes gene 
disruption by inversion of the floxed element (Hoess et al. 1986). The promoter of the Cre-
transgene determines the spatial and temporal expression profile of Cre-recombinase and 
thus the profile of gene disruption. Inducible promoters allow for selective gene knockout 
(Metzger and Chambon 2001). 
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Figure 1.1: Cre-loxP and FLP-FRT recombination system. A) Palindromic sequences (black) of 
the loxP and FRT recombination sites with asymmetric core (red). B) A tissue specific 
promoter (TSP) drives the expression of Cre or FLP recombinase. The enzymes recognize their 
respective recombination sites and excise the flanked DNA segment “B”. Adapted by 
permission from Macmillan Publishers Ltd: [Nature Reviews Genetics] (Lewandoski 2001), 
copyright (2001). 
 
1.2 Eukaryotic cell membranes 
In 1972 Singer and Nicholson proposed the “fluid mosaic model” of lipid membranes (Singer 
and Nicolson 1972). In this model, they describe the lipid membrane of the cell as a 
homogenous liquid phase that allows for free lateral movements of proteins. The matrix of 
the membrane consists of polar lipids with hydrophobic and hydrophilic portions. They form 
a bilayer structure with hydrophobic tails pointing towards the inside and hydrophilic heads 
contacting the water interface (see figure 1.2 A). Major lipid constituents of eukaryotic 
membranes are glycerophospholipids, sphingolipids and sterols (Bretscher and Raff 1975).  
Soon there were the first doubts with regard to the random organization of proteins and 
lipids in membranes substantiated by experimental evidence showing heterogeneous lipid 
distributions and constrictions of lateral protein movements (Hui and Parsons 1975; Jain and 
White 1977; Wunderlich et al. 1978; de Laat et al. 1979). Lipid species are asymmetrically 
A) 
B) 
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distributed among the cytosolic and extracellular leaflet (Bretscher 1972; Gordesky and 
Marinetti 1973). Sphingomyelin for instance, the most prevalent sphingolipid, localizes 
almost exclusively to the anti-cytosolic leaflet of membranes (Emmelot and Van Hoeven 
1975). Furthermore, the “fluid mosaic model” fell short with regard to the effects of lipid 
interactions and was refined by Simons and Ikonen in 1997 (Simons and Ikonen 1997). Lipid 
interactions prompt the accumulation of certain lipids in distinct domains and/or cell 
compartments. The updated model stresses that domains and their connectivity properties 
modulate the diffusional movement of proteins (see figure 1.2 B). Domain formation 
facilitates lipid-mediated protein-protein interactions. This is achieved by limiting the lateral 
movement of proteins and stabilization of protein complexes within the lipid domain 
(Bagatolli et al. 2010).  
 
 
Figure 1.2: Models of the eukaryotic cell membrane. A) The fluid mosaic model as proposed 
by Singer and Nicolson 1972. Embedded in a homogenous matrix of phospholipids, proteins 
freely move in the lipid bilayer. B) Lateral membrane structures – lipid domains. According to 
the model of Simmons and Ikonen 1997, lipid interactions result in lateral segregation and 
domain formation of certain lipid species. Domain formation confines the diffusional 
movement of proteins. Figure 1.2 A) from (Singer and Nicolson 1972). Reprinted with 
permission from AAAS. Figure 1.2 B) reprinted from (Bagatolli et al. 2010), copyright (2010), 
with permission from Elsevier. 
 
 
1.2.1 Biophysical properties of ceramide 
Ceramide is a sphingolipid composed of sphingosine linked to a fatty acid chain by an amid 
ester bond with a hydrogen atom as a head group. Ceramide is the basic unit of all complex 
sphingolipids (Reichel 1940). More than 200 structurally distinct ceramide species exist in 
mammals differing in their acyl chains, hydroxylations and desaturations (Hannun and Obeid 
A) B) 
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2011). They are amphiphiles, but with a hydrophobic, non-polar character (Veiga et al. 
1999). Therefore, ceramides are virtually insoluble in water and exclusively found in 
membranes. Their interbilayer movement is marginal, restricting ceramides to the 
compartments of generation. In vitro data show that spontaneous intrabilayer “flip-flop” of 
ceramide occurs at low rate (Bai and Pagano 1997; Contreras et al. 2005) and may be 
restricted by domain formation (Marchesini and Hannun 2004). Ceramides can form pores in 
mitochondria and permeabilize the membrane (Ruiz-Arguello et al. 1996; Siskind and 
Colombini 2000). Moreover, ceramide directly interacts and modulates the activity of 
cathepsin D (Heinrich et al. 1999), phospholipase A2 (Huwiler et al. 1998), kinase suppressor 
of Ras (Zhang et al. 1997), ceramide-activated protein serine–threonine phosphatases 
(CAPP) (Kowluru and Metz 1997), protein kinase C isoforms (Huwiler et al. 1998), potassium 
channel Kv1.3 (Gulbins et al. 1997) and calcium release-activated calcium (CRAC) channels 
(Lepple-Wienhues et al. 1999). In the membrane, ceramides feature a high capacity for 
intermolecular hydrogen bonding. They act as both, hydrogen bond acceptors and donors 
for other lipid species and spontaneously self-associate (Shah et al. 1995; Simons and Ikonen 
1997; Brown and London 1998; Holopainen et al. 1998; Kolesnick et al. 2000). Hydrophobic 
van der Waals forces of saturated acyl chains strengthen the interaction of ceramide species 
(Artetxe et al. 2013). The net result of this tight interaction is a lateral segregation from 
other lipid species and domain formation (Holopainen et al. 1998; Kolesnick et al. 2000). 
Microdomains of ceramide fuse and give rise to macrodomains (Grassmé et al. 2001). 
 
1.2.2 Ceramide rich domains (CRDs) and transmembrane signaling 
The first demonstration of ceramide-rich domain (CRD) formation in vitro by Huang et al. in 
1996 involved the addition of ceramide to a phasphatidylcholine bilayer. NMR spectroscopy 
revealed lateral separation of ceramide into domains (Huang et al. 1996). Computer models 
predicted that domain structure may affect the reaction yields of signal transduction 
pathways (Melo et al. 1992; Thompson et al. 1995). In living cells, fluorescent 
immunostainings showed the aggregation of ceramide in distinct lipid domains after 
stimulation with CD95 and first insights to the physiological function of CRDs were 
elucidated (Grassmé et al. 2001). The following paradigmatic scheme was deduced 
describing how transmembrane signaling via CRDs may succeed: 
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An extracellular stimulus induces the generation of ceramide. The net gain in ceramide levels 
leads to ceramide self-association, lateral segregation from other lipid species, and CRD 
formation. CRDs reorganize membrane proteins through trapping, stabilization and 
clustering of receptors. High receptor density facilitates the formation of protein di- and 
oligomers. Recruitment of intracellular proteins and complex formation activates second 
messengers and downstream cytoplasmic signaling cascades. In CD95 signaling for instance, 
ceramide is produced via the activation of acid sphingomyelinase. After an initial activation 
via the CD95 receptors, the enzyme is relocated to the outer leaflet and induces the 
formation of CRDs. The activated CD95 receptors become immobilized within the CRDs. 
Clustering of receptors provides for a feed forward mechanism that amplifies and focuses 
the signal transduction response (see figure 1.3). Finally, the death-induced signaling 
complex (DISC) is formed to elicit apoptosis (Grassmé et al. 2003a). 
 
 
Figure 1.3: Ceramide-rich domains (CRDs) and transmembrane signaling. Initially, activation 
of the CD95 receptor by its ligand results in the relocalistion of acid sphingomyelinase (ASM) 
from the lysosome to the outer leaflet of the membrane. ASM hydrolyzes its substrate 
sphingomyelin and produces ceramide. The net gain in ceramide levels results in the 
formation of CRDs. CD95 clusters within the CRDs and become spatially organized. The signal 
transduction response is enhanced and intracellular complex formation induces apoptosis. 
Figure reprinted from (Grassmé et al. 2007), copyright (2007), with permission from Elsevier. 
 
 
The initiating stimuli of CRD formation include for instance CD95 ligand (Grassmé et al. 
2001), TNF-α (Zhang et al. 2006), endostatin (Jin et al. 2008), CD40 ligand (Grassmé et al. 
2002), Rituximab (CD20) (Bezombes et al. 2004), TRAIL (Dumitru and Gulbins 2006), UV-C 
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(Charruyer et al. 2005), ionizing radiation (IR) (Bionda et al. 2007), Pseudomonas aeruginosa 
(Grassmé et al. 2003b), Rhinovirus (Grassmé et al. 2005), cisplatin (Lacour et al. 2004), 
reactive oxygen species (ROS) (Scheel-Toellner et al. 2004), and endotoxin (LPS) (Cuschieri et 
al. 2007). Cellular outcomes of CRD transmembrane signaling include apoptosis (Grassmé et 
al. 2001; Lacour et al. 2004; Scheel-Toellner et al. 2004; Szabo et al. 2004; Charruyer et al. 
2005; Zhang et al. 2006; Bionda et al. 2007; Cuschieri et al. 2007; Jin et al. 2008), growth 
arrest (Bezombes et al. 2004), internalization of pathogens (Grassmé et al. 2003b; Grassmé 
et al. 2005), release of reactive oxygen species (ROS) (Zhang et al. 2008), and induction of 
inflammation (Teichgraber et al. 2008). Deregulated ceramide metabolism and membrane 
organization has been implied to be involved in many disease pathologies including vascular 
disorders (Garcia-Barros et al. 2003), metabolic disorders (Lang et al. 2007), cancer 
(Goldkorn et al. 2013), infections (Grassmé et al. 2003b), lung diseases (Teichgraber et al. 
2008), liver diseases (Seino et al. 1997) and diseases of the central nervous system (He et al. 
2010). Furthermore, disease treatment may be affected by the target cell`s ability to form 
CRDs (Lacour et al. 2004). Consequentially, it is of capital importance to analyze the enzymes 
involved in the modulation of ceramide levels.  
1.3 Ceramide generation 
Ceramide can be generated via the de novo- (Mandon et al. 1992; Merrill and Wang 1992) 
and the salvage- pathway (Hoekstra and Kok 1992) (see figure 1.4). Both can be differentially 
activated, depending on stimulus and cell type (Kitatani et al. 2008).  
a) The de novo pathway is the entry point of sphingolipid metabolism and resides in 
the endoplasmic reticulum (ER). First, the substrates serine and palmitate are 
converted by serine palmitoyl transferase (SPT) to produce dihydrosphingosine 
(Williams et al. 1984). Ceramide is synthesized by activity of dihydro-ceramide 
synthase (CerS) attaching a fatty acid chain to dihydrosphingosine.  
b) In the salvage-pathway, the acid sphyingomyelinase catalyzes the breakdown of 
sphingomyelin to produce ceramide in the lysosome. Ceramide is hydrolysed by the 
acid ceramidase that generates sphingosine. Sphingosine can leave the lysosome and 
is recycled by ceramide synthase producing ceramide. The neutral sphingomyelinase 
consumes sphingomyelin in cytoplasmic domains. 
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Figure 1.4: Metabolic pathways of ceramide generation. In the de novo pathway, the 
substrates serine and palmitate are conversed by serine palmitoyl transferase (SPT) to 
produce dihydrosphingosine. Ceramide is synthesized by activity of dihydro-ceramide 
synthase (CerS) attaching a fatty acid chain to dihydrosphingosine. In the salvage-pathway, 
sphyingomyelinases catalyze the breakdown of sphingomyelin and complex sphingolipids 
(SLs) in the lysosome. Ceramide is further hydrolyzed by ceramidases. Sphingosine is then 
recycled by ceramide synthase. 
 
 
1.4 N-acylsphingosine amidohydrolase 1 (AC) 
Humans carry 5 genes that encode for ceramide degrading enzymes. According to their pH 
optima of activity, acid ceramidase (AC), neutral ceramidase (NC), alkaline ceramidase 1 
(ACER1), alkaline ceramidase 2 (ACER2), and alkaline ceramidase 3 (ACER3) catalyze 
hydrolysis of ceramides to generate sphingosine (SPH) and free fatty acid. Acid ceramidase 
(N-acylsphingosine amidohydrolase 1, AC) was first identified 5 decades ago in rat brain 
homogenates (Gatt 1963) and purified in 1995 from urine (Bernardo et al. 1995). AC 
catalyzes the deamidation of ceramide to sphingosine with highest rates at a pH of 4.5. 
Apart from this “forward” hydrolysis mode at a pH of 4.0 – 5.0, the enzyme can work in 
“reverse” mode at a pH of 5.5 – 6.5 and synthesize ceramide (He et al. 2003). Further factors 
that affect AC activity and mode are the lipid composition (Okino et al. 2003) and zinc 
concentrations (He et al. 2003). Exemplarily, phosphatidylserine activates the “reverse 
mode” while sphingomyelin and zinc promote the “forward mode” (He et al. 2003; Okino et 
al. 2003). The activity of AC further depends on the presence of the co-factors saposin C 
(sapC) and saposin D (sapD) (Azuma et al. 1994; Klein et al. 1994; Linke et al. 2001). Finally, 
the acyl chain length and saturations of the ceramide substrate affect the metabolic rate in 
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vitro. In these experiments, AC prefers saturated lipids with medium acyl chain length (≥ C6 
and ≤ C16) (Momoi et al. 1982).  
 
1.4.1 Structural features of AC 
The human AC gene (gene symbol: ASAH1) is located on the short arm of chromosome 8 (Li 
et al. 1999). The gene contains 14 exons with an open reading frame of 1185 bp that encode 
for 395 amino acids (Koch et al. 1996). The 2.6 kb full length mRNA transcript holds a 110-bp 
3-prime untranslated sequence and a 18 bp poly(A) tail. AC mRNA expression is high in 
kidney and brain and marginal in skeletal muscle and testis as was shown in the mouse (Li et 
al. 1998) and illustrated in the human Expressed Sequence Tag (EST) profile (TiGER database, 
Johns Hopkins University, MD, USA). In the endoplasmatic reticulum (ER), the spliced mRNA 
is translated and the AC prepolypeptide synthesized. The prepolypeptide acquires N-linked 
glycosylations in the ER, which increase its molecular weight and are essential for full 
enzyme activity (Ferlinz et al. 2001). Subsequently, the AC precursor is shuttled through the 
Golgi network. Only the fraction of AC protein that is mannose-6-phosphorylated by N-acetyl 
glucosamine phosphotransferase (NAGPT) is addressed to the endo-lysosomal 
compartment. The non-phosphorylated fraction is released through the secretory pathway 
(Ferlinz et al. 2001). In late endosomes the 53 kDa precursor is processed and yields two 
subunits (Koch et al. 1996). An autocatalytic self-cleavage mechanism activates AC 
(Shtraizent et al. 2008). The α-subunit of 13 kDa and the β-subunit of 40 kDa form the 
mature heterodimeric AC protein by disulfide bonding (Bernardo et al. 1995). The presence 
of both subunits is essential for AC activity (Li et al. 1999; Park and Schuchman 2006). The 
positively charged AC binds to the negatively charged surface of 
Bis(monoacylglycero)phosphate (BMP) at the inner membrane of lysosomes. This adhesion 
positions AC to the interface of the inner membrane and allows for the degradation of its 
lipid substrate (Gallala and Sandhoff 2011). Furthermore, BMP facilitates the binding of the 
co-factor saposin D to AC, permitting enhanced AC activity (Azuma et al. 1994). AC fulfills 
housekeeping function by regulating ceramide levels in lysosomes (Sugita et al. 1972). A 
secreted form of AC has also been reported (Romiti et al. 2000). 
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1.4.2 Genotype/phenotype relations 
Mutations in the ASAH1 gene result in a rare disease, named Farber lipogranulomatosis 
(Farber et al. 1957; Sugita et al. 1972; Bar et al. 2001). The functionality of AC is limited by 
point mutations or minor deletions of the DNA sequence that result in exon skipping, 
abnormal splicing or enhanced proteolysis of the mature protein (Park and Schuchman 
2006). The reduction of ceramide conversion by AC results in the accumulation of lipids in 
lysosomes. The clinical picture most prevalently presents with abnormalities in the joints, 
throat, liver, and central nervous system (Zhang et al. 2000; Devi et al. 2006). Tissues display 
infiltration of lipid-laden macrophages (Bar et al. 2001). A genetic knockout of both Asah1 
alleles in the mouse genome, deleting exon 3 to 5, was reported to be lethal at the four-cell 
stage (Li et al. 2002; Eliyahu et al. 2007). Mortality of early embryos was ascribed to 
increased ceramide levels (Perez et al. 2005; Eliyahu et al. 2007). Therefore, AC expression 
during early embryogenesis is essential to overcome ceramide induced cell death. In a 
knock-in mouse model, a single nucleotide within a conserved gene region of Asah1 was 
exchanged (Alayoubi et al. 2013). Consequential conversion of proline 362 to an arginine 
peptide was reported to reduce AC activity to 10% of the wild type enzyme in Farber 
patients (Moser et al. 1989). Presumably the saposin D binding site of AC is mutated 
(Alayoubi et al. 2013). Knock-in mice were retarded in their growth and viable up to 13 
weeks. Increase in cellular ceramide levels seems to promote the release of MCP-1 which is a 
chemo-attractant for macrophages (Alayoubi et al. 2013). Some human cancers display 
elevated levels of AC expression (Seelan et al. 2000; Elojeimy et al. 2007). Elevated AC 
expression in cancer cells confers resistance to chemotherapy and ionizing radiation in vitro 
(Saad et al. 2007; Mahdy et al. 2009). The consequences of elevated AC expression in an 
organism are not ascertained at present. 
 
Table 1.1: Summary – Acid ceramidase (AC) 
 Human Mouse 
Gene Symbol ASAH1 Asah1 
Cytogenetic location 8p22-p21.3 8 A4 
Transcript 
 
mRNA: 2618 bp mRNA: 2251 bp 
cDNA = 80% identical (Li et al. 1998) 
Protein  395 amino acids 
(1-21 = signaling peptide; 22-142 = 
α-subunit; 143-395 = β-subunit) 
394 amino acids 
(1-18 = signal peptide; 19-141 = α-
subunit, 142 -394 = β-subunit) 
amino acids = 90% identical (Li et al. 1998) 
Catalytic activity N-acylsphingosine + H2O = carboxylate + sphingosine 
Genetic disorder Farber disease 
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1.5 Acid lysosomal sphingomyelin phosphodiesterase 1 (ASM) 
Sphingomyelinases catalyze the conversion of sphingomyelin to ceramide and 
phosphorylcholine by hydrolization of the phosphodiester bond. At least three different 
sphingomyelinases exist. They differ in their pH values of maximum enzyme activity and 
nomenclature distinguishes the three enzymes with the prefixes acid-, neutral-, or alkaline. 
The first described sphingomyelinase, acid sphingomyelinase (Acid lysosomal sphingomyelin 
phosphodiesterase I, ASM) was purified from urine (Quintern et al. 1987). ASM fulfills a dual 
role in the cell (Schissel et al. 1998). The glycolysation pattern destines whether the enzyme 
has a housekeeping function in lysosomes or reorganizes microdomain structures at the cell 
surface (Newrzella and Stoffel 1996; Schissel et al. 1998; Jenkins et al. 2011).   
 
1.5.1 Structural features of ASM 
The human ASM gene (gene symbol: SMPD1), mapped to the short arm of chromosome 11 
(11p15.1-p15.4), is 4585 bp long with an open reading frame of 1890 bp (da Veiga Pereira et 
al. 1991; Schuchman et al. 1992). Six exons encode for 629 amino acids. Exon 2 encodes 
about 44% of the 75 kDa acid sphingomyelinase prepolypeptide (Schuchman et al. 1992). 
The glycosylated prepolypeptide is synthesized at the rough endoplasmatic reticulum and is 
processed to a 72 kDa precursor protein. The majority of the enzyme is modified within the 
trans-golgi-network by mannose-6-phosphate binding which ensures transport to the 
lysosomal compartment (Ferlinz et al. 1997). In the acidic compartment the enzyme matures 
to the active 65 KDa lysosomal ASM (L-Smase) form (Jenkins et al. 2011). L-Smase is exposed 
to Zn2+ in the acidic compartment and by tight interaction its activity becomes “Zn2+-
independent” (Schissel et al. 1998). A yet to be identified lysosomal thiol protease 
inactivates L-SMase and produces a 52 kDa form. This protease is a potent regulator of L-
SMase activity and sphingolipid signaling (Jenkins et al. 2011). Precursor ASM proteins that 
do not obtain a mannose-6-phosphate are released into the extracellular milieu via the Golgi 
secretory pathway. Trafficking of secretory ASM (S-Smase) through the Golgi secretory 
pathway requires “complexing” of N-glycans in order to prevent digestion by 
endoglycosidase (Hurwitz et al. 1994; Schissel et al. 1998). In comparison to L-Smase, S-
Smase does not encounter a source of Zn2+. Hence, S-Smase remains “Zn2+- dependent” 
(Schissel et al. 1998). A third form of ASM is stored in secretory lysosomes in the vicinity of 
the plasma membrane. This signaling pool of ASM can be released in a syntaxin 4 dependent 
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exocytic pathway (Perrotta et al. 2010). Stress stimuli can induce the recruitment of ASM to 
the outer membrane to form CRDs (Cremesti et al. 2001; Grassmé et al. 2001; Abdel Shakor 
et al. 2004; Rotolo et al. 2005; Bao et al. 2010; Avota et al. 2011). The translocation of the 
enzyme to the outer leaflet depends on functional microtubules (Grassmé et al. 2003a), 
functional lipid domains (Lacour et al. 2004), and phosphorylation of Ser508 of ASM (Zeidan 
and Hannun 2007).  
 
1.5.2 Genotype/phenotype relations 
Genetic mutations in the ASM gene lead to the autosomal recessive disease of Niemann-
Pick. Reduced activity of an abnormal ASM gene product causes the accumulation of 
sphingomyelin in cells (Niemann 1914; Brady et al. 1966). In the Niemann-Pick type A 
variant, neurodegeneration leads to early death of infants. Type B Niemann-Pick patients 
suffer from progressive visceral impairments (Schuchman and Miranda 1997). More than 
100 mutations are described that alter amino acids of the ASM peptide and reduce its 
functionality (Schuchman 2007). A knockout of the ASM gene to serve as a murine model of 
Niemann-Pick disease was established by Hourinouchi et al. (Horinouchi et al. 1995). 
Knockout animals fail to thrive and display lipid loaded foam cells in major organs 
(Horinouchi et al. 1995). The mouse model was utilized to ascertain the stress induced 
formation of ceramide-rich domains and subsequent reorganization of membrane proteins 
(Cremesti et al. 2001; Grassmé et al. 2001; Dumitru and Gulbins 2006). A conditional 
knockout model of the ASM, allowing for temporal and spatial control of the genetic 
disruption, does not exist at present. 
 
Table 1.2: Summary – Acid sphingomyelinase (ASM) 
 Human Mouse 
Gene Symbol SMPD1 Smpd1 
Cytogenetic location 11p15.1-p15.4 7 E3 
Transcript 
 
mRNA: 2482 bp     mRNA: 2430 bp 
cDNA = 81% identical (Newrzella and Stoffel 1992) 
Protein  629 amino acids 627 amino acids 
amino acids = 82% identical (Newrzella and Stoffel 1992) 
Catalytic activity Sphingomyelin + H2O = N-acylsphingosine + phosphocholine 
Genetic disorder Niemann-Pick disease 
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1.6 Aim of the study 
The current study aims to establish two transgenic mouse models with modified sphingolipid 
metabolism. 
In a “gain of function” model, AC expression cassettes will be introduced into the murine 
genome. The expression cassette comprises a CAG-promoter that drives the transcription of 
Asah1 complementary DNA (cDNA). The genetic components of the expression cassette will 
be assembled by DNA cloning techniques. After verification of expression cassette 
functionality, the DNA will be delivered to the murine genome by pronuclear injections into 
fertilized eggs. Transgenic offspring will be identified by PCRs. Founder lines will be 
established and their genotype and phenotype will be characterized. Generated CAG-Asah1 
mice may allow assessing the biological significance of enhanced ceramide hydrolysis.  
Furthermore, a targeting construct to introduce recombination sites into the murine Smpd1 
gene will be generated. In the targeting construct, loxP sites are inserted by DNA cloning 
techniques and flank exon 2 of genomic Smpd1 DNA. The cloning procedures will be 
reexamined by PCRs and restriction enzyme digests. Moreover, the recombination 
competence of the Cre/loxP system will be confirmed in E. coli. Subsequently, we will 
transfect murine ES cells with our targeting construct. Individual ES cell clones are screened 
for homologous recombination events and the integration of the targeting construct at the 
Smpd1 locus by PCRs. Clones with a recombined Smpd1 locus will be utilized for the injection 
into murine blastocysts to obtain chimeras. The offspring of chimeras will be reexamined for 
the modified Smpd1 locus. The conditional knockout may allow for temporal and spatial 
control of Smpd1 gene disruption. Prevention of ceramide synthesis by ASM can be analyzed 
in single cell types, tissues or at a defined time point.    
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2. MATERIALS 
2.1 Enzymes and antibodies 
AccuPrime™ DNA polymerase Invitrogen™ (Karlsruhe, Germany) 
α-acid ceramidase ProSci Incorporated (Poway, CA, USA) 
α-actin Santa Cruz Biotechnology, Inc. (Delaware 
Ave, CA, USA) 
Alkaline phosphatase-coupled  
secondary antibodies  
Santa Cruz Biotechnology, Inc. (Delaware 
Ave, CA, USA) 
DNA ligase (supplied with buffer) T4 DNA ligase; New England BioLabs 
(Beverly, MA, USA) 
DNA polymerase I - large Klenow fragment New England BioLabs (Beverly, MA, USA) 
Proteinase K Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Restriction enzymes (supplied with buffer) New England BioLabs (Beverly, MA, USA) 
Standard Taq DNA polymerase Non commercial, made by Dr. R. Waldschütz 
 
2.2 Molecular markers 
DNA ladder 100 bp Invitrogen™ (Karlsruhe, Germany) 
DNA ladder 1 kb New England BioLabs (Beverly, MA, USA) 
Protein ladder Page Ruler Fermentas 
 
2.3 Kits for molecular biology 
QIAquick® Gel Extraction Kit            QIAGEN GmbH (Hilden, Germany) 
EndoFree® Plasmid Maxi Kit QIAGEN GmbH (Hilden, Germany) 
Effectene® Transfection Reagent QIAGEN GmbH (Hilden, Germany) 
 
2.4 Bacterial strains and eukaryotic cell lines  
E. coli DH10B (for propagation of plasmid 
DNA) 
Escherichia coli strain K-12, substrain DH10B; 
Taxonomy ID: 316385 (NCBI); (Durfee et al. 
2008); purchased from GIBCO®, Invitrogen™ 
(Karlsruhe, Germany) 
E. coli 294-Cre   Gene Bridges GmbH (Heidelberg, Germany), 
(Buchholz et al. 1996) 
E. coli 294-FLP Gene Bridges GmbH (Heidelberg, Germany), 
(Buchholz et al. 1996) 
GL261 Established mouse glioma cell line (Szatmari 
et al. 2006). Kind gift of Prof. Dr. M. Weller 
(University of Zürich) 
R1 mouse embryonic stem cells Received from Prof. Dr. T. Möröy 
Mouse embryonic fibroblasts (MEFs) Generated by Dr. R. Waldschütz from 
matings of neomycin and hygro resistant 
mouse strains 
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2.5 DNA material 
2.5.1 Vectors 
 
2.5.2 Primers and oligonucleotides 
Name Sequence (5` - 3´) 
PB3 CTTCCATTTGTCACGTCCTG 
Litmus28 New England BioLabs (Beverly, MA, USA) 
Litmus28-Smpd1/NeoR/loxP Generated in this project 
Litmus28-Smpd1 Generated in this project 
Litmus28-Smpd1/LK/loxP Generated in this project 
pBlueSpec2SK Constructed by Dr. R. Waldschütz 
pBS-loxP Unknown origin 
pBS-Smpd1/LK/loxP Generated in this project 
pBS-Smpd1/loxP Generated in this project 
pBSpec2-DT Generated in this project 
pBSpec2Z Constructed by Dr. R. Waldschütz 
pBSpec2Z-Asah1 Generated in this project 
pJK plasmid From the laboratory of Prof. Dr. Gulbins 
(made by Jutta Kun) 
pK11rev2 Constructed by Dr. R. Waldschütz 
pLCAG-DnmtI From the laboratory of Prof. Dr. T. Möröy 
pNeb-bGHpA/SCS/Asah1/hGHpA/FRT/SCS Generated in this project 
pNeb-
bGHpA/SCS/CAG/Asah1/hGHpA/FRT/SCS 
(referred to as “CAG-Asah1”) 
Generated in this project 
pNeb-
bGHpA/SCS/CAG/Asah1/hGHpA/NeoR/SCS 
(referred to as CAG-Asah1/NeoR) 
Generated in this project 
pNEB193bGHpA/SCS/L2/SCS Constructed by Dr. R. Waldschütz 
pNEB-bGHpA/SCS/lck/iCre/hGHpA/FRT/SCS Constructed by Dr. R. Waldschütz 
pNEB-bGHpA/SCS/lck/ICre/hGHpA/NeoR/SCS Constructed by Dr. R. Waldschütz 
pKO-DT From the laboratory of Prof. Dr. T. Möröy 
pk18 Unknown origin 
pk18-CAG Generated in this project 
pK18-bGHpA/SCS/CAG Generated in this project 
pCMV-Sport6  imaGenes GmbH (Berlin, Germany); 
Genbank accession: BC003204 
pPS-Smpd1 Converted phage (Dr. R. Waldschütz) 
pPS-Smpd1/DT Generated in this project 
pPS-Smpd1/KO Generated in this project 
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PKLink1 GTTTAAACATAACTTCGTATAGTATACATTATACGAAGTTATGTACACTGCA 
PKLink2 GTGTACATAACTTCGTATAATGTATACTATACGAAGTTATGTTTAAACTGCA 
Asah1.2 CAATTCCCCTCATTTCCTCTC 
Asah1.3 GAAGAAGCCAAGAACACAC 
Asah1.4 TCATAGACATCCAAAGACTC 
Asah1.6 CTTCTGTGTGGTGTGATTTAG 
CAG4 CTCTAGAGCCTCTGCTAACC 
DTA1 CTCCATCAACGGTTCAGTGAG 
DTA2 CAAACTGCCGTAACCTCTGC 
hGHas2 GGGTTAGTGCCCCCGTCCCATC 
dSCS2.4 GGCATCTCTGAACATCAGGTG 
bpA1 GCTGGTTCTTTCCGCCTCAG 
loxPfor AGAATAACTTCGTATAATGTATGC 
loxPSmpd1 CGAAGTTATAAGCTCTAGCAGTACATC 
Smpd1.3 GGCTATACAGAGAAACCCTGTC 
Smpd1.5 CTTCTCAGTTTAATGACCAGCTG 
Smpd1.8 GAAGGTCTGGAAGAGTTGCTC 
Smpd1.10 CAAGAAAGGGTCACGAGTCAC 
Smpd1.12 GCAAAGTCTTATTCACTGCTCTC 
Smpd1.13 GACATCAGTATCTCCCACACAC 
Smpd1.14 GTGTCCTCAGCACTCTCTACTG 
Smpd1.15 GACAAAGAGTGAGGTGAGTCAG 
Smpd1.16 ATCAGTGTAAGGGCCTGTGG 
Neo1F TATTCTGCCTTCCTGATGATAACTG 
Ragf GCTGATGGGAAGTCAAGCGAC 
Ragr GGGAACTGCTGAACTTTCTGTG 
 
2.6 Chemicals 
Acetic acid (CH3COOH) Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Acrylamide Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
Agar Biozym Scientific GmbH (Oldendorf, 
Germany) 
Agarose Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
Ammonium persulfate  (APS) Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Ampicillin   Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Aprotinin Serva Electrophoresis GmbH (Heidelberg, 
Germany) 
Bacto-Agar Beckton, Dickinson and Company (Franklin 
Lakes, NJ, USA) 
Bacto-tryptone Beckton, Dickinson and Company (Franklin 
Lakes, NJ, USA) 
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Bovine serum albumin (BSA) Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
Bradford reagent BioRad (München, Germany) 
Bromophenol blue Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Calcium chloride (CaCl2) Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Chemiluminescence detection reagent CDP-Star®; PerkinElmer (Waltham, MA, USA) 
Chloroform (CHCl3)    Ridel-de Haën® (Seelze, Germany) 
Deoxycholic acid  Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Deoxyribonucleotides (dNTP´s)   Bio-Budget Technologies GmbH (Krefeld, 
Germany) and PEQLAB Biotechnology GmbH 
(Erlangen, Germany) 
DMSO Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
EDTA Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Eosin Merck KGaA (Darmstadt, Germany) 
Ethidium bromide Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Ethanol (C2H5OH) Carlo Erba Reagents (Val de Reuil, France) 
Evagreen® Biotium, Inc. (Hayward, CA, USA) 
FBS Gibco/Invitrogen (Karlsruhe, Germany) 
Gelatin Merck KGaA (Darmstadt, Germany) 
Geneticin (G418) Gibco/Invitrogen (Karlsruhe, Germany) 
Glycerol Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Glycine Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
Glucose Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
HEPES Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
Isopropanol Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Kanamycin Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Leupeptin Serva Electrophoresis GmbH (Heidelberg, 
Germany) 
Magnesium chloride (MgCl2) Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Magnesium sulfate (MgSO4) Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Methanol (CH3OH)   Carlo Erba Reagents (Val de Reuil, France) 
2-Mercaptoethanol   GIBCO®, Invitrogen™ (Karlsruhe, Germany) 
Mitomycin C Sigma-Aldrich Chemie GmbH (Steinheim, 
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Germany) 
Non-fat dry milk powder AppliCHem (Darmstadt, Germany) 
NP-40 Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Penicillin/Streptomycin Gibco/Invitrogen (Karlsruhe, Germany) 
Phenol (C6H5OH) Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
Potassium acetate (CH3CO2K) Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Potassium chloride (KCl) Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Potassium dihydrogen phosphate (KH2PO4) Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Protease inhibitor cocktail tablets (cOmplete 
Mini EDTA-free) 
Roche AG (Basel, Switzerland) 
RBM14-12 (synthetic ceramide analog) (Bedia et al. 2007; Bedia et al. 2010); 
provided by Prof. Dr. A. Delgado (Barcelona, 
Spain) 
D(+)-Saccharose Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
Sodium acetate (CH3COONa)   Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Sodium chloride (NaCl) Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
Sodium dodecyl sulphate (SDS)   Serva Electrophoresis GmbH (Heidelberg, 
Germany) 
Sodium phosphate dibasic (Na2HPO4) Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Sodium hydroxide (NaOH) Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Sodium periodate (NaIO4) Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Sodium fluoride (NaF) Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Sodium pyrophosphate (Na4P2O7) Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Tris Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
Triton X-100 Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Tween Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Umbelliferone Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
Xylene cyanol Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
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Yeast extract Carl Roth GmbH & Co. KG (Karlsruhe, 
Germany) 
  
2.7 Solutions and buffers 
2.7.1 Molecular Biology 
DNA and protein buffers 
Bacterial lysis buffer           
      
0.2 N NaOH          
1% SDS  
Neutralization buffer           3 M Potassium acetate  pH 5.2 
PCR buffer (10x) 200 mM Tris-HCl pH 8.3 
500 mM KCl 
14 mM MgCl2 
0.1% Gelatin 
Resuspension buffer  50 mM Glucose  
10 mM EDTA          
25 mM Tris-HCl  pH 8.0  
Sucrose lysis buffer 250 mM D(+)-Saccharose 
Protease inhibitor cocktail tablet (1 per 10 
ml) 
TE buffer                      
   
10 mM Tris/HCl pH 7,6 
1 mM EDTA 
Tissue lysis buffer 10% 10x PCR-buffer Mg-free 
0.5 mM MgCl2 
0.045% Tween-20 
0.045% NP-40 
Proteinase K 300 µg/ml 
  
Agarose gel electrophoresis 
DNA loading buffer (6x) 
 
50% Glycerol  
0.02% Bromophenol blue  
0.04% Xylene Cyanol  
1 mM EDTA 
TAE buffer (50x) 2 M Tris 
950 mM Acetic acid 
62.5 mM EDTA 
 
Agar plates 
Ampicillin (100x) 10 mg/ml 
Kanamycin (1000x) 50 mg/ml 
LB (Lysogeny Broth) medium                10 g/l Bacto-tryptone  
10 g/l NaCl 
5 g/l yeast extract  
Adjust pH to 7.5 with NaOH 
LB (Lysogeny Broth) agar plates LB medium with 1.5% Bacto-Agar was 
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 autoclaved and cooled down to 50°C. 1% 
Ampicillin (100x) or 0.1% Kanamycin (1000x) 
was added. The media was mixed and 
poured into 90 mm Petri dishes. After 
hardening of the agar, plates were stored at 
4°C 
  
2.7.2 Cell culture 
Supplements  
Dulbecco's modified Eagle's medium 
(DMEM) 
GIBCO®, Invitrogen™ (Karlsruhe, Germany) 
Fetal Bovine Serum (FBS) GIBCO®, Invitrogen™ (Karlsruhe, Germany) 
KNOCKOUT™ DMEM GIBCO®, Invitrogen™ (Karlsruhe, Germany) 
L-Glutamine GIBCO®, Invitrogen™ (Karlsruhe, Germany) 
LIF (leukemia inhibitory factor)                   ESGRO® mLIF; Merck KGaA (Darmstadt, 
Germany) 
MEM-non-essential amino acids                  GIBCO®, Invitrogen™ (Karlsruhe, Germany) 
Nucleosides: adenosine, guanosine, uridine, 
cytidine, thymidine 
Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) 
100x Penicillin/streptomycin GIBCO®, Invitrogen™ (Karlsruhe, Germany) 
Sodium pyruvate GIBCO®, Invitrogen™ (Karlsruhe, Germany) 
Trypsin   GIBCO®, Invitrogen™ (Karlsruhe, Germany) 
 
Media and buffers 
Complete MEM  
 
500 ml MEM    
10% FBS   
10 mM HEPES pH 7.4   
2 mM L-Glutamine   
1 mM Sodium pyruvate   
0.1 mM Non-essential amino acids   
1% 100x Penicillin/streptomycin 
ES cell medium                   500 ml Knockout-DMEM 
0.1 mM Non-essential amino acids  
0.1 mM 2-Mercaptoethanol  
15% FBS  
1% 100× Nucleosides  
6000 U LIF  
0.1 M L-Glutamine  
ES cell freezing medium 20% DMSO 
50% FBS 
30% ES cell medium 
10x HEPES-saline        
 
200 mM HEPES  
1.32 M NaCl  
10 mM CaCl2   
7 mM MgCl2   
8 mM MgSO4   
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54 mM KCl 
ES cell lysis buffer  100 mM Tris pH 8.3 
5 mM EDTA   
0.2% SDS  
200 mM NaCl    
0.1 µg/ml Proteinase K 
Mouse Embryonic Fibroblast (MEF-) medium 
 
440 ml KNOCKOUT™ DMEM,  
50 ml Fetal Bovine Serum  
5 ml L-Glutamine  
100× nucleosides  3 mM Adenosine 
3 mM Guanosine 
3 mM Uridine 
3 mM Cytidine 
3 mM Thymidine 
Phosphate Buffered Saline (PBS)          
 
137 mM NaCl  
2.7 mM KCl   
7 mM CaCl2  
0.8 mM MgSO4  
1.4 mM KH2PO4  
6.5 mM Na2HPO4 
Adjust pH to 7.6 
Trypsin     0.25% Trypsin   
5 mM Glucose   
1.3 mM EDTA 
in PBS 
  
2.7.3 Biochemistry   
Western Blotting 
Alkaline wash buffer    
 
100 mM Tris pH 9.5  
100 mM NaCl 
Blocking buffer 5% of non-fat dry milk powder in TBS-T (see 
below) 
Running buffer 25 mM Tris  
250 mM Glycine  
0.1 % SDS  
Running gel (10%)  3.75 ml Solution A (see below) 
5.0 ml Solution B (see below) 
6.11 ml H2O  
75 µl 20% SDS  
30 µl TEMED  
30 µl 10% APS in H2O 
SDS lysis buffer 25 mM HEPES pH 7.4 
0.1% SDS 
0.5% Deoxycholic acid 
1% Triton X-100 
10 mM EDTA 
10 mM Sodium pyrophosphate 
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10 mM Sodium fluoride 
125 mM NaCl 
SDS sample buffer (5x)  
 
62.5 mM Tris pH 6.8,   
10% Glycerol,   
2% SDS,   
0.04% Bromphenol blue  
5% 2-Mercaptoethanol 
Solution A 40% Acrylamide  
(39.2 g Acrylamide /100 ml;  
0.8 g Bis-Acrylamide /100 ml) 
Solution B 3M Tris pH 8.8 
Solution C 3M Tris pH 6.8 
Stacking gel 0.63 ml Solution A  
0.21 ml Solution C  
4.1 ml H2O  
0.025 ml 20% SDS  
0.02 ml TEMED  
0.02 ml 10% APS in H2O 
Transfer buffer          
 
25 mM Tris  
192 mM Glycine  
20% Methanol 
10 x Tris-buffered Saline supplemented with 
0.1% Tween-20 (TBS-T) 
200 mM Tris pH 7.4  
1500 mM NaCl  
1% Tween-20 
 
2.8 Equipment 
Cell culture incubator ThermoFisher Scientific (Waltham, MA, USA) 
Culture flasks and plates TPP® (Trasadingen, Switzerland) 
Cryotubes ThermoFisher Scientific (Waltham, MA, USA) 
Disposable polystyrene cuvettes  Sarstedt AG & Co (Nümbrecht, Germany) 
DNA annotation and analysis software Vector NTI 10.3.0; Invitrogen™ (Karlsruhe, 
Germany) 
Electrophoretic transfer cell Mini Trans-Blot® Cell; BioRad (München, 
Germany) 
Electroporation cuvettes Gene Pulser cuvettes 0,4 cm; BioRad 
Electroporation device Gene Pulser Xcell™; BioRad 
Filter Paper Whatman (Mainstone, United Kingdom) 
Fluorescence microplate reader BMG Labtech (Offenburg, Germany) 
Gel-documentation device AlphaImager® HP; Alpha Innotech/Biozym 
Scientific GmbH (Oldendorf, Germany) 
Horizontal gel electrophoresis chamber PEQLAB Biotechnology GmbH (Erlangen, 
Germany) 
Hybond nitrocellulose membrane GE Healthcare (Chalfont St Giles, United 
Kingdom) 
Image analysis software ImageJ; Rasband, W.S.,  U. S. National 
Institutes of Health (Bethesda, Maryland, 
USA); open-source software: 
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http://imagej.nih.gov/ij/, (Schneider et al. 
2012). 
Laminar flow hood Biohit/Sartorius Antares (Milano, Italy) 
Neubauer chamber 0.1 mm Marienfeld (Lauda-Königshofen, Germany) 
Optical adhesive film Sarstedt AG & Co (Nümbrecht, Germany) 
Power source PEQLAB Biotechnology GmbH (Erlangen, 
Germany) 
Porcelain mortar W.Haldenwanger Technische Keramik GmbH 
& Co. KG (Waldkraiburg, Germany) 
Real-Time PCR System ABI PRISM® 7300 Real-Time PCR System, 
Applied Biosystems (Foster City, CA, USA) 
Shaking incubator Eppendorf AG (Hamburg, Germany) 
Sonicator Model GE 50, 50 W model, ALLTECH Assoc. 
Inc. (Deerfield, IL, USA) 
Thermal cycler C1000™ thermal cycler; BioRad (München, 
Germany) 
96 U-bottom well plate Sarstedt AG & Co (Nümbrecht, Germany) 
UV-spectrophotometer Eppendorf AG (Hamburg, Germany) 
Vertical protein electrophoresis system Mini-PROTEAN® system; BioRad (München, 
Germany) 
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3. METHODS 
3.1 Manipulation of DNA 
3.1.1 Digestion of DNA by restriction enzymes 
Restriction enzyme digests were performed for the purpose of plasmid identification, 
generation of DNA fragments for ligation, and linearization of DNA fragments prior to 
pronuclear injection. Digests of plasmid DNA (500-3000 ng) were performed in reaction 
volumes of 10 – 20 µl under conditions and durations that accounted for the enzyme(s) 
properties used in the reaction (according to the manufacturer`s protocols and compatibility 
table; New England BioLabs, Beverly, MA, USA). 
 
3.1.2 Agarose gel electrophoresis 
Agarose gel electrophoresis serves to separate linear DNA fragments according to their 
length. The concentration of agarose affects the separation properties of the negatively 
charged DNA in the gel matrix when an electric current is applied. For the analysis of DNA 
fragments with a size > 1 kb, 1% agarose was solved in 100 ml 1 x TAE buffer by boiling. To 
analyze DNA fragments with a size < 1 kb, 2% agarose was used. Furthermore, the DNA 
intercalating agent ethidium bromide (1 µl) was added to the agarose-matrix. The solution 
was poured into a gel tray with combs and left for 20 minutes to solidify. The tray was placed 
in a horizontal gel electrophoresis chamber connected to a power source. DNA samples 
were mixed with DNA loading buffer and loaded into the slots. Electrophoresis was started 
by applying an electric field with a constant voltage of 100 V. The fluorescence of ethidium 
bromide was visualized by excitation with ultraviolet (UV) light in a gel-documentation 
device. The length of the DNA fragments was deduced from a DNA standard ladder that was 
run parallel to the samples. Agarose gels served to identify and isolate desired DNA 
fragments. 
 
3.1.3 DNA purification of agarose gels 
DNA was extracted from agarose gels to isolate a fragment of interest and cleanup DNA from 
enzymatic reactions. The desired DNA fragment was excised from the agarose gel with a 
scalpel and processed according to the QIAquick Gel Extraction Kit protocol (buffers supplied 
with the kit: QG, PE). Briefly, the gel was solubilized at 50°C in buffer QG (3x gel volume) for 
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10 min. Isopropanol was added (1x gel volume) and mixed followed by application of the 
sample to a QIAquick column (supplied with the kit) and subsequent centrifugation at 13000 
rpm. The column was washed once with 750 µl buffer PE. DNA was eluted into a clean 
Eppendorf-tube by applying 30 µl TE buffer to the column.   
 
3.1.4 Filling of 5` protruding ends 
The cloning strategy preferably was based on the ligation of compatible sticky ends. If this 
was not possible, the strategy relied on blunt-end cloning. To this end, fill-in reactions using 
the DNA polymerase I - large Klenow fragment were performed. Klenow is able to fill-in 5` 
overhangs. The reactions, involving linearized vectors or DNA fragments, were set up as 
follows: 
DNA       20 µl 
10 x Restriction enzyme buffer 2 (NEB)  3 µl 
Klenow (5 U/µl)     1.5 µl 
dNTP`s (10 mM)     5.5 µl 
 
The reactions were carried out at RT for 30 minutes. Prior to using the DNA for ligation, 
Klenow was either inactivated at 75°C for 30 min or removed by purifying the DNA via gel 
electrophoresis and subsequent extraction. 
 
3.1.5 Generation of linker from oligonucleotides 
Two oligonucleotides were annealed to serve as a linker that yields two new restriction sites 
(PmeI and BsrGI) needed for following cloning steps. The reaction mixture, comprising 1 µl 
Tris (stock: 1 M) added to 10 µl PKLink1 and 10 µl PKLink2 (stocks: 100 µM) in a PCR tube, 
was put in a thermal cycler. The PCR program served to heat the reaction up to 95°C and 
subsequently cool it down with a ramp rate of 0.1°C/sec to RT. Slow cooling allowed 
annealing of the complementary strands. This yielded an adapter with four bases as 
overhangs on both sides. 
 
3.1.6 Ligation of DNA fragments into plasmids 
In order to incorporate a DNA fragment into a linearized plasmid vector backbone, a DNA 
ligase was utilized. The Ligase catalyzes the formation of phosphodiester bonds, thereby 
joining cohesive or blunt end termini. Ligations were performed with a molar insert: vector 
DNA ratio of 3:1 (about 100 ng vector backbone). The reaction was made up of 1 µl 10x DNA 
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ligase buffer, 1 µl DNA ligase, DNA and was filled up with ddH2O to a final volume of 10 µl. 
For ligation of cohesive ends, reactions were performed at RT for 2 hours. To facilitate blunt 
end ligation, the reaction was left at RT overnight.  
 
3.2 Transformation of competent bacteria with plasmid DNA 
Plasmid DNA preparation was used to transform chemo-competent E. coli (DH10B). 1-4 µl of 
DNA was added to 100 µl of competent bacteria in a 1.5 ml reaction tube, gently mixed, and 
incubated for 20 minutes on ice. Bacteria were heat-shocked for 45 seconds at 42˚C. After 
the heat shock, the tube was incubated on ice for 10 minutes. Subsequently, 900 µl of LB 
medium was added and the tube incubated at 37°C for 30 minutes. Bacteria were pelleted 
by centrifugation at 3000 rpm for 2 minutes and the pellet resuspended in 50 µl of LB 
medium. The solution was distributed on a LB agar plate with appropriate antibiotic to select 
for bacteria that propagate the plasmid. Bacterial colonies were picked after 12-14 hours of 
incubation at 37°C.  
 
3.3 Isolation of plasmid DNA 
3.3.1 Mini-preparation 
Single colonies were picked from a LB-agar plate with a pipette tip and added to 2 ml of LB 
medium with appropriate antibiotic. The culture was grown overnight at 37°C in a shaking 
incubator. After incubation, cells were transferred to a 2 ml reaction tube and pelleted by 
centrifugation at 13000 rpm for 1 minute. The supernatant was removed and the bacteria 
resuspended in 100 µl resuspension buffer. For cell lysis, 200 µl bacterial lysis buffer was 
added and mixed. Subsequently, 150 µl neutralization buffer was added and mixed by 
inverting 5 times. Tubes were centrifuged at 13000 rpm for 5 minutes. In the meantime, 
1000 µl of 100% ethanol was added to new 1.5 ml Eppendorf-tubes. After centrifugation, the 
supernatant (~450 µl) was transferred to the Ethanol containing tubes for precipitation. 
Tubes were centrifuged at 13000 rpm for 15 minutes. Pellets were washed with 600 µl of 
80% ethanol and air dried for 5 – 10 minutes prior to resuspension in 30 µl buffer TE. 
 
3.3.2 Maxi-preparation 
For large-scale plasmid preparation, 250 ml of LB medium with appropriate antibiotic were 
inoculated with bacteria to propagate the plasmid of interest. The culture was incubated in a 
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shaking incubator at 200 rpm overnight. The plasmid was harvested according to the 
protocol of the Endofree® plasmid Maxi kit based on alkaline lysis (the following reagents 
are supplied with the kit: P1, P2. P3, QBT, QC, QN, ER, and TE). Briefly, cells were centrifuged 
and the pellet resuspended in 10 ml buffer P1. 10 ml of buffer P2 were added, gently mixed 
and incubated for 5 minutes at RT. Following mixing with buffer P3, the solution was 
incubated on ice for 20 min. The lysate was poured into a QIAfilter Cartridge (supplied with 
the kit) and incubated for 10 min. The lysate was filtered into a 50 ml tube. Buffer ER, 2.5 ml, 
was added and incubated on ice for 30 min. The filtered lysate was applied to an 
equilibrated (buffer QBT) QIAGEN-tip 500 (supplied with the kit). The column was washed 
twice with 30 ml of buffer QC to dispose the plasmid DNA of proteins and RNA. DNA was 
eluted with 15 ml buffer QN and precipitated by adding 0.7 volumes isopropanol with 
subsequent centrifugation at 8000 rpm for 1 hour. Pellets were washed with 5 ml endotoxin-
free 70% ethanol and air dried for 5 – 10 minutes. Plasmid DNA was dissolved in 50 µl 
endotoxin-free buffer TE (supplied with the kit). DNA concentrations were determined by 
means of a UV-spectrophotometer at a wavelength of 260 nm.    
 
3.4 Analysis of ligation events by colony PCR 
Plasmid DNA was screened for successful ligation events by colony PCR. To this end, plasmid 
DNA was added to a standard PCR reaction that included one primer hybridizing with its 
corresponding complementary DNA on the vector backbone and the other primer targeted 
to the inserted DNA fragment. The PCR reaction solely amplified a DNA fragment in the case 
that the DNA fragment was inserted with the correct orientation into the plasmid backbone. 
After transformation of plasmids into competent E. coli and overnight growth on LB agar 
plates at 37 °C, colonies were picked off with a pipette tip. The same tip was then dipped 
into a 0.2 ml tube containing reagents of the PCR reaction (10% PCR buffer (10x), 200 µM 
dNTPs, primers (150 pmol), standard Taq polymerase (1 unit/25 µl), and nuclease-free 
ddH2O) and rubbed to the walls in a circular motion for 3 seconds. Subsequently, the same 
tip was used to inoculate an Eppendorf-tube with 1 ml fresh LB medium and selective 
antibiotic. The labeling of the Eppendorf-tubes corresponded to the labeling of the PCR 
reaction tubes. About 30 colonies per ligation were processed in this way. DNA amplification 
was performed in a thermal cycler. The lid was preheated to 104°C and the reactions were 
heated and cooled according to the following thermal protocol: 
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Thermal Protocol - “Standard PCR” 
Step Temperature Time 
1 95°C 4:00 min 
2 94°C 0:15 
3 58°C 0:30 
4 72°C 1:00 
5 Go to step 2     (34x) 
6 72°C 9:00 
7 4°C “Forever” 
 
The PCR reaction product was analyzed by agarose gel electrophoresis. Inoculated LB-
medium of colonies that showed successful amplification of a PCR product was used for 
Mini-preparation of plasmid DNA and further assessment by restriction enzyme digests. 
 
3.5 Verification of recombination competence in bacteria 
The pPS-Smpd1/KO plasmid contains recombination sites that flank the second exon of the 
Smpd1 gene and the neomycin cassette. In order to verify at an early stage that the 
introduced sites are competent for recombination, the plasmid construct was transformed 
into E. coli strains 294-Cre and 294-FLP (Buchholz et al. 1996). The strains hold 
corresponding recombinase genes in their genome. After overnight growth of bacteria in LB 
medium at 37°C and subsequent isolation of plasmid DNA by mini-preparation (see above, 
paragraph 3.3.1), restriction enzyme digests with BstBI and XhoI were performed. The DNA 
fragments were separated on a 1% agarose gel.   
 
Figure 3.1: Scheme of the procedure to test for recombination competence. A DNA sequence 
of a plasmid is flanked by either loxP or FRT sites. The plasmid is transformed into 
recombinase expressing bacteria (Cre or FLP recombinase) and the bacteria left to grow. The 
enzymes recognize their respective recombination sites and remove the flanked DNA 
sequences. This can be confirmed by restriction enzyme digestion of purified plasmid DNA 
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and subsequent visualization of DNA fragments on an agarose gel. Figure adapted from 
(Buchholz et al. 1996), by permission of Oxford University Press. 
 
3.6 Embryonic stem (ES-) cell culture methods 
3.6.1 Preparation of mouse embryonic fibroblast (MEF) feeder layers 
Prior to the culturing of ES cells, feeder cells were prepared. Mouse embryonic fibroblasts 
(MEFs) allow for the continuous growth of ES cells in an undifferentiated state. Thereby, 
pluripotency of ES cells is maintained which is crucial for effective contribution of modified 
ES cells to the germline. The surfaces of 6 tissue culture flasks, 225 cm2, were coated with 20 
ml of 0.2% gelatin in PBS for 2 hours. The gelatin was aspirated and flasks were washed once 
with 20 ml of PBS prior to adding 15 ml prewarmed MEF medium. Ready to use fibroblasts 
were removed from the liquid nitrogen (LN2) –tank and the cryotubes thawed at 37°C in a 
water bath. Fibroblasts were diluted in 30 ml of prewarmed MEF medium in a sterile tube 
and 5 ml of the fibroblast solution was pipetted to each culture flask. Cells were grown in a 
cell culture incubator (5% CO2 and 37°C) and split 1:3 after 3 days. Confluent monolayers (70 
– 100%) were division-inactivated by mitomycin C. The mitomycin C stock (20x mitomycin C 
stock: 2 mg mitomycin C dissolved in 10 ml PBS) was diluted in MEF medium (1:20). The 
original medium in the culture flasks was aspirated and 20 ml of the mitomycin C containing 
medium was added. Cells were left for 2-3 hours in the incubator. Subsequently, the 
medium was removed and fibroblasts were washed twice with PBS to remove remains of the 
drug. Next, the cells were harvested and frozen (in medium supplemented with 20% DMSO). 
In order to use the MEFs as feeder layer for the culturing of ES cells, fibroblasts were thawed 
and plated with the previous MEF-concentration/plate area ratio on gelatin coated plastic 
ware to obtain a confluent layer. Prior to usage as a feeder plate, the MEF medium was 
aspirated, the culture plate washed once with PBS and ES cell medium added.   
 
3.6.2 ES cell culture  
Murine ES cells of the R1-129 line were cultured under a laminar flow hood under sterile 
conditions and kept in a cell culture incubator at 5% CO2 and 37°C. In order to keep the stem 
cells in an undifferentiated, pluripotent state, cells were constantly cultured in ES cell 
medium and grown on MEF feederlayers. The medium was invariably changed every 24 
hours. A vial of ES cells was thawed and diluted in 10 ml ES cell medium. The cells were 
centrifuged at 1200 rpm for 5 minutes and the pellet resuspended in 5 ml ES cell medium. 
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The cell solution was transferred to a T25 culture flask. After 24 hours, ES cells were split 1:6 
by transferring the cells to two T75 culture flasks (à 150 cm2). This involved trypsinization, 
spinning (5 min at 1200 rpm), resuspension (in 5 ml ES medium) and transfer (2.5 ml to each 
T75 culture flask) of ES cells. Cells were grown until the plate was dense with oval, shiny 
clones with clear boundaries (~ 5 x 107 cells/T75 flask) and used for electroporation. 
 
3.6.3 Electroporation of ES cells 
DNA was introduced into mouse embryonic stem cells by electroporation. An electrical pulse 
opens pores in the ES cells for a short time frame and suffices for the linearized DNA of the 
targeting construct to enter the cell.  
Plasmid DNA (90 µg, EndoFree® Plasmid Maxi Kit derived) of the targeting construct, pPS-
Smpd1/KO, was digested by the restriction enzyme KpnI. DNA was solved in a final volume of 
150 µl in ddH2O supplemented with KpnI (4 µl), and appropriate restriction buffer. The 
reaction was incubated at 37°C overnight. To remove contaminating proteins from the DNA, 
the sample volume was increased to 300 µl with ddH2O and an equal volume 
phenol:chloroform 1:1 was added and the tube vortexed. The solution was centrifuged at 
13000 rpm for 2 minutes and the protein-free aqueous phase removed into a fresh reaction 
tube. In order to precipitate the DNA, 0.1 volumes sodium acetate 3.0 M, pH 5.5, and 2.5 
volumes cold 100% ethanol were added and the reaction tube put into a -20°C freezer and 
left overnight. The next day, the tube was centrifuged at 13000 rpm at 4°C for 15 minutes. 
The pellet was washed once with 500 µl 80% ethanol, air dried, and finally dissolved in 40 µl 
TE buffer. In order to ensure completeness of the DNA digestion by KpnI, 2 µl of linearized 
DNA were run in a 1% agarose gel and compared to an undigested pPS-Smpd1 plasmid DNA 
sample. 
Cells of two T75 culture flasks (à 150 cm2; ~ 5 x 107 cells) were trypsinized, centrifuged (1100 
rpm, 5 minutes, RT) and suspended in 2 ml PBS (4°C). An electroporation cuvette was loaded 
with 30 µl DNA solution (~ 30 µg DNA) and 1 ml of cell suspension. The electroporation was 
carried out in “time constant” mode using an electroporation device with the following 
settings: voltage: 800 V, time constant: 0.2 ms, capacitor 10 µF, and resistor/pulse 
controller: infinity. Afterwards, the cuvettes were kept at 4°C for 20 minutes. The solution of 
each approach was diluted 1:10 with ES cell medium and divided over 14 petri dishes (1 
ml/dish). Another 15 ml of ES cell medium was added to each dish. The medium was 
METHODS 
 
32 
 
changed every 24 hours. One day post electroporation, the medium was supplemented with 
175 µg/ml geneticin (G418) to select for integration of the targeting construct. After 7 days 
of selection, ES cell clones were picked. 
 
3.6.4 Collection of ES cell clones 
After seven days of selection, single ES cell clones were visible under the microscope. The 
media of the first petri dish was aspirated and changed for PBS. Next, 15 µl of PBS were 
added to the wells of a new 96 U-bottom well plate. Microscope assisted, a single clone was 
freed from the feeder layer with a 20 µl pipette tip. The clone was sucked into the tip in a 
volume of 2.5 µl fluid and transferred to a well of the 96 well plate. The procedure was 
repeated and the 96 well plate filled with one clone per well. Every twelfth well, the 
procedure was interrupted to add 35 µl of trypsin to the clone containing wells. The plate 
was incubated at 37°C for 10 minutes. Afterwards, 75 µl of ES cell medium was added and 
the cells of the clones singularized by pipetting up and down (10x). The cells were 
transferred to a normal 96 well plate with MEF feeder layer. Then, the collection of ES cell 
clones was continued. The 14 petri dishes were processed in this way and three 96 well 
plates were filled with ES cell clones. When individual clones reached 60% percent 
confluence, cells were transferred to 24 well plates with feeder layer. At this stage, 148 
clones showed normal growth in 24 well plates and were further processed. After 2 days of 
further culturing in the 24 well plate, cells were trypsinized and singularized in 750 µl ES cell 
medium. Three-quarter of cells (500 µl) were diluted in ES cell freezing medium 1:1 v/v, 
transferred to cryo tubes in a precooled cryo box, and kept at -80°C for one night. The next 
day, clones were frozen in liquid nitrogen. The other quarter of ES cells was left to grow for 
another 2 days in the 24 well plate and then lysed in 400 µl ES cell lysis buffer to obtain DNA 
samples.  
 
3.6.5 ES cell screening by PCR 
DNA of 148 ES cell clones was screened for the integration of the targeting construct at the 
Smpd1 locus by PCR. DNA samples were heated to 95°C for 10 minutes in order to inactivate 
proteinase K which was a constituent of the ES cell lysis buffer. PCR master mixes were 
assembled and contained: 10% PCR buffer (10x), 200 µM dNTPs, 150 pmol primers, DNA 
Polymerase (1 unit/25 µl), and nuclease-free ddH2O. DNA (1 µl, ca. 100 ng) was added to a 
0.2 ml PCR reaction tube to yield a total reaction volume of 25 µl. Standard Taq polymerase 
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was used for the amplification of DNA templates up to 1 kb. Larger DNA fragments were 
amplified by AccuPrime™ DNA polymerase. Reaction tubes were put into the thermal cycler 
and reaction products were analyzed via agarose gel electrophoresis. 
The following primerpairs, DNA polymerases, and thermal protocols were utilized: 
Primer pair Polymerase Thermal protocol 
Neo1F and Smpd1.3 AccuPrime™ DNA polymerase “Long range” PCR 
PB3 and Smpd1.16 AccuPrime™ DNA polymerase “Long range” PCR 
Smpd1.14 and Smpd1.15 Standard Taq polymerase “Standard” PCR 
DTA1 + DTA2 Standard Taq polymerase “Standard” PCR 
 
Thermal protocols: 
“Standard” PCR: see paragraph 3.4 
“Long range” PCR: 
Step Temperature Time 
1 95°C 4:00 min 
2 94°C 0:30 
3 56°C 1:00 
4 68°C 4:00 
5 Go to step 2     (34x) 
6 68°C 5:00 
7 4°C “Forever” 
 
3.7 Blastocyst injections 
Targeted R1-129  ES cells were injected into C57BL/6 blastocysts. Injected embryos were 
surgically transferred into the uterine horns of pseudopregnant recipient females. Chimeras 
were identified by patches of agouti (129 mouse strain) and black coat color (C57BL/6 mouse 
strain). Chimeras were mated with C57BL/6 mice. The agouti coat color of the R1-129 strain 
is dominant to the black coat color of C57BL/6 mice. In the case that R1-129 ES cells 
contributed to the germline of chimeras, the progeny were agouti. Genomic DNA of agouti 
offspring was examined by PCRs.  
The blastocyst injections and surgical procedures were supervised by Dr. Ralph Waldschütz 
and performed by Wojziech Węgrzyn of the "Zentrales Tierlaboratorium" (ZTL), the Central 
Animal Facility of the University Hospital Essen. 
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3.8 Transfection of GL261 cells 
The functionality of the AC expression construct was tested in vitro. To this end, GL261 cells 
were transfected with the CAG-Asah1/NeoR plasmid. Transfections were performed with the 
aid of Effectene® reagent according to the manufacturer`s protocol. Briefly, GL261 cells (1.5 x 
105 cells/well) were seeded on a 6 well plate one day prior to transfection. At the day of 
transfection, cells displayed 60% confluence. Plasmid DNA (0.4 µg), purified by maxi-
preparation (see above, paragraph 3.3.2), was diluted to a volume of 100 µl in buffer EC 
(supplied) and 3.2 µl Enhancer (supplied) were added. After 5 minutes of DNA condensation, 
10 µl Effectene® reagent was added. For the formation of Effectene®-DNA complexes the 
solution was incubated for 10 minutes. The transfection mixture was diluted in 600 µl 
medium and added drop-wise to a 6 well plate. After 24 hours, medium was exchanged for 
selective medium containing the antibiotic geneticin (G418) at a concentration of 400 µg/ml 
in complete MEM. After one week of selection, an untransfected control well showed no 
more viable cells. Transfected cells were constantly grown in medium with the selective 
drug. Aliquots of transfected cells were frozen in liquid nitrogen. By this means, GL261 cells 
were transfected with the CAG-Asah1/NeoR or an empty pJK plasmid. Geneticin (G418) was 
removed 48 hours prior to any experiment. 
 
3.9 Pronuclear injections  
The CAG-Asah1 transgene cassette flanked by unique restriction enzyme sites (PmeI, AscI) 
was separated from the cloning vector. The transgene construct was purified of plasmid 
backbone DNA and the ethidium bromide dye, which is mutagenic and might alter the ES cell 
genome. To this end, the digested DNA was extracted twice from agarose gels. First, the 
7274 bp transgene construct was purified of an ethidium bromide containing gel. The second 
agarose gel run was performed without ethidium bromide. In order to identify the construct 
on the DNA, the first lane, loaded with a DNA ladder, and a second lane, loaded with a small 
fraction of digested DNA, was dissected from the rest of the agarose gel and retroactively 
stained with ethidium bromide. To this end, the gel fragment was put into a 50 ml Falcon 
tube with 25 ml of TAE buffer and 2 µl of ethidium bromide and left for 15 minutes. The gel 
was reassembled and the ethidium bromide stained DNA ladder and digested DNA of the 
first two lanes were used as orientation for the excision of ethidium bromide -free DNA 
transgene construct from lane 3 to 5. The DNA was purified with the Qiaquick Gel Extraction 
Kit. Afterwards, the linearized transgene construct was injected into the pronuclei of 
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fertilized eggs of B6C3F1 mice (see figure 3.2). The eggs were transferred back to the uterus 
of pseudopregnant C57BL/6 recipients. Transgenic animals were identified by PCR (see 
paragraph 3.10) and crossed back to the C57BL/6 background. 
The pronucleus injections and surgical procedures were supervised by Dr. Ralph Waldschütz 
and performed by Wojziech Węgrzyn of the "Zentrales Tierlaboratorium" (ZTL), the Central 
Animal Facility of the University Hospital Essen. 
 
 
Figure 3.2: Pronuclear injection. a) Microscopic view of a holding capillary (hc) steadying a 
fertilized egg (zp: zona pelucida, pb: polar body, fp: female pronucleus, mp: male 
pronucleus). b) DNA of the linearized CAG-Asah1 transgene construct was injected into the 
male pronucleus of B6C3F1 derived eggs. Reprinted by permission from Macmillan Publishers 
Ltd: [Nature Protocols] (Ittner and Gotz 2007), copyright (2007). 
 
 
3.10 Genotyping of mice 
3.10.1 Isolation of genomic DNA from mouse tail tissue 
Tail biopsies (0.5 – 1 cm) of candidate mice were taken 4 weeks after birth with a medical 
scalpel. The tissue was incubated in 100 µl tissue lysis buffer at 55°C on a shaker overnight. 
In order to inactivate proteinase K, samples were heated to 95°C for 15 minutes. Lysates 
were diluted with 900 µl nuclease-free ddH2O to be ready for PCR-genotyping. 
 
3.10.2 PCR detection of transgenic mice 
Differentiation of wild type and transgenic mice was facilitated by PCRs in conjunction with 
the tail tissue derived genomic DNA templates. A master mix was assembled and contained: 
10% PCR buffer (10x), 200 µM dNTPs, 150 pmol primers, standard Taq polymerase (1 unit/25 
µl), and nuclease-free ddH2O. Primers were designed to amplify wild type and transgene 
specific sequences. The DNA (2.5 µl) was added to a 0.2 ml PCR reaction tube to yield a total 
reaction volume of 25 µl. The reaction tubes were put into the thermal cycler and 
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temperated according to the “Standard” PCR protocol (see paragraph 3.4). Reaction 
products were analyzed via agarose gel electrophoresis. The identification of founders was 
performed by multi-plex PCR amplifying a CAG-Asah1 specific sequence (Asah1.2 and CAG4) 
and an endogenous control sequence (Ragf and Ragr; recombination activating gene 1 
(Rag1), chromosome 2E2). General genotyping was performed with a single primer pair 
(Asah1.3 and Asah1.6) that allowed for reliable differentiation of transgenic and wild type 
mice.   
 
3.11 Animal husbandry 
Mice were maintained under specific pathogen free (SPF) conditions. Animals were provided 
with a standard rodent diet and had access to water ad libitum. The mice were kept in a 
room with a 12h/12h light/dark cycle, constant temperature (22°C), and constant humidity 
(55 ± 10%). Health monitoring was performed according to the guidelines of the Federation 
of European Laboratory Animal Science Associations (FELASA). The animal husbandry was 
policed by the "Zentrales Tierlaboratorium" (ZTL), the Central Animal Facility of the 
University Hospital Essen. All animal experiments were approved by the “Animal Care and 
Use Committee“ of the Bezirksregierung Düsseldorf, Germany in accordance with the 
german animal welfare act/„Tierschutz Gesetz“ (TSG). 
 
Table 3.1: Approved animal experiment projects. 
TSG-ID Title 
G 1157/10 „Analyse der Rolle von Ceramid bei Tumormetastasierung mit Hilfe eines 
konditionellen „Knock-out“ des Gens für die saure Sphingomyelinase und 
ubiquitärer Überexpression der sauren Ceramidase in der Maus“ 
 
3.12 Real-time PCR for the determination of transgene copies 
The number of transgene copies in the genome of the four transgenic founder lines was 
determined by real-time PCR. For the quantitative measurement, a Rag primer pair (Ragf and 
Ragr) served as endogenous control. An Asah1 primer pair (Asah1.3 and Asah1.4) was used 
for the amplification of a sequence within exon 11 of endogenous Asah1 DNA as well as the 
Asah1 cDNA template of the transgene cassette (see figure 3.3). 
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Figure 3.3: Strategy of CAG-Asah1 transgene copy number quantification. Primer Asah1.3 
and Asah1.4 bind to sequences within exon 11 of the endogenous Asah1 gene (wild type) and 
amplify a template of 128 bp. In comparison to wild type mice, CAG-Asah1 transgenic 
animals hold additional PCR templates due to the cDNA sequence of the transgene cassette. 
 
 
The PCR reactions were performed in a 96-well plate and carried out in triplicates using 
different vessels for the primer sets. The two master mixes contained the following 
components per PCR reaction: 10% PCR buffer (10x), 5% Evagreen® (20x), 200 µM dNTPs, 
primers (150 pmol), standard Taq polymerase (1 unit/25 µl), and nuclease-free ddH2O. The 
mastermix was distributed in a 96 well plate and 2 µl of DNA template, isolated from mouse 
tail tissue (see paragraph 3.10.1), was added. The final volume was 25 µl per reaction. The 
plate was sealed with an optical adhesive film. Subsequently, the plate was inserted into a 
real-time PCR System. The fluorescence was analyzed during the run of the following 
thermal protocol: 
 
Thermal protocol: 
 Step Temperature Time 
Amplification 1 95°C 10:00 min 
2 94°C 0:15 
3 58°C 0:30 
4 72°C 1:00 
5 Go to step 2 (34x) 
Dissociation 6 95°C 0:15 
7 60°C 0:30 
8 95°C 0:15 
 
The specificity of the reaction was controlled by ascertaining the melting curves and 
visualization of the PCR fragments on an agarose gel. The analysis was performed according 
to the comparative 2-∆∆Ct Ct method (Livak and Schmittgen 2001; Ballester et al. 2004a; 
Bubner and Baldwin 2004). Evagreen® acquires fluorescent properties upon intercalation 
with double stranded DNA. This signal is proportional to the quantity of DNA produced 
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during the PCR reaction. The amount of initial target sequence (X0) determines the number 
of targets (X) at cycle n (Xn = X0 * 2
n), and at which cycle a defined threshold (Ct value) of 
fluorescence intensity is reached. Hence, Ct values can be related to the initial amounts of 
DNA template (see figure 3.4). The Ct values observed for the Asah1 reactions were 
normalized to the Ct values of an endogenous control amplicon (Rag primer) to compensate 
for variances in DNA template concentration. The Ct value was then set into relation to a 
calibrator – Ct values of a wild type mice holding two alleles of Asah1. The data were 
transferred to the linear form by 2-ΔΔCt calculation. 
 
 
Figure 3.4: Fluorescence plot of a DNA dilution series during real-time PCR. The fluorescence 
accumulation of a marker that incorporates into the PCR product is recorded after each cycle 
(C) of the thermal protocol and plotted against the cycle number. Initial cycles define the 
baseline of background fluorescence. The threshold (t) is set above the baseline and is 
crossed at the beginning of the exponential phase. The cycle of threshold attainment 
represents the Ct value of a sample. In the dilution series, the Ct value increments one value 
with each 2 fold dilution of DNA template. Figure from (Bubner and Baldwin 2004), copyright 
2004, with kind permission from Springer Science and Business Media. 
 
 
3.13 Protein analysis 
3.13.1 Protein extraction of culture cells  
Protein extracts were obtained from cultured GL261 cells. GL261 cells were mobilized with 
trypsine and washed twice with PBS. For immunoblot analysis, cells were resolved in 500 µl 
SDS lysis buffer, supplemented with protease inhibitors aprotinin (10 µg/ml) and leupeptin 
(10 µg/ml). In order to determine AC activity, cells were lysed in 750 µl of sucrose lysis 
buffer. Next, cells were transferred to 1.5 ml reaction tubes, lysed on ice for 5 minutes and 
then sonicated, 3x 10 seconds at 25% output control. Subsequently, cell lysates were 
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centrifuged for 10 minutes at 13000 rpm and 4°C to remove cellular debris. The supernatant 
was transferred to a new Eppendorf tube and used for experiments or snap-frozen with 
liquid nitrogen and stored at -80°C. 
 
3.13.2 Determination of protein concentrations 
Concentrations of solubilized proteins were determined with a spectrophotometer by the 
Bradford method (Bradford 1976). The Bradford reagent contains an acidic dye with an 
absorbance maximum of 465 nm. However, when the dye binds to basic or aromatic amino 
acids of proteins, a color change occurs that shifts the absorbance maximum to 595 nm. 
Preliminary, the concentrated Bradford reagent was diluted with distilled water in a 1:5 
ratio. A standard curve was established by usage of five BSA protein standards of 1, 3, 5, 10 
and 20 µg/µl. Duplicates of standards and samples were added to 1 ml Bradford reagent in 
disposable polystyrene cuvettes. The absorbance was measured at 595 nm with a 
photometer. The absorbance of the samples was compared to the standard curve and 
protein concentrations deduced. 
 
3.13.3 Immunoblot analysis 
In order to quantify specific proteins, immunoblot analysis was performed. The method 
comprises sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), Western 
blotting, and antibody detection of proteins (Renart et al. 1979). During SDS-PAGE, proteins 
complexed with sodium dodecyl sulfate (SDS) are separated within a polyacrylamide gel 
according to their electrophoretic mobility. The mobility is antiproportional to the protein 
mass. The resulting protein pattern is subsequently immobilized by “Western blot” transfer 
to a nitrocellulose membrane. Primary antibodies are applied to specifically detect their 
epitope on a target protein. Polyclonal secondary antibodies, linked to reporter enzymes, 
bind specifically for the species of the primary antibody. The addition of a substrate results 
in a colorimetric conversion. The amount of visualized product is proportional to the amount 
of target protein on the nitrocellulose membrane.  
 
3.13.3.1 Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
The acrylamide gel consists of two layers that polymerize within a glass chamber. First, the 
running gel solution was prepared and poured into the chamber to fill 4/5 of the space. A 
layer of distilled water ensures that the free edge of the gel is plane. After polymerization, 
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the water was removed and the solution of the stacking gel was poured into the remaining 
space of the chamber. A comb was inserted and the gel left for polymerization. The stacking 
gel ensures that proteins line up before they entry into the running gel. In the running gel, 
proteins are separated according to their mass. Proteins (25 µg) were solved in sodium 
dodecyl sulfate (SDS) sample buffer and boiled for 5 minutes. The denatured protein 
samples and a protein molecular weight marker were loaded into the wells of a 10% 
acrylamide gel. For the initial run through the stacking gel, a constant ampere of 50 mA was 
applied to the vertical protein electrophoresis system. When the bromphenol dye reached 
the running gel, the ampere was increased to 75 mA. Electricity was turned off when the 
bromophenol dye was leaking out of the running gel.  
 
3.13.3.2 Western Blot and protein detection 
The transfer onto a hybond nitrocellulose membrane was performed with aid of an 
electrophoretic transfer cell. A “gel sandwich” was prepared. Fiber pads, filter papers, the 
acrylamide gel, and the nitrocellulose membrane were equilibrated with transfer buffer and 
assembled in a plastic cassette according to the manufacturer`s instructions. The cassette 
was placed in the tank and the tank filled with transfer buffer. The blot was run at a voltage 
of 80 V for 2 hours at 4°C. Afterwards, the nitrocellulose membrane was retrieved from the 
“gel sandwich” and washed with TBS. The membrane was incubated in blocking buffer at 4°C 
overnight. The next day, the membrane was washed with TBS-T 3 x 10 minutes under 
constant shaking. The primary antibody was diluted in TBS-T (α-acid ceramidase 1:5000 and 
α-actin 1:2000) and incubated at 4°C overnight. Once again, the membrane was washed 3 x 
10 minutes in TBS-T. The secondary antibody was diluted 1:30000 in TBS-T and incubated for 
2 hours at 37°C. One more time, the membrane was washed 3 x 10 minutes in TBS-T. The 
secondary antibodies are coupled to an alkaline phosphatase. Accordingly, the membrane 
was then washed in an alkaline wash buffer, 2 x 5 minutes. Molecules labeled with alkaline 
phosphatase were detected with the chemiluminescent substrate CDP-Star®. The substrate 
was added to cover the membrane and incubated for 5 minutes. Excess substrate was 
removed and the blot placed in a film cassette. In a dark room, photographic films were 
exposed and developed. The signals on the films were quantified with an image analysis 
software. 
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3.13.4 Acid ceramidase activity assay 
Acid ceramidase activity was determined in a fluorogenic assay according to the publications 
of Bedia et al. (Bedia et al. 2007; Bedia et al. 2010). The metabolic conversion of the 
substrate RBM14-12, a synthetic ceramide analog, was determined after 2 hours of 
incubation in an acidic buffer at 37°C. RBM14-12 holds a 2-oxo-2H-chromen-7-yloxy 
coumarin ring residue. Upon hydrolysis of the substrate by acid ceramidase, the residue can 
be transformed into the fluorescent molecule umbelliferone (see figure 3.5). Intermediary 
steps involve 1. periodate oxidation of the aminodiol at alkaline pH and 2. β-elimination of 
the aldehyde oxidation product. The kinetic characteristics of RBM14-12 hydrolysis were 
ascertained by Bedia et al. (Bedia et al. 2010). For the employed 25 µg of protein and 2 hours 
of incubation at 37°C, the linearity of the reaction kinetics has been previously reported 
(Bedia et al. 2010). Because the reaction is sensitive to the presence of detergents (Bedia et 
al. 2010), no detergents were utilized in the activity assay.  
 
 
Figure 3.5: Enzymatic conversion of RBM14-12. The ceramide analog RBM14-12 holds a 
coumarin residue in the sphingoid base. 1) Acid ceramidase cleaves the amide bond that links 
the fatty acid to the sphingoid base. 2) The alkaline buffer containing NaIO4 oxidizes the 
METHODS 
 
42 
 
remaining aminodiol of the sphingoid base, and 3) generates the fluorophore umbelliferone 
by β-elemination of the oxidized product. Figure from (Bedia et al. 2007), copyright 2007, 
with permission from WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. 
 
 
Protein (25 µg) solved in 25 µl sucrose lysis buffer, 74.5 µl sodium acetate buffer (25 mM, pH 
4.5) and 0.5 µl of Rbm14-12 substrate (final concentration 20 µM) were added to a well of a 
96 well plate. “No substrate” (Protein solved in 25 µl sucrose lysis buffer + 75 µl sodium 
acetate buffer) and “No protein” (25 µl sucrose lysis buffer + 74.5 µl sodium acetate buffer 
and 0.5 µl of Rbm14-12 substrate) reactions served as negative controls. The plate was left 
for 2 hours in a 37°C incubator. The reactions were stopped by the addition of 50 µl 
methanol. Subsequently, 100 µl of a 2.5 mg/ml NaIO4 fresh solution in 100 mM 
glycine/NaOH buffer, pH 10.6 was added. The plate was left in the dark for 2 hours. During 
this incubation step, the converted substrate undergoes oxidation and β-elimination. A 
plateau of florescence production was already seen after one hour (see appendix 9.1). This 
ensured that the produced fluorescence solely depended on the initial substrate conversion 
by AC. Fluorescence was quantified with a fluorescence microplate reader using an 
excitation of 360 nm and an emission of 446 nm. Umbelliferone standards were used to 
present the conversion of substrate by AC as pmol umbelliferone/hour/µg protein. 
 
3.14 Mass spectrometry (MS) of sphingosine in mouse tissues 
Sphingosine was quantified in murine tissue samples. To this end, mice were sacrificed and 
intracardially perfused with 0.9% NaCl to wash the blood out of the tissues. Skin and bone of 
the ribcage were removed to gain access to the heart. The aorta abdominalis infrarenalis 
was cut to allow for the efflux of blood. A butterfly needle (0.8 x 20 mm) was inserted into 
the left ventricle of the heart. NaCl was flowing through a standard infusion tube with a drop 
height of 80 cm into the mouse. Mice were perfused for 5 minutes. Subsequently, liver, 
kidney and spleen tissue (about 200 mg) were collected and snap frozen in liquid nitrogen. 
Tissues were mechanically pulverized with a porcelain mortar. Powdered samples were 
transferred to Eppendorf tubes and 1 ml of methanol was added. The samples were 
sonicated until the powder was completely dissolved. Protein concentrations were 
determined via Bradford assay (see above, paragraph 3.13.2). The samples were send on dry 
ice to the Department of Nutritional Toxicology, Institute of Nutritional Science, University 
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Potsdam, Germany. The quantification of sphingosine by mass spectrometry (MS) was 
performed by the group of Prof. Dr. Burkhard Kleuser. 
 
3.15 Statistics 
Data are given as mean ± SD. Statistical significances between organs from wild type and 
acid ceramidase transgenic mice were determined by Student`s t-test; *p<0.05. 
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4. RESULTS 
4.1 Results of the CAG-Asah1 mouse model 
4.1.1 General strategy for the generation of CAG-Asah1 transgenic mice 
The plasmid expressing the Asah1 cDNA was constructed by insertion of the following DNA 
fragments into the pNEB plasmid: (i) A polyadenylation signal (bGH-polyA) in order to 
prevent formation of hybrid proteins in the case that the construct integrates into coding 
genomic DNA. (ii) Two heterologous Drosophila melanogaster derived “SCS” insulator 
elements. Insulators protect gene expression from chromosomal positional effects and block 
enhancer activated transcription (Dunaway et al. 1997; Recillas-Targa et al. 2002; West et al. 
2002). They frame the following elements of the transgene cassette. (iii) A CAG promoter. 
The CAG promoter is composed of the cytomegalovirus (CMV) early enhancer element and 
chicken beta-actin promoter. In transgenic models, the promoter is established and known 
to drive high expression levels of the gene next in line (Niwa et al. 1991; Okabe et al. 1997; 
Xu et al. 2001). (iv) The murine AC complementary DNA (cDNA). A plasmid containing the 
full-length Asah1 cDNA was purchased from imaGenes (imaGenes GmbH, Berlin, Germany, 
Genbank accession: BC003204). (v) A polyadenylation signal from the human growth 
hormone (hGH polyA) at the 3` end of the mRNA is important for nuclear export, translation 
and stability of mRNA (Guhaniyogi and Brewer 2001).  
 
4.1.2 Outline of the cloning procedures in detail 
The pCMV-Sport6 plasmid contained the Asah1 cDNA. In order to obtain applicable 
restriction enzyme sites flanking the Asah1 cDNA, the DNA segment was inserted into the 
pBSpec2Z plasmid backbone. The cDNA fragment was mobilized by digesting the pCMV-
Sport6 plasmid with the enzymes SacII and MscI (blunt end). The pBSpec2Z plasmid was 
opened by the enzymes BamHI and SacII. The 5` overhang of the BamHI site was filled by the 
polymerase I large Klenow fragment to generate blunt ends compatible to the MscI site. The 
resulting plasmid was denoted pBSpec2Z-Asah1. Now the cDNA was flanked by a BamHI and 
a XbaI restriction site. The cDNA was mobilized yet again by BamHI and XbaI and ligated into 
the pNeb-bGHpA/SCS/lck/iCre/hGHpA/FRT/SCS plasmid, opened by BamHI and NheI. In this 
cloning step, the XbaI and the NheI produce compatible overhangs. The resulting plasmid 
was denoted as pNeb-bGHpA/SCS/Asah1/hGHpA/FRT/SCS. 
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The CAG promoter was derived from the pLCAG-DnmtI plasmid. The promoter was 
subcloned into the pk18 plasmid. To this end, the CAG-fragment was obtained by restriction 
digest with DraI (blunt end) and XbaI. The DNA fragment was inserted to the pk18 plasmid 
that was linearized by XbaI and SmaI (blunt end). The resulting plasmid was denoted pk18-
CAG.  
In order to position the polyadenylation signal (bGHpA) and the insulator element (SCS) ”5`” 
of the CAG promoter, the corresponding elements were isolated from the 
pNEB193bGHpA/SCS/L2/SCS plasmid by KpnI and PmlI (blunt end). The pK18-CAG plasmid 
was digested with the endonucleases HincII (blunt end) and KpnI. The resulting plasmid was 
denoted pK18-bGHpA/SCS/CAG. 
In the final cloning step, the fragment comprising the bGHpA/SCS/CAG segment of the pK18-
bGHpA/SCS/CAG plasmid was inserted into the pNeb-bGHpA/SCS/Asah1/hGHpA/FRT/SCS. In 
this cloning step, the bGHpA and SCS element were exchanged and the CAG promoter was 
added upstream of the Asah1 cDNA. The donor plasmid, pK18-bGHpA/SCS/CAG, as well as 
the destination plasmid, pNeb-bGHpA/SCS/Asah1/hGHpA/FRT/SCS, were cut by AscI and 
FseI. After ligation, the plasmid holding the complete transgene construct could be denoted 
as pNeb-bGHpA/SCS/CAG/Asah1/hGHpA/FRT/SCS, but is referred to as “CAG-Asah1” (see 
figure 4.1). 
For cell culture experiments a neomycin resistance cassette was inserted into the CAG-Asah1 
transgene construct. The neomycin cassette was derived from the pNEB-
bGHpA/SCS/lck/Icre/hGHpA/NeoR/SCS plasmid and mobilized by the enzymes BamHI and 
PmeI. The CAG-Asah1 transgene construct was linearized by the same enzymes. The 
resulting plasmid was denoted as CAG-Asah1/NeoR.  
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Figure 4.1: Graphical map of the CAG-Asah1 plasmid. The graphic displays the molecule map 
of the CAG-Asah1 plasmid. Functional features, restriction sites, and primer binding sites of 
the targeting vector are shown and labeled (see droplines). By molecular cloning techniques 
the following genetic elements were assembled: A polyadenylation signal (bGH-polyA), two 
heterologous Drosophila melanogaster derived “SCS” insulator elements (SCS-Insulator), a 
CAG promoter (CAG-Promoter), the acid ceramidase cDNA (Asah1), and a polyadenylation 
signal from the human growth hormone (hGH polyA). Transcripts of the Asah1 cDNA are 
driven by the CAG4 promoter and terminated by the bGH-polyA. The pNEB plasmid backbone 
further features a replication origin (COLE1-ORI) and an ampicillin resistance gene (APr). The 
specified restriction enzymes and primers allow to comprehend and review the hereinafter 
referred restriction enzyme digests and PCRs.  
 
 
4.1.3 Verification of CAG-Asah1 expression vector generation 
The Asah1 expression vector was generated according to the cloning strategy. Single cloning 
steps were controlled by diagnostic restriction enzyme digests and/or PCRs. The restriction 
enzymes were chosen to yield unique patterns of DNA fragments on the agarose gel that 
verified the integration of inserts in the plasmid backbone. The correct orientation of the 
Kpn I (11774)
KkpnI(11774
) 
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inserts was further confirmed by PCRs using plasmid DNA as a template. The PCRs were 
performed with one primer hybridizing with its corresponding complementary DNA on the 
vector backbone and the other primer targeted to the inserted DNA fragment. Only a correct 
orientation of the insert juxtaposes the primers and yields a DNA amplicon of a defined 
length. The same way, the final plasmid construct was reexamined. The CAG-Asah1 plasmid 
was digested with either BsrGI, SacI, XbaI or PvuI (see figure 4.2 A). Furthermore, the primer 
sets CAG4 + Asah1.6, Asah1.3 + hGHas2 and dScs 2.4 + bpA1 were used in PCR reactions (see 
figure 4.2 B). The DNA “fingerprint” of the CAG-Asah1 plasmid was expected to yield the 
following fragment patterns: BsrGI 6572 bp and 3377 bp, SacI 5138 bp and 4811 bp, XbaI 
4788 bp, 3516bp and 1645 bp, PvuI 6940 bp, 2113 bp and 896 bp. Primer set CAG4 + 
Asah1.6: 1159 bp, primer set Asah1.3 + hGHas2: 564 bp, and primer pair dScs 2.4 + bpA1: 
2961 bp. The signals on the agarose gels reflected the expected band patterns indicating 
successful realization of the CAG-Asah1 plasmid. 
 
 
A) 
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Figure 4.2: Verification of Asah1 expression vector generation. A) The CAG-Asah1 plasmid 
was digested with either BsrGI, SacI, XbaI or PvuI. Incubation and buffer conditions of the 
reactions conformed to the specifications of the manufacturer. The resulting DNA fragments 
and molecular markers (100 bp marker and 1 kb marker) were separated on an 1% agarose 
gel. BsrGI digestion yields fragments of 6572 bp and 3377 bp. The restriction enzyme SacI 
produces a 5135 bp and 4811 bp fragment. Three fragments of 4788 bp, 3516bp and 1645 bp 
are generated by XbaI digestion. PvuI digestion yields fragments of 6940 bp, 2113 bp and 896 
bp. B) PCR reactions were performed with the CAG-Asah1 plasmid template and reaction 
products run on an 1% agarose gel. The primer set CAG4 + Asah1.6 produced an amplicon of 
1159 bp. The PCR reaction with the primers Asah1.3 + hGHas2 resulted in a 564 bp fragment. 
Primers dScs 2.4 + bpA1 amplified a 2961 bp fragment. 
 
 
4.1.4 AC expression and activity in vitro 
“Plasmid fingerprinting” verified the generation of the CAG-Asah1 plasmid. Next, AC 
expression and activity was ascertained in CAG-Asah1 transfected cells. The in vitro 
experiments were performed one time (n = 1) and merely served to indicate the 
functionality of the CAG-Asah1 transgene cassette. In order to perform cell culture 
B) 
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experiments, a neomycin resistance cassette was inserted into the CAG-Asah1 plasmid. This 
cloning step was verified by restriction enzyme digestion with EcoRI and agarose gel analysis 
(see figure 4.3). The murine cell line GL261 was transfected with the CAG-Asah1/NeoR 
plasmid. Cells were cultured and selected in the presence of the antibiotic geneticin (G418). 
Geneticin was removed 48 hours prior to any experiment. AC protein expression and 
enzyme activity of whole cell lysates was investigated and compared to lysates of control-
vector (pJK plasmid) transfected cells. Protein samples (25 µg) were analyzed by SDS-PAGE, 
subsequent Western blots, and detection of the murine acid ceramidase β-subunit with a 
specific antibody (see figure 4.4). The housekeeping protein actin was detected with an 
antibody to serve as a loading control. Immunoblots of GL261 lysates stably transfected with 
CAG-Asah1/NeoR showed increased levels of AC protein (1.7 fold, densitometric analysis) in 
comparison to control-vector transfected cells. 
Moreover, the activity of AC was ascertained by quantification of fluorescent umbelliferone 
that was produced upon hydrolization of the synthetic RBM14-12 ceramide analog. RBM14-
12 was incubated with 25 µg protein of GL261 cell lysates in an acidic buffer (pH 4.5) at 37°C. 
The enzymatic conversion was stopped with methanol after 2 hours. The coumarin residue 
of hydrolyzed RBM14-12 was transformed to fluorescent umbelliferone (see above, figure 
3.5) and quantified with a fluorescence reader. Protein lysates of CAG-Asah1/NeoR stably 
transfected GL261 cells generated 2276 pmol umbelliferone/hour/mg protein (see figure 
4.5). This was 6.1x higher than the AC activity of lysates derived from untransfected cells 
(370 pmol umbelliferone/hour/mg protein) and 4.9x higher than in lysates of control-vector 
(461 pmol umbelliferone/hour/mg protein) transfected cells.  
 
 
A) B) 
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Figure 4.3: Generation of CAG-Asah1/NeoR. A neomycin resistance cassette was inserted into 
the CAG-Asah1 plasmid. The sequence of the antibiotic resistance gene was derived from the 
pNEB-bGHpA/SCS/lck/Icre/hGHpA/NeoR/SCS plasmid cut with the restriction enzymes BamHI 
and PmeI. Utilizing the same enzymes, the recipient CAG-Asah1 plasmid was opened. A) 
Generation of CAG-Asah1/NeoR was verified by digestion with EcoRI and subsequent agarose 
gel electrophoresis. The 1 kb molecular marker indicates the size of separated DNA 
fragments: 3599 bp, 3121 bp, 2665 bp, and 2306 bp. B) Graphical map of the CAG-
Asah1/NeoR plasmid. The neomycin cassette consists of a PGK-promoter, the neomycin 
phosphotransferase gene (NeoR), and a PGK-polyA transcriptional stop signal. The CAG-
Asah1 expression cassette remained intact as the neomycin cassette was positioned between 
the hGH-polyA and the distal SCS` insulator element. EcoRI restriction sites are indicated (see 
droplines). 
 
 
 
 
Figure 4.4: Immunoblot analysis of AC with whole cell lysates. GL261 cells that were either 
transfected with the CAG-Asah1/NeoR plasmid or an empty vector control plasmid (pJK) were 
lysed. Proteins (25 µg) were separated via SDS-PAGE and immobilized by subsequent 
Western blotting. The AC protein of 53 kDa was detected using a murine acid ceramidase 
antibody that specifically binds to the β-subunit. The housekeeping protein actin (43 kDA) 
was detected to serve as a loading control. 
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Figure 4.5: AC activity assay with whole cell lysates. The substrate RBM14-12 was incubated 
at 37°C for 2 hours in an acidic buffer (pH of 4.5) in the presence of protein lysates obtained 
from untransfected, empty vector control (pJK) transfected and CAG-Asah1/NeoR transfected 
GL261 cells. Hydrolysis rates were determined with a fluorescence reader (extinction 360 nm, 
emission 446 nm) detecting the fluorescent substrate conversion product umbelliferone. 
Results are denoted with the measurement unit pmol umbelliferone/hour/mg protein; n = 1. 
 
 
4.1.5 Pronuclear injections of CAG-Asah1 
The in vitro investigations of CAG-Asah1 functionality legitimized the deployment of the 
expression cassette for the generation of transgenic mice. The CAG-Asah1 expression 
cassette was separated from the vector backbone by restriction enzyme digestion with PmeI 
and AscI. The linearized fragment was extracted twice from agarose gels to clean the DNA of 
ethidium bromide and prevent cotransfer of vector backbone specific sequences (see figure 
4.6). About 100 fertilized eggs were injected with the CAG-Asah1 DNA. The eggs were then 
transferred to the uterus of pseudopregnant recipients. Transgenic founders were identified 
by PCR using DNA of mouse tail tissue as a PCR template (see figure 4.7). In the PCR reaction, 
two primer sets were employed: One pair amplifies a CAG-Asah1 specific sequence (CAG4 + 
Asah1.2), the other pair (Ragf + Ragr) produces an amplicon of an endogenous control 
sequence in the murine genome. Consequentially, transgenic mice were expected to display 
a fragment of 476 bp in addition to the endogenous control fragment of 295 bp. PCR 
reactions were analyzed on an agarose gel. The outcome of two sessions (injections of 2 x 50 
fertilized eggs) was the generation of 4 transgenic mice. All four mice were female. One 
mouse died at the age of 5 weeks. Three founder lines were established – denoted F1, F2 
and F3. Two lines were backcrossed to the C57BL/6 background. 
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Figure 4.6: Linearization of the CAG-Asah1 expression cassette. The CAG-Asah1 plasmid was 
digested with the restriction enzymes PmeI and AscI. The resulting fragments were separated 
on a 1% agarose gel stained with ethidium bromide. The transgene construct DNA of 7274 bp 
was cut off the gel lanes and purified while the vector backbone of 2675 bp remained in the 
gel. In a second agarose gel run the expression cassette was extracted without the 
mutagenic ethidium bromide dye. The CAG-Asah1 DNA was purified and injected into the 
pronuclei of fertilized eggs of B6C3F1 mice. 
 
 
 
 
Figure 4.7: Outcome of the pronuclear injections with the CAG-Asah1 expression cassette. 
The CAG-Asah1 transgene construct was injected into the male pronuclei of fertilized eggs of 
B6C3F1 mice. Eggs were transferred back to the uterus of pseudopregnant recipients. After 
delivery, tail tissue derived DNA templates of the progeny were analyzed by multiplex PCRs 
and subsequent separation of DNA fragments on a 2% agarose gel. Mice with the ID number 
78042 and 78043 display a transgene specific band (476 bp) generated by the primers 
Asah1.2 and CAG4 in addition to the signal (295 bp) of the endogenous control primers (Ragf 
+ Ragr). The same way, two further transgenic founders were identified.   
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4.1.6 Genotyping of CAG-Asah1 transgenic mice 
General genotyping of mice was performed with an optimized PCR approach. In comparison 
to the PCR that was used for the identification of founders, this PCR approach only required 
a single primer pair (Asah1.3 + Asah1.6) which allowed for reliable differentiation of 
transgenic and wild type mice. The primers were designed in a way that the intron between 
exon 11 and exon 12 was flanked (see figure 4.8 A). Amplification of a DNA template of wild 
type tissue solely yielded a fragment of 339 bp. In comparison, a DNA template of transgenic 
origin displayed a reaction product with reduced size (252 bp) due to the absence of the 
intron (87 bp) (see figure 4.8 B).  
 
 
 
 
Figure 4.8: Genotyping of CAG-Asah1 transgenic mice. A) Strategy for the identification of 
CAG-Asah1 transgenic mice. The wild type Asah1 gene locus holds exonic and intronic 
sequences while in the cDNA of the transgene cassette intronic sequences are absent. Primer 
Asah1.3 and Asah1.6 bind to sequences within exon 11 and exon 12, respectively. The 
amplicon of a transgenic template is shorter by the size of the intron (87 bp) in comparison to 
a wild type template. B) Example of an agarose gel image. PCR amplification resulted in a 
A) 
B) 
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339 bp fragment for wild type DNA templates. A 252 bp fragment is visible in the case of 
transgenic DNA templates. PCR reactions without DNA template (ddH2O) served as a 
negative control. A 100 bp marker indicates the sizes of PCR amplicons. 
 
 
4.1.7 Determination of CAG-Asah1 copy quantity in founders 
The number of transgene copies in the genome of the four transgenic founder lines was 
determined by real-time PCR. The chemical compound Evagreen® acquires fluorescent 
properties upon intercalation with double stranded DNA. This signal is proportional to the 
quantity of DNA produced during the PCR reaction. Tail tissue derived genomic DNA (n = 3 
for each founder) was used as a template. An Asah1 primer set (Asah1.3 + Asah1.4) was 
used for the amplification of a DNA fragment present on the wild type Asah1 locus as well as 
the Asah1 cDNA template of the transgene cassette. A Rag primer set served as endogenous 
control. Reactions were carried out in triplicates using different vessels for the two primer 
sets and fluorescence was analyzed with a real-time PCR System. Ct values, the cycle (C) at 
which a defined threshold (t) of fluorescence intensity is crossed, were determined. By 
means of the Ct values, the initial amounts of DNA template can be deduced. To this end, Ct 
values observed for the Asah1 reactions were normalized to an endogenous control (Ragf 
+Ragr) to compensate for variances in DNA template concentration. The Ct value was then 
set into relation to a calibrator – a DNA template of a wild type mouse (holding two alleles of 
Asah1). The data were transferred to the linear form by 2-ΔΔCt calculation (see table 4.1 and 
appendix). 
In addition to the real-time PCR approach, the standard genotyping PCR allowed for an 
assessment of transgene copy numbers. The primer set Asah1.3 and Asah1.6 amplifies the 
intron spanning amplicon of 339 bp of the endogenous Asah1 gene and in case of transgene 
presence an additional smaller amplicon (252 bp) of the cDNA templates. Therefore, the 
DNA templates “compete” for the resources in the PCR reaction. The number of PCR cycles 
was reduced to 28 and the signal ratios of the reaction products on the agarose gel were 
densitometrically determined. The more the ratio of the two DNA signals on the agarose gel 
shifts towards the transgene site, the more CAG-Asah1 template was present (see table 4.1). 
This technique is also termed semi-quantitative competitive PCR (cPCR) (Hubner et al. 1999). 
Genomic DNA samples of 3 animals (n = 3) were used for founder F1, F2 and F3, a single DNA 
sample of founder F4 was run in triplicate (n = 1).  
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qPCR analysis revealed that founder F2 derived animals display the highest numbers of CAG-
Asah1 integrates (nAsah1 = 46.09 ± 5.18, including 2 endogenous Asah1 copies). Founder F1 
animals held 22.09 ± 1.22 copies of nAsah1, while the offspring of founder F2 bore 16.72 ± 
1.98 nAsah1 copies. Semi-quantitative cPCR affirmed the qPCR results and Asah1 gene 
dosage succession F2 > F1 > F3. The wild type signal in the PCR product of founder F4 
template was nearly absent.   
 
Table 4.1: Quantitative real-time PCR (qPCR)- and semi-quantitative competitive PCR (cPCR) 
results of transgene copy analysis in CAG-Asah1 founders. qPCR data represent the number 
of Asah1 copies (nAsah1 = cDNA Asah1 copies + 2 endogenous Asah1 copies) after 2-ΔΔCt 
calculation. Signals of cPCR reaction products on the agarose were densitometrically 
determined and ratios of transgene to wild type signals calculated. Data are presented as 
mean ± SD. 
 
 
 
4.1.8 Quantification of sphingosine by mass spectrometry  
Sphingosine is the reaction product of ceramide hydrolysis by AC. An enhanced catalytic 
activity of AC in the CAG-Asah1 mouse model should result in elevated levels of its reaction 
product in comparison to wild type mice. To examine sphingosine levels, murine liver, kidney 
and spleen tissue samples were collected after perfusion of animals with 0.9% NaCl. Samples 
of wild type mice (liver: n = 3, kidney: n = 6 , and spleen: n = 3) and CAG-Asah1 mice of 
founder line F2 (liver: n = 3, kidney: n = 6, and spleen: n = 3) were snap frozen in liquid 
nitrogen and mechanically pulverized. Powdered tissue samples were diluted in 1 ml of 
methanol and solved by sonication. Quantification of sphingosine by mass spectrometry was 
performed by the group of Prof. Dr. Burkhard Kleuser (see figure 4.9).  
Wild type liver samples display 29.4 ± 24.8 (mean ± SD) pmol sphingosine/mg protein. CAG-
Asah1 liver samples showed 4.3 fold higher sphingosine levels (126.1 ± 38.2 pmol 
sphingosine/mg protein). There is a significant difference between the two groups (p = 
Founder 1 Founder 2 Founder 3 Founder 4
qPCR nAsah1 22.09 ± 1.22 46.09 ± 5.18 16.72 ± 1.98 Not
determined
cPCR
Ratio 0.65 ± 0.03 1.39 ± 0.02 0.20 ± 0.03 10.85 ± 0.76
Gel
image
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0.021). CAG-Asah1 kidneys contained sphingosine levels of 99.5 ± 35.1 pmol sphingosine/mg 
protein, while wild type kidneys held 35.1 ± 13.3 pmol sphingosine/mg protein. Sphingosine 
levels were elevated 2.8 fold in CAG-Asah1 kidneys compared to wild types (p = 0.002). 
Spleen tissue of wild type (29.9 ± 24.5 3 pmol sphingosine/mg protein) and CAG-Asah1 
animals (74.7 ± 10.9 3 pmol sphingosine/mg protein) were significantly different in their 
sphingosine concentrations (2.5 fold, p = 0.045).  
 
liv
er
ki
dn
ey
sp
le
en
0
50
100
150
200
wild type
CAG-Asah1
*
*
*
S
P
H
 [
p
m
o
l 
/ 
m
g
 p
ro
te
in
]
 
Figure 4.9: Quantification of sphingosine by mass spectrometry. Murine livers, kidneys and 
spleens were collected after perfusion of animals with 0.9% NaCl via the heart. Tissue 
samples were snap frozen in liquid nitrogen, mechanically pulverized, and diluted in 1 ml 
methanol. Samples were sonicated until the powder was completely dissolved. Protein 
concentrations were determined via Bradford assay. Tissue samples of wild type mice (liver: n 
= 3, kidney: n = 6, and spleen: n = 3) and CAG-Asah1 mice (liver: n = 3, kidney: n = 6, and 
spleen: n = 3) were analyzed by mass spectrometry in the Department of Nutritional 
Toxicology, Institute of Nutritional Science, University Potsdam, Germany. The quantification 
of sphingosine by mass spectrometry was performed by the group of Prof. Dr. Burkhard 
Kleuser. Data are expressed as the mean ± SD with the measurement unit pmol/mg protein. * 
indicates a p value < 0.05 of a Student`s t-test. 
 
 
4.2 Results of the Smpd1 conditional knockout mouse model 
4.2.1 General strategy for the conditional knockout of the murine Smpd1 gene 
In order to generate mice with a conditional null mutation of the Smpd1 gene, a targeting 
vector based on genomic DNA of the Smpd1 locus on chromosome 7 of the mouse was 
designed. In addition to the phage library derived genomic DNA, the replacement vector 
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holds two loxP sites that flank exon 2. Upon homologous recombination, this will allow for 
Cre-recombinase mediated excision of exon 2. Disruption of exon 2 was chosen since this 
reportedly results in a functional null allele in the mouse and resembles an authentic model 
of Niemann-Pick disease type A and B (Horinouchi et al. 1995). Further features of the vector 
comprise a FRT flanked neomycin (NeoR) cassette and a diphtheria toxin A (DTA) cassette. 
Both allow for the selection towards the desired targeting events in ES cells (Yanagawa et al. 
1999). The targeting construct was linearized by KpnI and electroporated into ES cells. With 
the antibiotic geneticin (G418), ES cells were positively selected for the presence of the 
neomycin phosphotransferase protein. The neomycin cassette can be deleted later in the 
process by the action of the FLP recombinase enzyme. DTA allows for the negative selection 
of insertional events that are not based on homologous recombination. ES cell clones were 
screened for homologous recombination events at the Smpd1 locus. Positive ES cell clones 
were injected into C57BL/6 blastocysts. Germline transmission of the ﬂoxed allele was 
conﬁrmed by the appearance of agouti fur, and PCRs. The neomycin cassette can be deleted 
later in the process by crossbreeding with mice expressing FLP recombinase. Following 
production of Smpd1-ﬂox mice, it needs to be verified that the targeted allele still produces 
normal amounts of ASM protein. Finally, investigating Cre-mediated excision of the floxed 
sequence can confirm that deletion of exon 2 results in a functional null allele. 
 
4.2.2 Outline of the cloning procedures in detail  
The cloning strategy involved the sequential assembly of genetic features yielding the 
targeting vector pPS-Smpd1/KO. First, the DTA cassette was positioned 5` to the Smpd1 
genomic DNA. Then exon 2 of Smpd1 was flanked with loxP sites and a neomycin cassette 
was inserted. 
 
 4.2.2.1 Cloning of the DTA cassette into pPS-Smpd1 
The DTA cassette was positioned at the 5´ end of the final targeting construct. The DTA 
cassette was excised of the pKO-DT vector by the activity of the restriction enzymes XbaI and 
RsrII. The 5` overhang of the RsrII site was filled by the polymerase I - large Klenow fragment 
to generate blunt ends. As an intermediate step in order to obtain convenient restriction 
sites (EcoRV and NotI), the 1177bp fragment was cloned into the pBlueSpec2SK plasmid. To 
this end, pBlueSpec2SK was linearized by XbaI and the blunt cutter SmaI. The resulting 
pBSpec2-DT was cleaved by EcoRV and NotI to re-isolate the DTA cassette and clone the 
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fragment (1201 bp) into the pPS-Smpd1 vector that was previously opened by NotI and SwaI. 
In this step, EcoRV and SwaI produce compatible blunt ends. The resulting plasmid was 
denoted as pPS-Smpd1/DT. 
 
4.2.2.2 Modifications surrounding exon 2 of Smpd1 
For the addition of features adjacent to exon 2, a better manageable portion of the genomic 
DNA, limited to exon 1 to exon 5, was isolated from pPS-Smpd1 and cloned into the multiple 
cloning site of a Litmus28 vector. The 4413 bp fragment was generated by XhoI and BstBI. 
Subsequently, Litumus28 was linearized by the same enzymes (XhoI and BstBI). The 
compatible DNA sequences were ligated and the resulting plasmid was denoted as Litmus28-
Smpd1. 
Addition of a loxP site 3` of exon 2: In order to obtain a vector with a loxP site 3` of exon 2, 
Litmus28-Smpd1 was linearized by NheI cutting its restriction site in the intron between 
exon 2 and 3. In addition, SacII with a cleavage site 3´ of exon 1 was utilized to result in a 
1928 bp fragment comprising exon 1 and exon 2 of Smpd1. This fragment was cloned into 
the pBS-loxP vector, cleaved with XbaI and SacII. NheI and XbaI cohesive overhangs are 
compatible. The ligation resulted in a plasmid with a loxP site positioned according to the 
objective and was denoted as pBS-Smpd1/loxP.  
 Insertion of the neomycin cassette and second loxP site 5´ of exon 2: Applicable restrictions 
sites (BsrGI and PmeI), needed for the insertion of the neomycin cassette, were inserted into 
pBS-Smpd1/loxP by means of a linker (LK). This adapter was synthesized by the annealing of 
two oligonucleotides (see above, paragraph 3.1.5) and was cloned into a NsiI restriction site 
5` of exon 2. The resulting plasmid was denoted as pBS-Smpd1/LK/loxP. Subsequently, pBS-
Smpd1/LK/loxP was linearized by SacII and HindIII and the fragment comprising exon 1, exon 
2 and the loxP site was cloned into the Litmus28-Smpd1 plasmid opened with NheI and SacII 
– denoted as Litmus28-Smpd1/LK/loxP. Subsequently, the restriction enzymes BsrGI and 
PmeI with cleavage sites included in the linker were employed to yield suited sites for the 
pK11rev2 plasmid derived neomycin cassette and loxP site. pK11rev2 was linearized by 
Acc65I and SmaI. Acc65I produced restriction overhangs, which are compatible with BsrGI 
derived cohesive ends. SmaI and PmeI form blunt ends. The resulting vector was denoted 
Litmus28-Smpd1/NeoR/loxP.  
Finally, the DNA with the applied modifications had to replace the DNA that equates to the 
genomic locus. To this end, Litmus28-Smpd1/NeoR/loxP and pPS-Smpd1/DT were cut by 
RESULTS 
 
59 
 
XhoI and BstBI. The 6341 bp fragment bearing the applied modifications in the surroundings 
of exon 2 replaced 4413 bp of the originating material in the pPS-Smpd1/DT vector. The final 
construct was simply denoted as pPS-Smpd1/KO (see figure 4.10).  
 
 
 
Figure 4.10: Graphical map of the pPS-Smpd1/KO plasmid. The graphic displays the molecule 
map of the pPS-Smpd1/KO plasmid. Functional features, restriction sites, and primer binding 
sites of the targeting vector are shown and labeled (see droplines). The replacement vector is 
based on genomic DNA of the Smpd1 locus of the mouse. The plasmid holds two loxP sites 
that flank exon 2 of Smpd1. Additional features of the vector comprise a FRT flanked 
neomycin cassette (PGK-promoter + NeoR gene + PGK –polyA) and a diphtheria toxin A 
cassette (RNApol II –promoter + DTA gene + SV40 poly A). Both allow for the selection 
towards the desired targeting events in ES cells. The pPS-Smpd1/KO plasmid backbone 
further features a replication origin (COLE1-ORI) and an ampicillin resistance gene (APr). The 
specified restriction enzymes and primers allow to comprehend and review the hereinafter 
referred restriction enzyme digests and PCRs.  
 
pPS-Smpd1/KO
13973 bp
AP r
DTA
Exon 1
NeoR
Exon 3
Exon 5
Exon 2
Exon 6
SV40-polyA
PGK-polyA
Smpd1.8
Smpd1.10
Smpd1.5
Smpd1.12
Smpd1.13
Smpd1.14
Smpd1.15 loxPfor
loxPSmpd1
PB3
DTA1
DTA2
Neo1F
RNApol II-Promoter
PGK-Promoter
COLE1 ORI
Exon 4
loxP
loxP
FRT
FRT
BstBI (1995)
Not I (670)
Xho I (8336)
Kpn I (11774)
Pml I (2435)
Pml I (7969)
Sac I (657)
Sac I (2239)
Sac I (7004)
Hin dIII (1928)
Hin dIII (2843)
Hin dIII (8692)
Hin dIII (11743)
Kpn I (11774)
KkpnI(11774
) 
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4.2.3 Verification of pPS-Smpd1/KO targeting vector generation 
In order to generate mice with a conditional null mutation of the Smpd1 gene, a targeting 
vector based on genomic DNA of the Smpd1 locus was designed. The cloning strategy 
involved the sequential addition of features to a pBlueScript plasmid. Single cloning steps 
were controlled by diagnostic restriction enzyme digests and PCRs. The completed targeting 
vector, pPS-Smpd1/KO, was also reexamined by restriction enzyme digests and PCRs. pPS-
Smpd1/KO was digested with either SacI, HindIII, PmlI or (NotI + XhoI), (see figure 4.11 A). 
Furthermore, the primer sets Smpd 1.5 + PB3, Smpd 1.12 + PB3, loxP for + Smpd1.8, loxP for 
+ Smpd1.10, loxPSmpd1 + Smpd1.8 and loxPSmpd1 + Smpd1.10 were used in PCR reactions 
(see figure 4.11 B). The “fingerprint” of the pPS-Smpd1/KO plasmid was expected to yield 
the following DNA fragment patterns: SacI 7626 bp, 4765 bp and 1582 bp, HindIII 5849 bp, 
4158 bp, 3051 bp, and 915 bp, PmlI 8439bp and 5534 bp, NotI + XhoI 7666 bp and 6307 bp. 
Primer set Smpd1.5 + PB3: 1314 bp, Smpd 1.12 + PB3: 507 bp, loxP for + Smpd1.8: 1732 bp, 
loxP for + Smpd1.10: 3579 bp, loxPSmpd1 + Smpd1.8: 1704 bp and loxPSmpd1 + Smpd1.10: 
3552 bp. The signals on the agarose gels reflected the expected band patterns. Restriction 
enzyme digests and PCR analysis confirmed the integrity of the pPS-Smpd1/KO targeting 
construct. 
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Figure 4.11: Verification of pPS-Smpd1/KO plasmid generation. A) The pPS-Smpd1/KO 
plasmid DNA was digested with restriction enzymes. Four reaction preparations with pPS-
Smpd1/KO plasmid DNA and either SacI, HindIII, PmlI or (NotI + XhoI) were incubated. 
Conditions of the reactions (buffer, incubation temperature and duration) conformed to the 
specifications of the restriction enzyme supplier. The resulting DNA fragments and molecular 
markers (100 bp marker and 1 kb marker) were separated on an agarose gel. SacI digestion 
yields fragments of 7626 bp, 4765 bp and 1582 bp (lane 1). Four fragments of 5849 bp, 4158 
bp, 3051 bp, and 915 bp were generated by HindIII digestion (lane 2). The restriction enzyme 
PmlI produced fragments of 8439bp and 5534 bp (lane 3). Double digestion with NotI and 
XhoI yielded fragments of 7666 bp and 6307 bp (lane 4). B) PCR reactions were performed 
with the pPS-Smpd1/KO plasmid template and reaction products run on an agarose gel. The 
primer set Smpd 1.5 + PB3 produced an amplicon of 1314 bp (lane 1). The PCR reaction with 
the primers Smpd 1.12 + PB3 resulted in a 507 bp fragment (lane 2). Primers loxP for + 
Smpd1.8 amplified a 1732 bp fragment (lane 3). A 3580 bp DNA fragment is produced by the 
primers loxP for + Smpd1.10 (lane 4). loxPSmpd1 + Smpd1.8 yielded a 1704 bp fragment (lane 
5) and loxPSmpd1 + Smpd1.10 generated a 3552 bp fragment (lane 6).  
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4.2.4 Evaluation of the recombination competence of pPS-Smpd1/KO 
The pPS-Smpd1/KO plasmid holds two loxP sites flanking exon 2 of the Smpd1 sequence. 
Upon homologous recombination, this is supposed to allow for Cre recombinase mediated 
excision of the exon and produce a null-allele. Furthermore, the vector features a FRT 
flanked neomycin cassette. On the one hand, the cassette is essential for the selection of 
transfected ES cells. On the other hand, the neomycin phosphotransferase may cause 
unwanted phenotypic side effects in the mouse. The selection gene shall be deleted by 
crossbreeding the Smpd1-flox animals with FLP recombinase expressing transgenic mice. In 
order to verify at an early stage that the recombination sites of the targeting vector are 
competent for recombination, the pPS-Smpd1/KO plasmid was transformed into E. coli 
strains 294-Cre and 294-FLP. The strains hold the corresponding recombinase genes in their 
genome. After overnight growth at 37°C in LB medium and subsequent isolation of plasmid 
DNA, the recombination competence of the construct was ascertained. pPS-Smpd1/KO 
plasmid DNA harvested from E. coli DH10B (no recombinase), E. coli 294-Cre, and E. coli 294-
FLP was digested by the restriction enzymes BstBI and XhoI. The DNA fragments were 
separated on an agarose gel and analyzed (see figure 4.12).    
The pPS-Smpd1/KO plasmid DNA of E. coli DH10B yielded two DNA fragments of 7632 bp 
and 6341 bp. The 6341 bp fragment corresponds to the sequence that comprises the Cre 
and FRT recombination sites. DNA of E. coli 294-Cre and E. coli 294-FLP likewise displayed a 
fragment of 7632 bp. Cre-mediated excision of exon 2 of E. coli 294-Cre plasmid DNA was 
evident due to the presence of a second 3223 bp fragment. The DNA fragment size equates 
to a pPS-Smpd1/KO plasmid reduced by the size of the floxed DNA segment (3118 bp). 
Analogously, the E. coli 294-FLP derived plasmid DNA displayed a second signal of 4565 bp. 
The FRT-flanked neomycin cassette (1776 bp) was deleted. The Cre and FLP enzyme 
recognized the respective recombination sites within the pPS-Smpd1/KO plasmid and excise 
the flanked DNA sequences. Both recombination systems, Cre-loxP and FLP-FRT, were 
functional. 
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Figure 4.12: Recombination competence of pPS-Smpd1/KO plasmid. The ability of 
recombinases to remove FRT and loxP flanked DNA sequences of the pPS-Smpd1/KO plasmid 
was tested in E. coli. The pPS-Smpd1/KO plasmid was transformed into E. coli strains DH10B, 
294-Cre and 294-FLP and the bacteria cultured. Upon recovery of the plasmid DNA, 
restriction enzyme digests with BstBI and XhoI were performed. DNA fragments and a 1 kb 
molecular marker were separated on an agarose gel. The pPS-Smpd1/KO plasmid DNA of E. 
coli DH10B displays two DNA fragments of 7632 and 6341 bp. DNA of E. coli 294-Cre and E. 
coli 294-FLP likewise show a fragment of 7632 bp. The second band of the E. coli 294-Cre 
plasmid DNA of 3223 bp equates to a pPS-Smpd1/KO plasmid reduced by the nucleotides of 
the floxed DNA segment (3118 bp). The second signal of the E. coli 294-FLP derived plasmid 
DNA of 4565 bp is reduced due to the removal of the FRT flanked neomycin cassette (1776 
bp).  
 
 
4.2.5 Linearization of the pPS-Smpd1/KO targeting construct 
The plasmid design of the pPS-Smpd1/KO targeting construct included a singular KpnI 
restriction enzyme site between the short and long arm of homology. The restriction site 
was utilized to open the vector backbone and facilitate targeting of the Smpd1 locus in ES 
cells. To this end, pPS-Smpd1/KO plasmid DNA was incubated with the KpnI restriction 
enzyme at 37°C overnight. The DNA was cleaned of the restriction enzyme by 
phenol:chloroform extraction, precipitated, and dissolved in TE buffer. In order to ensure 
completeness of the DNA digestion by KpnI, 2 µl of linearized DNA were run on an agarose 
gel and compared to an undigested pPS-Smpd1 plasmid DNA sample (see figure 4.13). 
The gel image showed one defined signal of 13973 bp for the KpnI digested pPS-Smpd1/KO 
plasmid. Signals of circular plasmid conformations, as can be seen in the lane of the 
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undigested pPS-Smpd1/KO plasmid, were absent. This confirmed complete digestion and 
linearization of the targeting construct.  
 
 
 
Figure 4.13: Linearization of the pPS-Smpd1/KO targeting construct. The pPS-Smpd1/KO 
plasmid was digested with the restriction enzyme KpnI. The reaction in a volume of 150 µl 
ddH2O was incubated at 37°C overnight. The DNA was purified of the KpnI protein by 
phenol:chloroform extraction, precipitated, and dissolved in 40 µl TE buffer. In order to 
ensure completeness of the DNA digestion by KpnI, 2 µl of linearized DNA were run in a 1% 
agarose gel and compared to an undigested pPS-Smpd1 plasmid DNA sample and a 1 kb 
molecular marker. The KpnI digested pPS-Smpd1/KO plasmid of 13973 bp displays one 
defined signal. Signals of circular plasmid conformations are absent.  
 
 
4.2.6 ES cell screening for targeting events 
Generation of the pPS-Smpd1/KO plasmid was verified by restriction enzyme digests and its 
recombination competence validated in E. coli. DNA of the pPS-Smpd1/KO plasmid was 
linearized by KpnI and purified of contaminating proteins. The linearization of the pPS-
Smpd1/KO plasmid DNA was controlled and considered suitable for the transfection of ES 
cells. Next, murine R1-129 ES cells were transfected with pPS-Smpd1/KO by electroporation. 
A single electrical pulse of 800 V and 10 µF was utilized to open the membranes of the ES 
cells allowing the exogenous DNA to enter the nucleus. One day post electroporation, ES 
cells were cultured in medium supplemented with geneticin (G418) to select for ES cells with 
integrated targeting construct. After 7 days, single ES cell clones were picked and separately 
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cultured. Part of ES cells from individual clones was transferred to cryo tubes and frozen. The 
other part was used to obtain genomic DNA samples. DNA of 148 ES cell clones was 
screened for the integration of the targeting construct at the Smpd1 locus by PCR methods. 
First, PCRs over the “short arm of homology” were performed to test for homologous 
recombination at the Smpd1 locus. Second, the presence of the distal loxP site was validated 
with primers that flank the recombination site. Finally, absence of the DTA cassette was 
checked by PCR. A correctly targeted ES cell clone should feature a single integration event 
of the targeting construct altering one allele of Smpd1. 
 
4.2.6.1 Verification of homologous recombination 
The ES clones were tested for the presence of the targeting construct at the Smpd1 locus. In 
case of gene targeting, genomic DNA and targeting vector DNA interact. In order to test for 
the integration of vector specific sequences at the Smpd1 locus, PCRs with primers that 
frame the “short arm of homology” were performed. Primer pairs were designed in a way 
that one primer binds to an endogenous DNA sequence outside of the targeting construct 
just beyond the “short arm” of homology while the other primer was positioned in a vector 
specific exogenous DNA sequence (see figure 4.14). Solely a homologous recombination 
event juxtaposes the primers and allows for PCR amplification of a sequence created by the 
novel junction. Long flanking regions decrease the efficiency of PCR amplification. In order to 
obviate this effect, a “nested PCR” approach was performed (Nitschke et al. 1993; Rolig et al. 
1997). A nested PCR is achieved by performing a PCR reaction on a PCR reaction product. 
Therefore, two sets of primer pairs were used in frequency. The external primer pair Neo1F 
+ Smpd1.3 produced a DNA fragment of 2558 bp. This fragment served as a template of the 
internal primer pair PB3 + Smpd1.16. An amplicon of 2220 bp was expected on the agarose 
gel. A total of 148 ES clone DNA samples were investigated by nested PCRs (see figure 4.15).  
Three ES cell clones were identified on the agarose gel image with a signal that matched the 
size of the spanned short arm of homology - 4A4, 4B4 and 1D5. 
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Figure 4.14: Verification of homologous recombination by PCR. Schematic representation of 
the strategy to detect homologous recombination events by PCR. The nested PCR approach 
comprises two primer sets framing the “short arm” of homology. In the case of gene 
targeting, genomic DNA and targeting vector DNA interact. Vector specific sequences 
integrate into the murine genome by homologous recombination. Primer pairs were designed 
in a way that one primer (Smpd1.3 and Smpd1.16) is located just beyond the “short arm” of 
homology, the other primer (Neo1F and PB3) is positioned in a vector specific sequence. 
Homologous recombination juxtaposes the primers and allows for PCR amplification of a 
sequence created by the novel junction. Two successive PCR runs (“nested” PCR) reduce non-
specific signals. Primer Smpd1.16 + PB3 (purple) amplify a secondary target within the 
product of the first run (Smpd1.3 + Neo1F, green). Numbered boxes show exons of the Smpd1 
locus. Yellow triangles represent loxP- and blue triangles FRT- recombination sites. 
 
 
 
 
Figure 4.15: Homologous recombination at the Smpd1 locus. Genomic DNA of 148 ES cell 
clones was tested by a nested PCR approach for the exchange of DNA sequences by 
homologous recombination with the pPS-Smpd1/KO targeting vector. The internal primer 
pair (PB3 and Smpd1.16) frames the “short arm of homology” and amplifies a DNA fragment 
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of 2220 bp. Lanes of the agarose gel refer to the PCR signals of single ES cell clones (an 
extract of 58 PCR reactions is shown). Three clones display a signal of 2220 bp - 1D5, 4A3 and 
4B4. (ES wt = clone with wild type genomic background; neg. = water added to the PCR 
reaction) 
 
 
4.2.6.2 Confirming the presence of the distal loxP site 
ES cell clones 4A3, 4B4, and 1D5 were further checked for the presence of the distal loxP site 
by PCR. Primers Smpd1.14 and Smpd1.15 flank the distal loxP site (see figure 4.16 A). Thus, 
next to the wild type Smpd1 signal a further band was expected on the agarose gel due to 
the added bases of the loxP site (see figure 4.16 B).  
The three clones were positive for the PCR signal of the distal loxP site. In addition to the 
wild type amplicon of 296 bp, a DNA amplicon with additional 34 bp due to the 
recombination site was present.   
 
 
 
 
 
Figure 4.16: Confirming the presence of the distal loxp site in ES cell clones by PCR. A) Primers 
Smpd1.14 and Smpd1.15 flank the distal loxP site. A wild type Smpd1 allele produces a PCR 
signal of 262 bp. The template of a recombined allele generates a PCR product of 296 bp due 
to the 34 bp of the loxP sequence. Numbered boxes show exons of the Smpd1 locus. Yellow 
triangles represent loxP- and blue triangles FRT- recombination sites. B) DNA templates of 
the 3 candidate clones (1D5, 4A3 and 4B4) show a signal for the distal loxP site (296 bp) next 
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to the signal of the wild type configuration (262 bp) on the agarose gel image. A sample with 
no DNA template (ddH2O) served as negative control. A 100 bp marker indicates the sizes of 
PCR amplicons. 
 
 
4.2.6.3 Testing for presence of the diphteria toxin-A cassette signal 
A diphteria toxin-A cassette (DTA cassette) was included in the targeting construct to induce 
apoptosis in cells that bear random integration events of the plasmid derived DNA in their 
genome. However, this selection procedure is not absolute. For instance, the integration into 
an epigenetically “shut down” locus may hinder the production of the toxin. The three ES 
clone candidates may possess the recombined allele and still hold random integration events 
in their genome. Therefore, the three clones were tested for the presence of the DTA-
cassette. Primers (DTA1 + DTA2) that specifically bind to the DTA-cassette were utilized in 
PCRs (see figure 4.17 A). An additional endogenous control sequence was amplified (Ragf + 
Ragr) to facilitate the interpretation of the PCR outcome. A PCR signal for the DTA template 
of 386 bp in addition to the control fragment (295 bp) would exclude the corresponding ES 
cell clone from blastocyst injections (see figure 4.17 B).    
The 386 bp PCR product of the DTA primers was present in the positive control. ES cell 
clones 4A3, 4B4, and 1D5 displayed the 295 bp fragment of the endogenous control while 
the signal of the DTA cassette was absent.  
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Figure 4.17: Testing for the presence of the diphteria toxin-A cassette signal in ES cell clones 
by PCR. A) A diphteria toxin-A cassette (DTA cassette) was included in the pPS-Smpd1/KO 
targeting construct (grey arrow). In the case of pPS-Smpd1/KO random integration, the DTA 
gene will produce the toxin and induce apoptosis of the ES cell. Primers DTA1 and DTA2 
specifically bind to the DTA-cassette and were utilized in PCRs to indicate random integration 
events. Numbered boxes show exons of the Smpd1 locus. Yellow triangles represent loxP- and 
blue triangles FRT- recombination sites. B) Multiplex PCRs with the DTA cassette specific 
primer pair (DTA1 + DTA2) and a primer pair (Ragf + Ragr) that amplifies an endogenous 
control sequence were performed. The DNA of ES cell clones served as a template and 
reaction products were visualized on an agarose gel. ES cell clones 4A3, 4B4, and 1D5 display 
a PCR reaction product for the internal control fragment of 295 bp. The 386 bp PCR product 
of the DTA primers can be seen in the positive control (DTA control) and is absent in the 
reactions of the ES cell clones 4A3, 4B4, and 1D5. A 100 bp marker indicates the sizes of PCR 
amplicons. 
 
 
4.2.3 Outcome of the blastocyst injections 
The results of the ES cell screening legitimated the use of ES cell clones 4A4, 4B4 and 1D5 for 
the injection into murine blastocysts. The three clones displayed a PCR signal affirming 
recombination of the Smpd1 locus. The presence of a distal loxP site and the loss of the DTA-
cassette during recombination were affirmed by PCRs.   
Frozen ES cells of clones 4A4, 4B4 and 1D5 were thawed, cultured and expanded. Three 
series of blastocyst injections were performed using ES cells of either clone 4A4, 4B4 or 
clone 1D5 (performed by Dr. Ralph Waldschütz and Wojziech Węgrzyn). Targeted R1-129 ES 
cells derived from an agouti mouse strain were injected into blastocysts of the black C57BL/6 
strain. Injected embryos were transferred surgically to the uterine horns of pseudopregnant 
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recipient females. Two weeks after birth, contribution of targeted ES cells to the offspring 
was identified by patches of agouti coat color (see figure 4.18).  
For each ES clone, mice with a high degree of chimerism, thus a high degree of R1-129 ES cell 
contribution, were generated. 
 
 
 
 
Figure 4.18: Photo of a chimeric mouse after injection of R1-129 ES cells into C57BL/6 
blastocysts. R1-129 ES cells of clones 4A4, 4B4 and 1D5 were injected into C57BL/6 
blastocysts. Injected embryos were transferred surgically to the uterine horns of 
pseudopregnant recipient females. Two weeks after birthing, contribution of ES cells to the 
offspring became apparent by patches of agouti coat color. An agouti coat is characteristic of 
the R1-129 strain, while C57BL/6 mice are black. The mouse in the photo was considered 
being 50% chimeric.  
 
 
4.2.4 Germline transmission and reexamination of the Smpd1 locus 
Mice with a high degree of chimerism, ≥ 75% of R1-129 ES cell contribution, were mated 
with C57BL/6 mice. Contribution of the R1-129 ES cells to the germline was identified by the 
dominant agouti fur of the 129 strain. Mating pairs of each ES cell clone were able to litter 
agouti offspring. Tail biopsies of the agouti animals were taken and lysed to obtain DNA 
samples. The samples were used to repeat the previously described nested PCR over the 
short arm of homology and the PCR that identifies the distal loxP site (see table 4.2). 
DNA samples of clone 4B4 derived animals were tested positive for the nested PCR signal. 
Germline animals of clone 1D4 and 4A4 did not display the signal of the short arm of 
homology. Genomic DNA of clone 1D4 and 4A4 was positive for the distal loxP PCR signal. 
Clone 4B4 derived animals on the other hand were negative for the distal loxP site 
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identifying PCR. All animals were excluded from further mating due to the incorrectly 
targeted Smpd1 locus. 
 
Table 4.2: Summary of blastocyst injections and analysis of germline animals. 
ES Clone ID Chimera generation 
with ≥ 75% ES cell 
contribution 
Germline 
transmission 
PCR analysis 
Targeted Smpd1 
locus 
Distal loxP site 
4B4 Yes Yes Yes No 
1D5 Yes Yes No Yes 
4A3 Yes Yes No Yes 
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5. DISCUSSION 
5.1 Discussion on the transgenic CAG-Asah1 mouse model 
In the present study, the CAG-Asah1 transgenic mouse model was established. In this gain of 
function model, an expression cassette was inserted into the murine genome. The 
expression cassette drives the transcription of an Asah1 cDNA template under control of a 
CAG-promoter. AC hydrolyzes ceramide and produces sphingosine. Elevated sphingosine 
levels were affirmed in examined tissues of CAG-Asah1 animals. The mouse model therefore 
allows investigating the biological effects that result from enhanced ceramide consumption.  
 
5.1.1 Design of the CAG-Asah1 expression cassette 
In the CAG-Asah1 transgene design, DNA sequences were assembled that in conjunction 
constitute an expression cassette driving the synthesis of AC mRNA transcripts. The 
transcriptional start site resides in the CMV early enhancer/chicken β-actin (CAG) promoter 
sequence. The CAG promoter ubiquitously allows for the expression of the linked gene in 
transgenic mice (Okabe et al. 1997). The chicken insulator sequences of the CAG promoter 
decrement regulation by silencer elements (Niwa et al. 1991). Still, CAG driven transgenes 
were reported to display cell type and tissue specific expression due to chromosomal 
positional effects (Ida-Hosonuma et al. 2002; Hino et al. 2004; Wang et al. 2004; Baup et al. 
2009). The heterologous Drosophila melanogaster derived “SCS” insulator elements were 
included in the CAG-Asah1 design to provide for additional shielding of the expression 
cassette from gene regulatory elements (Kellum and Schedl 1992; Dunaway et al. 1997; 
West et al. 2002; Gilbert et al. 2006). The shielding is mediated by the BEAF32 (boundary 
element-associated factor of 32kD) proteins which bind to the SCS sequences and constitute 
a barrier for regulatory elements (Zhao et al. 1995). Furthermore, SCS insulator elements 
block the formation of heterochromatin (Sun and Elgin 1999; West et al. 2002). A valid full-
length complementary DNA (cDNA) sequence of Asah1 was accessible from the cDNA library 
of the Mammalian Gene Collection (MGC) program of the National Institute of Health (NIH, 
Bethesda, MD, USA) (Strausberg et al. 1999). The sequence includes the translational start- 
and stop codon. The transcriptional stop signal was attached downstream of the Asah1 
cDNA. The polyadenylation signal from the human growth hormone (hGH polyA) at the 3` 
end of the mRNA is important for nuclear export, translation and stability of mRNA 
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(Guhaniyogi and Brewer 2001). In addition to the stretch of adenine bases, a GU-rich 
downstream sequence is required to stall transcription by RNA polymerase II and induce 
cleavage at the poly A site (Gromak et al. 2006). The importance of these nucleotides for the 
termination of transcription has been proven (Gromak et al. 2006), however the underlying 
mechanism is not fully known (Kuehner et al. 2011). Therefore, the entire hGH sequence was 
included in the CAG-Asah1 transgene design to grant transcriptional termination. Insertion 
of a transgene into coding genomic DNA may result in the production of hybrid mRNAs and 
proteins (Moyer et al. 1994; Ballester et al. 2004b). As an unintentional consequence, 
enzyme functions of the endogenous protein may be ascribed to the protein of interest. 
Another polyadenylation signal (bGH-polyA), upstream of the expression cassette, was 
included in the CAG-Asah1 design to prevent synthesis of hybrid proteins.  
 
5.1.2 Cloning and validation of the CAG-Asah1 expression cassette  
Serial assemblage of DNA segments was achieved by single cloning steps that each involved 
the following actions: 1. restriction enzyme digestion of the donor and destination plasmid, 
2. purification and ligation of the DNA sequences, 3. transformation of bacteria with the 
ligation product, and 4. screening of antibiotic resistant bacterial colonies. Preferentially, the 
cloning strategy looked out for restriction enzyme sites that allowed joining DNA segments 
by directional cloning. This implies that both donor and destination plasmid are digested 
with two different restriction enzymes producing noncomplementary cohesive ends at 
either site of the DNA fragment. DNA segments are forced to ligate in the desired 
orientation while self-ligation is prevented. Directional cloning was reported to produce high 
numbers of recombinant plasmids (Revie et al. 1988). Alternatively, cohesive-end ligation 
was combined with blunt end ligation. Partially, the blunt ends had to be procured by 
Klenow filling of 5` protruding ends with dNTPs. After transformation, E. coli were selected 
based on the antibiotic resistance provided by the plasmid. Subsequently, plasmid DNA of 
resistant E. coli was screened for the correct joining of the DNA segments by PCRs. 
Frequently in this study, high numbers of antibiotic resistant E. coli transformants were 
observed on the agar plates. Much of the growing E. coli colonies were false positives due to 
recircularization of excess linearized plasmid backbones. In order to characterize a large 
scale of antibiotic resistant E. coli in a rapid and effective way, colony PCRs were performed 
using the bacteria directly for PCR amplification (Zon et al. 1989). If about 2% of the E. coli on 
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the plate held a recombinant plasmid, this was sufficient to identify an appropriately sized 
PCR product on an agarose gel indicative of a correct clone. The plasmid DNA of these clones 
was purified and further investigated by restriction enzyme digests. Finally, the realization of 
the expression cassette in accordance to the cloning strategy was accurately tested. After 
completion of the last cloning step, restriction enzyme digests and PCR analysis confirmed 
the integrity of the construct. 
Prior to the pronuclear injection, the functionality of the expression cassettes was validated. 
In order to ascertain the ability to increase protein levels and activity of AC, the construct 
was transfected into GL261 cells. Prior to transfection, a neomycin resistance cassette was 
inserted into the CAG-Asah1 expression plasmid to allow for selection of cells with 
expression cassette DNA. Western Blots with cell lysates showed that CAG-Asah1 
transfected cells displayed a 1.7 fold increase in AC protein levels in comparison to control-
vector transfected cells. For the determination of AC activity, a recently described 
fluorogenic ceramide analog was employed (Bedia et al. 2007; Bedia et al. 2010). In contrast 
to the hitherto utilized radioactive (Mitsutake et al. 1997) and fluorogenic assays (Tani et al. 
1998; He et al. 1999), the current assay does not require chromatography. The enzymatic 
conversion of the substrate can be directly read from a microtiter plate in a fluorescence 
reader. The data showed that AC activity of CAG-Asah1 transfected cells was increased 6.1 
fold in comparison to untransfected and 4.9 fold in comparison to vector control transfected 
cells. The in vitro results indicated that the CAG-Asah1 construct was functional and justified 
to proceed in the use the CAG-Asah1 expression plasmid for the generation of transgenic 
mice. However, validating a transgene construct in vitro does not guarantee its expression in 
vivo (Haruyama et al. 2009). 
 
5.1.3 Generation and identification of CAG-Asah1 transgenic mice 
Prior to pronuclear injection, the expression construct was linearized and prokaryotic 
sequences (bacterial ori) removed. Transfection with linear DNA was reported to result in a 
five-fold higher integration efficiency (Brinster et al. 1985) and improve the transgene 
expression rate (Kjer-Nielsen et al. 1992) in comparison to transfection with supercoiled 
DNA. Furthermore, linearization secures that the DNA strand integrates with the required 
topology of the CAG-Asah1 expression cassette into the genome. Integration of the 
transgene is presumed to occur at sites in the genome with a spontaneous double strand 
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break (Palmiter and Brinster 1986). The 7274 bp long DNA of the CAG-Asah1 transgene 
cassette was injected into fertilized eggs of B6C3F1 mice. The length of the exogenous DNA 
is not a factor influencing transgene generation efficiency (Haruyama et al. 2009). Eggs of 
B6C3F1 mice were utilized as they, in comparison to the C57BL/6 strain, yield higher 
numbers of embryos after superovulation with superior visual and mechanical properties 
with regard to microinjection procedures (Teboul 2009). Intact eggs, about 60% of injected, 
were transferred into 8 pseudopregnant foster animals (performed by Dr. Ralph Waldschütz 
and Wojziech Węgrzyn). Per animal 30 fertilized eggs were transferred. At this point of the 
project, it was uncertain whether embryos that bear the CAG-Asah1 transgene in their 
genome are able to complete the complex developmental program despite potentially 
enhanced AC expression levels. A genetic knockout of both Asah1 alleles in the mouse 
genome was reported to be lethal at the 2 cell stage (Li et al. 2002; Eliyahu et al. 2007) and 
mortality of early embryos was ascribed to increased ceramide levels (Perez et al. 2005; 
Eliyahu et al. 2007). In conclusion, regulation of ceramide levels by AC is critical during early 
embryogenesis. Therefore, enhanced AC protein levels in our mouse model and disturbed 
ceramide levels could have resulted in lethality. On the other hand, a study of Eliyahu et al. 
showed that enrichment of the oocyte environment with a source of recombinant AC 
protein during in vitro fertilization improved survival rates of embryos (Eliyahu et al. 2010). 
Therefore, it was feasible that incorporation of the CAG-Asah1 trangene and elevated AC 
protein levels may be beneficial for embryos. Eventually, four transgenic founders holding 
copies of the CAG-Asah1 expression cassette in their genome were identified by PCR. 
Founder F4 died at the age of 5 weeks. The carcass was disposed of without pathological 
investigation. The three remaining founders showed no evident phenotypical abnormalities 
and passed the transgene to their offspring.  
 
5.1.4 Characterization of CAG-Asah1 transgene integration 
It is difficult to elucidate and characterize the integration sites in the genome of mice 
generated by transgene technology. The genetic modification occurs in a non-targeted 
manner and expression cassettes randomly integrate into the genome. The formation of 
concatemers, multiple copies of the expression cassette linked in a head-to-tail array, is 
feasible (Costantini and Lacy 1981; Bishop and Smith 1989). Single and multiple 
chromosomal integration sites were reported (Wagner et al. 1983; Brinster et al. 1985). 
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However, the determination of transgene copy numbers allows investigating the functional 
impact of gene dosage effects in future experiments and can aid with the maintenance of 
transgenic mouse strains. Therefore, an attempt was made to answer this question and 
obtain an estimate for the number of CAG-Asah1 expression cassettes that integrated into 
the genome of the founder lines. To this end, quantitative real-time PCR was performed. The 
quantification of transgene copies in animals by real-time PCR was previously employed in 
studies of Tesson et al. and Ballester et al. (Tesson et al. 2002; Ballester et al. 2004a). A wild 
type mouse holds two endogenous copies of the Asah1 gene. Accordingly, if a DNA fragment 
within an exon of the Asah1 gene is amplified, one has to expect that the transgenic mice 
hold additional templates for the initial round of PCR amplification. In the PCR reaction, the 
flurophore binds to double stranded DNA synthesized by the Taq polymerase. The more 
initial template, the earlier a certain threshold of fluorescence is reached. The cycle of 
threshold attainment relative to a wild type DNA template gives an estimate of transgene 
copies. The analysis of Ct values was performed according to the comparative 2-∆∆Ct Ct 
method (Livak and Schmittgen 2001; Ballester et al. 2004a; Bubner and Baldwin 2004). 
Founder F2 derived animals displayed the highest number of CAG-Asah1 integrates (nAsah1 
= 46.09 ± 5.18, including 2 endogenous Asah1 copies). Founder F1 animals held 22.09 ± 1.22 
copies of nAsah1, while the offspring of founder F3 bore 16.72 ± 1.98 nAsah1 copies. For 
organisms with a high number of transgene copies, the quantification was reported to be 
less accurate (Ballester et al. 2004a; Bubner and Baldwin 2004). This is due to the nature of 
the PCR technique following a 2n amplification of DNA within the exponential phase. If a 
transgene reaction sample reaches the threshold one cycle earlier than the wild type 
sample, the genome of the transgenic animal holds a double (21) amount of template. Yet 
another cycle earlier would imply that four times (22) the amount of DNA compared to wild 
type is present. In conclusion, the Ct difference between high-copy animals is very small. 
Mancini et al. quantified transgene copies in murine ES cells in an analogous way and 
observed comparable numbers of integrated transgene copies. It was stated that although 
exact numbers cannot be determined, values “probably reflect the amount of cassettes” 
(Mancini et al. 2011). 
In addition to the real-time PCR approach, our standard genotyping PCR allowed for an 
assessment of transgene copies. The single primer set amplified the intron spanning 
amplicon of 339 bp of the endogenous Asah1 gene and in case of transgene presence an 
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additional smaller amplicon of the cDNA templates (252 bp). Therefore, DNA templates 
“compete” for the resources in the PCR reaction. The densitometric analysis of the signal 
ratios can be interpreted. The more the ratio of the two DNA signals on the agarose gel shifts 
towards the transgene site, the more CAG-Asah1 template was present. This technique is 
also termed semi-quantitative competitive PCR (cPCR) (Hubner et al. 1999). One might argue 
that classical PCR is an endpoint measurement and as such is either positive or negative. 
However, it was clearly observed that the ratio of the two PCR signals varied between the 
four founders. The only reasonable explanation for the differences observed is the amount 
of the initial DNA template. The PCR techniques, real-time PCR and competitive PCR, point to 
the following succession of CAG-Asah1 gene dosage in founders: F4 > F2 > F1 > F3. Gene 
dosage may be one factor that determines protein expression levels (Friend et al. 1992; Liu 
et al. 1998). Linear relationships of transgene copy number and transcription levels have 
been reported (Swift et al. 1984; Grosveld et al. 1987). Regarding the results, one might 
speculate whether a high gene dosage in founder F4 may have correlated with high AC 
protein expression levels and activity, eventually causing death.  
 
5.1.5 Sphingosine levels in transgenic tissues 
The integration of CAG-Asah1 transgene cassettes into the mouse genome was proven. 
Next, the functionality of the expression cassette in the CAG-Asah1 mouse model was 
tested. To this end, sphingosine levels of CAG-Asah1 tissues were determined by mass 
spectrometry and compared to wild type tissues. Liver, kidney and spleen tissue of the 
founder F2 line were investigated as F2 animals held the highest gene dosage of CAG-Asah1 
(tissues of founder F4 were not available). Sphingosine is the reaction product of ceramide 
hydrolysis by AC. The analysis revealed that sphingosine levels were elevated in tissues of 
the CAG-Asah1 genetic background. Sphingosine levels of the liver were 4.3 fold higher, 
kidney 2.8 fold higher, and spleen 2.5 fold higher than in wild type tissues. The results can be 
explained by an enhanced catalytic activity of AC. In vitro transfection of cells with the CAG-
Asah1/NeoR plasmid resulted in increased AC protein levels and activity. Therefore, it seems 
reasonable to conclude that CAG-Asah1 transgene dependent AC expression is responsible 
for the altered sphingolipid metabolism in vivo. This allows for the qualitative statement that 
the CAG-Asah1 mouse model is functional. In conclusion, CAG-Asah1 transgenic mice were 
generated holding an altered ceramide metabolism.  
DISCUSSION 
 
78 
 
5.1.6 Considerations regarding the CAG-Asah1 mouse model 
In this project, CAG-Asah1 transgenic animals were generated displaying enhanced levels of 
the AC enzyme reaction product, sphingosine, in examined tissues. It has to be mentioned, 
however, that about 10% of transgenic animals that were generated by pronuclear injections 
show a phenotype due to disruption of host genome sequences (Gross and Stablewski 2013). 
Still, it is unlikely that the aberrant sphingosine levels observed, that can be logically 
explained by AC gain of function, are caused by disruption of another gene.  
While mutations that limit AC activity result in Farber lipogranulomatosis (Farber et al. 1957; 
Sugita et al. 1972), the CAG-Asah1 gain of function model seems to be without major 
obvious consequences for the mice and does not result in severe phenotypic changes, 
although further studies on the phenotype of these mice are required. The feasibility of 
elevating AC activity and levels of sphingosine in vivo may be explained by the observation 
that even in wild type animals AC expression and activity is variable between different cell 
types, as was reported by Li et al. (Li et al. 1998). There are multiple potential sites of AC 
activity regulation in the cell. Protein levels can be fine-tuned by the government of AC 
synthesis, maturation, trafficking, and degradation. Kinetics of AC enzyme reactions in the 
cell depend on pH, cofactors and lipid composition (see above, paragraph 1.4). The observed 
sphingosine levels, however, show that the lipid composition of CAG-Asah1 cells differs from 
corresponding wild type cells and is not maintained by potential regulation of AC. 
Regarding the transgene technology in general, the following knowledge was gained in the 
past that may concern the CAG-Asah1 mouse model: In gain of function models, the 
transcription level of a transgene within a founder line can change over time. For instance, a 
whole concatemer can be silenced by epigenetic changes such as DNA methylation and 
heterochromatin formation (Garrick et al. 1998; Henikoff 1998; Muskens et al. 2000; Calero-
Nieto et al. 2010). Furthermore, gene copies of a transgene may be lost (Gordon 1993). 
Concatemers are unstable and copies of the transgene and/or adjacent DNA sequences may 
be deleted (Chen et al. 1995; Pravtcheva and Wise 1995; Scrable and Stambrook 1999; 
Pravtcheva and Wise 2003). Suspicious variances in future scientific results between 
generations of CAG-Asah1 animals may be attributed to these issues of the transgene 
technology. The real-time PCR methods, which were established in this project, allow 
quantifying CAG-Asah1 transgene copy numbers and testing the persistence of the 
transgene.  
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Despite these inconveniences resulting from the technology, transgenic mouse models have 
led to a variety of important scientific findings (Conn 2011). The CAG-Asah1 mouse model 
can be a valuable tool in the scientific contexts described in the following paragraph. 
 
5.1.7 Perspectives of the CAG-Asah1 mouse model 
The crucial role of ceramide induced endothelial apoptosis and microvascular dysfunction in 
the context of single dose radio therapy was investigated by Kolesnick et al. (Fuks and 
Kolesnick 2005; Garcia-Barros et al. 2010; Truman et al. 2010). Studies which investigated 
tumor transplants in immunodeficient SCID mice with either ASM wild type or knockout 
background showed that tumor cure by radiation does not exclusively depend on DNA 
breakage induced apoptosis of malignant tumor cells, but may be ascribed to a ceramide 
mediated reduction of microcvascular density (Garcia-Barros et al. 2010). Furthermore, 
tumor cell resistance to radiotherapy can be mediated by upregulation of AC (Liu et al. 
2009). Collectively these studies led to the concept that radiotherapy depends on the 
ceramide pathway, reviewed in Henry et al. (Henry et al. 2013). In this context, studies with 
the CAG-Asah1 mouse model may lead to new insights that further clarify the molecular 
mechanism which underlie the concept and determine roles of ceramide and sphingosine in 
radiotherapy. Transgenic animals can be deployed as hosts for tumor transplants. According 
to this concept, reduced ceramide levels in endothelial cells of the microvasculature may 
confer resistance to tumor therapy. 
In cystic fibrosis (CF), patients lack of a functional cystic fibrosis transmembrane 
conductance regulator (CFTR) which increases the pH of intracellular vesicles to pH 5.9 
(Teichgraber et al. 2008). As a consequence, the enzyme kinetics of ASM and AC are 
modulated. On the one hand, ceramide production by ASM is lightly inhibited. On the other 
hand, AC switches from “forward” to “reverse” mode and produces ceramide. As an overall 
result, ceramide accumulates in epithelial cells of the lung. Apoptosis of ceramide-engorged 
epithelial cells leads to deposition of DNA and generation of a viscous mucus in the bronchi 
(Teichgraber et al. 2008). CF patients become highly susceptible to pulmonary inflammation. 
Normalization of pulmonary ceramide levels by ASM inhibition has become a clinical option 
for the treatment of cystic fibrosis (Riethmuller et al. 2009). A transfer of the CFTR knockout, 
(Dorin et al. 1992), to the CAG-Asah1 mouse model may show in how far modulation of AC 
can affect the CF phenotype. Small molecules that render AC activity might also be able to 
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normalize pulmonary ceramide levels in CF patients and provide a treatment option for the 
disease. 
Internalization of many pathogens into mammalian cells was reported to critically depend on 
formation of CRDs (Grassmé et al. 2003b; Grassmé et al. 2005). The exact mechanisms of 
how CRD induced signalosomes facilitate internalization is not yet known. Clustering of 
receptors, exclusion of receptors and recruitment of intracellular signaling molecules are 
processes discussed in the literature (Grassmé et al. 2003b; Grassmé et al. 2005). 
Independent of pathogen internalization, the host cell defense is likewise conducted by CRDs 
(Grassmé et al. 2003b). Exemplarily, CRD formation has been shown to be essential for the 
clearance of acute Pseudomonas aeruginosa infections. This is achieved by CRDs balancing 
the cytokine response and mediating apoptosis of infected cells (Grassmé et al. 2003b). In 
accordance with this, Jan et al. reported that expression of AC by a recombinant Sindbis virus 
reduced intracellular ceramide levels upon infection and prohibited apoptosis of host cells 
(Jan et al. 2000). It has been proposed that infections with human pathogens may be treated 
with drugs that modulate the activity of enzymes of ceramide metabolism (Gulbins et al. 
2004). Therefore, AC poses a candidate target for the treatment of infections. Investigations 
of host-pathogen interactions in CAG-Asah1 mice may deliver new insights in underlying 
mechanisms and validate AC as a drug target.  
Continuous loss of oocytes during the development of female mice, finalizing in menopause, 
is mediated by ceramide (Perez et al. 2005; Kujjo et al. 2013). In this context, Morita et al. 
demonstrated that the reserve of oocytes in young Smpd1 knockout mice was enhanced in 
comparison to wild type mice (Morita et al. 2000). In fertilized eggs, AC reduces the levels of 
ceramide and facilitates embryo survival past the two cell stage (Eliyahu et al. 2007). 
Furthermore, Eliayahu et al. showed that exogenous administration of AC protects murine 
oocytes as well as embryos in vitro (Eliyahu et al. 2010). Elementary pathways of oocyte and 
embryo protection by AC can be investigated in CAG-Asah1 animals. 
 
5.2 Discussion on the Smpd1 conditional knockout mouse model 
ASM catalyzes the conversion of sphingomyelin to ceramide. Stress induced formation of 
ceramide-rich domains by ASM and subsequent reorganization of membrane proteins has 
been observed in Smpd1 knockout mice (Cremesti et al. 2001; Grassmé et al. 2001; Dumitru 
and Gulbins 2006). This conventional Smpd1 knockout mouse model, generated by 
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Hourinochi et al., affects every cell of the organism at any time (Horinouchi et al. 1995). As a 
consequence, the function of the enzyme cannot be analyzed in a single cell type, tissue, or 
at a defined time point of development or disease. In order to have temporal and spatial 
control of the Smpd1 gene disruption, the current project aimed for the generation of a 
conditional knockout mouse model. To this effect, the following steps were taken and 
results obtained. The pPS-Smpd1/KO targeting vector was assembled by DNA cloning 
techniques. Diagnostic restriction enzyme digests and PCRs confirmed the realization of the 
targeting plasmid. Functionality of the Cre/loxP and FLP/FRT recombination system was 
validated in bacteria. The targeting vector was linearized and electroporated into murine ES 
cells. Integration of the exogenous DNA into the genome by homologous recombination at 
the Smpd1 locus was tested by PCR. ES cells of three clones were injected into blastocysts 
and germline competent chimeras obtained. Unfortunately, required genetic modifications 
of the Smpd1 locus were absent in offspring of chimeras. Recombination by Cre-
recombinase and the knockout of the Smpd1 gene cannot be achieved with the mice 
generated in this study.  
Therefore, the following discussion deals with the crucial points that may have caused failure 
of this project. First, the low number of targeted clones is discussed and the targeting vector 
design reviewed. Then, the rationale for observing partial gene targeting vector integration 
at the Smpd1 locus is provided. Furthermore, it is reasoned why discrepancies between PCR 
results with genomic DNA of ES cells and DNA of germline animals were observed. Finally, 
consequential insights enable recommending adjustments that can lead to the 
accomplishment of the knockout project. 
 
5.2.1 Homologous recombination efficiency at the Smpd1 locus  
Exchange of plasmid and genomic DNA by homologous recombination is an essential and 
critical step in gene targeting experiments. The mechanism of homologous recombination is 
based on the alignment of the linear targeting construct DNA to the genomic DNA via base 
pairing of the homology arms. Enzymes of the DNA repair machinery facilitate the exchange 
of DNA sequences (Vasquez et al. 2001). Targeting event frequency in mouse ES cells is 
rather low, 10-5 to 10-6 targeting events per transfected ES cell (Bollag et al. 1989), while 
random integration events occur at a 30000 fold higher frequency (Hasty et al. 1991b). In 
the present study, merely 3 out of 148 ES cell clones were identified with a signal that 
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matched the size of the spanned short arm of homology - 4A4, 4B4 and 1D5. In case the 
other 145 ES clones were true negatives for the PCR over the short arm of homology, the 
targeting frequency within geneticin resistant ES clones was very low (3/148 ~ 2%). A large-
scale mouse knockout program from the Wellcome Trust Sanger Institute reported 12% 
targeting efficiency for targeting constructs with 10 kb of homologous DNA and a DTA 
negative selection cassette (Skarnes et al. 2011). Thus, expectations of detecting targeted 
Smpd1 loci were considerably higher than observed in the present study. Therefore, in the 
following paragraph, parameters of homologous recombination efficiency, which could be 
optimized, are discussed. 
The design of the pPS-Smpd1/KO targeting vector particularly considered the following 
factors, which influence targeting frequency in ES cells. Recombination efficiency was 
reported to be higher in case the exogenous plasmid DNA is syngenic to the DNA of ES cells 
used for electroporation (te Riele et al. 1992). Therefore, genomic Smpd1 DNA of the 129 
strain was isolated from a Lambda phage library (done by Dr. Ralph Waldschütz). The length 
of the homologous sequences is another important determinant of recombination efficiency. 
Two arms of homology were created in the pPS-Smpd1/KO plasmid. A short arm of 1718 bp 
and a long arm of 4999 bp flank the heterologous DNA sequences. The short arm of 
homology included the sequence of exon 1 and the long arm of homology comprised the 
sequences of exon 3 to exon 6. It was reported that the short arm of homology can be as 
short as 0.5 kb without an effect on the quantity of recombination events (Hasty et al. 
1991a). However, recombination efficiency is higher when the sequence of the long arm of 
homology is longer (Thomas and Capecchi 1987; Shulman et al. 1990; Hasty et al. 1991a). If 
the sequence extends to 8 kb, recombination efficiency reaches a maximum (Lu et al. 2003). 
Therefore, extending the long arm of homology in the pPS-Smpd1/KO plasmid to 8 kb offers 
the possibility to enhance recombination efficiency. 
Positive and negative selection procedures allow enriching the fraction of targeted ES cells 
2000 fold (Mansour et al. 1988). A FRT flanked neomycin cassette was positioned in the 
intron upstream of exon 2. The neomycin phosphotransferase protein can be present in the 
ES cells either due to random integration of the pPS-Smpd1/KO plasmid into the genome or 
homologous recombination of the targeting construct at the Smpd1 locus. Looking at the 
neomycin selection in retrospect, it is conspicuous that of the 288 clones that were picked 
after selection, only 148 clones showed normal growth in the 24 well plates. The deviation 
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may be explained by untransfected ES cells that, due to a low metabolism, were able to 
survive selection but unable to proliferate. Geneticin was reported to be a differentiation 
inducing agent (Cuevas et al. 2004), and may compromise pluripotency of stem cells. Hence, 
the leeway of enhancing the drug dose rate seems marginal. Still, this could be an option to 
reduce the background of untransfected and enhance the fraction of targeted ES cells. 
 A diphtheria toxin A cassette was included in the strategy to selectively eliminate ES cells 
that bear random integration events in their genome. Expression of the DTA polypeptide 
inhibits RNA translation, protein synthesis, and specifically eliminates the ES cell (Palmiter et 
al. 1987). In case of homologous recombination, the DTA cassette detaches from the 
targeting vector, while the sequences that are flanked by the “arms of homology” integrate 
into the genome. This selection ought to enrich the quantity of ES cells with a recombined 
Smpd1 locus. Effectiveness of DTA counter selection in gene targeting experiments was 
reported by several studies (Yagi et al. 1990; Yanagawa et al. 1999; Skarnes et al. 2011). 
Utilization of an alternative negative selection system in the pPS-Smpd1/KO plasmid does 
not seem promising. For instance, viral thymidine kinase/ganciclovir selection was reported 
to be less effective than selection with diphtheria toxin (Yanagawa et al. 1999). 
Finally, linear DNA increases the chance of vector integration via homologous recombination 
(Hasty et al. 1992). For that reason, the plasmid design provided for a singular restriction site 
(KpnI) between the arms of homology. Overnight restriction enzyme digestion and 
visualization of the DNA on an agarose gel ensured linearity of the targeting plasmid. After 
linearization, vector backbone elements and the DTA cassette were situated external to the 
short arm of homology and can detach from the homologous sequences during 
recombination. This design was reported to be optimal in gene targeting experiments 
(LePage and Conlon 2006). 
Also with regard to the transfection method, it was aimed to facilitate maximum 
recombination efficiency in ES cells. Electroporation was the DNA delivery method of choice 
seeing that this simple technique was reported to be more effective in terms of 
recombination frequency than other DNA transfer methods (Nairn et al. 1993; Yanez and 
Porter 1999). High purity plasmid DNA was utilized. The concentration of vector DNA, about 
30 µg linear DNA were loaded into the electroporation cuvette, was reported not to be a 
critical factor for effective gene targeting (Thomas and Capecchi 1987). The electroporation 
pulse permeabilizes the membranes of the cell for a short fraction of a time and exogenous 
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DNA is able to enter the nucleus. In order to avoid the induction of karyotype alterations, a 
comparably mild electroporation pulse of 800 V, 10 µF for 0.2 ms was utilized for the 
transfection (e.g. in comparison to Nagy et al.: 250 V, 500 µF, 6-7 seconds (Nagy et al. 
2003)). Still, these settings were established to be efficient for gene targeting experiments 
(Tompers and Labosky 2004). Nevertheless, utilizing a more intense pulse and taking the risk 
of genomic aberrations could on the other hand produce more targeted ES cell clones. 
Furthermore, chromosome double strand breaks induced by DNA sequence detecting zinc 
finger nucleases promote homologous recombination (Rouet et al. 1994; Urnov et al. 2005; 
Meyer et al. 2010). Consequently, co-transfection with zinc finger mRNAs coding for 
nucleases that specifically cut within the Smpd1 locus may boost the exchange of DNA 
sequences. 
The sophisticated vector design and transfection method tried to take into account essential 
factors affecting targeting frequency. However, next to these variables, the chromatin 
structure of the targeted gene locus influences recombination efficiency (Capecchi 1989; 
Nickoloff 1992). Loci that are transcriptionally active in the ES cells are better accessible for 
the enzymatic machinery of homologous recombination (Muller 1999). Generation of the 
Smpd1 knockout mouse by Horinouchi et al. (Horinouchi et al. 1995) and generation of 
animals with a partially targeted Smpd1 gene in this study prove that, in general, the Smpd1 
locus allows for gene targeting.  
 
5.2.2 Loss of the distal loxP site in the process of Smpd1 gene targeting 
Although cells of animals referring to clone 1D5 and 4A4 displayed a specific PCR signal for 
the distal loxP site, the Smpd1 locus was unchanged. PCR signals over the short arm of 
homology could not be reproduced. The results suggest that these animals hold random 
integrations of the pPS-Smpd1/KO plasmid in their genome. In contrast, offspring referring 
to clone 4B4 displayed a targeted Smpd1 locus. However, the genetic modifications were 
only partially integrated. The distal loxP site appears to have detached from the targeting 
vector during the homologous recombination event. Loss of the distal loxP site and partially 
recombinant alleles are frequently observed in gene targeting experiments. A high-
throughput gene targeting pipeline for the generation of conditional knockout alleles 
reported that approximately half of the targeted clones miss the distal loxP site due to the 
internal homology region (Skarnes et al. 2011). Therefore, the internal arm of homology in 
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the pPS-Smpd1/KO plasmid is a potential cause of the observed configuration (see figure 
5.1). In the non-conditional knockout model of Horinouchi et al., the Smpd1 gene was 
disrupted by insertion of a neomycin cassette into exon 2. This resulted in a null allele and 
resembled an authentic model of Niemann-Pick disease type A and B (Horinouchi et al. 
1995). For this reason, the strategy of the conditional knockout model in this study aimed for 
an inducible disruption of exon 2 by flanking the sequence with loxP sites. Exon 2 is the 
largest exon (775 bp) and encodes about 44% of the ASM protein (Newrzella and Stoffel 
1992). Consequently, the floxed DNA sequence creates a relatively large internal arm of 
homology in the pPS-Smpd1/KO plasmid of 1228 bp. Unfortunately, longer sequences of 
homology promote recombination (Thomas and Capecchi 1987; Shulman et al. 1990; Hasty 
et al. 1991a) and may lead to loss of distal segments. Therefore, it would be prudent to flank 
a smaller Smpd1 exon with loxP sites. For instance, mutations in exon 4 of human SMPD1, 
the smallest exon (80 bp), were reported to result in aberrant ASM protein and Niemann-
Pick phenotype (Simonaro et al. 2002). The shorter sequence of internal homology may 
avert the loss of the distal loxP site.  
 
 
 
Figure 5.1: Schematic representation of the partially targeted Smpd1 locus. Mice derived 
from clone 4B4 were tested positive for the PCR signal of the template that is created by the 
novel junction of the recombined pPS-Smpd1/KO DNA sequence at the Smpd1 locus. The 
neomycin cassette and 5` loxP cassette are integrated into the murine genome. The distal 
loxP site could not be detected by PCR. Presumably, the distal loxP site detached from the 
targeting vector due to a recombination event between the short arm of homology (1718 bp) 
and the homology region comprising exon 2 (1228 bp, green lines). Integration of the pPS-
Smpd1/KO plasmid at the Smpd1 locus is incomplete. 
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5.2.3 Incongruent ES cell screening results by PCR methods  
The PCR based ES cell screening strategy was designed to indicate which ES clones bear a 
single integration of the targeting construct at the Smpd1 locus. Comparable conventional 
PCR based screening strategies have let to the generation of gene targeted mice (Collinson 
et al. 2002; Nguyen et al. 2005; Gao et al. 2010). Homologous recombination events at the 
Smpd1 locus were detected by nested PCRs over the short arm of homology. The second PCR 
served to exclude the scenario in which the DTA cassette is retained in the ES cells genome 
and disrupts the Smpd1 locus. Presence of the distal loxP site was confirmed by a third PCR.  
In order to frame the short arm of homology, it was unavoidable to amplify a DNA fragment 
of about 2 kb. The nested PCR method compensates for variations in quantity and quality of 
genomic DNA samples and enhances the specificity of the amplification reaction (Nitschke et 
al. 1993; Neumaier et al. 1998; Wienholds et al. 2003). A drawback of two step PCRs is an 
increased risk of contamination. Another shortcoming is that the PCR screen lacks a positive 
control. Still, targeting events were detected at the Smpd1 locus as was confirmed for the ES 
cells and germline offspring referring to clone 4B4. However, positive PCR signals with DNA 
of ES cell clones 1D5 and 4A4 could not be reproduced with genomic DNA of corresponding 
germline animals. This incongruity could be ascribed to the increased contamination risk of 
the two step PCR resulting in amplification of non-specific templates during the ES cell 
screening. Mixed ES cell clones may provide an alternative explanation. ES cell clones, 
composed of targeted as well as non-targeted cells, can produce the observed ES cell PCR 
signals and result in transmission of a non-targeted genome. Plasmid DNA residues in the 
genomic DNA samples of the ES cell clones may also explain deceptive PCR results. After 
electroporation, the ES cell medium was changed several times. In spite of this, plasmid DNA 
could have served as templates for the PCR amplification of the distal loxP site. Arguing 
against contamination of the DNA samples, however, are the PCR results of the diphtheria 
toxin A cassette detection. Plasmid contamination of the genomic DNA samples would have 
resulted in a cassette-specific PCR signal. Contamination of other PCR reaction components 
with plasmid DNA can be excluded on the basis of the utilized negative controls. 
ES cell screening by standard PCR is not without alternative. Modifications of the genome 
can be detected either by loss of allele (LOA-) assay (Frendewey et al. 2010) or Southern blot 
(Southern 1975). However, the LOA assay is based on allele quantification by real-time PCR 
and in turn bears similar pitfalls as standard PCR. Southern blot strategies must be 
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accounted for in the targeting vector design and labeled hybridization probes need to be 
generated and established.  
In the present study, the PCR screening was not able to identify the ES cell clones, which 
were utilized for blastocyst injections, as non-recombined. The PCR detecting the distal loxP 
site confirmed the presence of the recombination site, but did not prove its integration at 
the Smpd1 locus. Providing this missing information seems vital for detecting targeted ES cell 
clones and making a success of the project. Long-range PCRs over the long arm of homology 
or Southern blots may complement the ES cell screening strategy in order to detect 
incorporation of the distal loxP site at the Smpd1 locus.  
 
5.2.4 Perspectives of the conditional Smpd1 knockout mouse model 
A range of options emerges from the discussion and encourages proceeding with the 
project. Adjustments can increase recombination efficiency, reduce the risk of losing the 
distal loxP site, and improve the screening of ES cells. 
Regarding recombination efficiency, it was emphasized that extension of the long arm of 
homology can produce more targeted clones. Additionally, a more intense electroporation 
pulse and stronger geneticin selection could enhance the fraction of recombined ES cell 
clones. Application of the novel zinc finger technology could also constitute a solution. In 
order to prevent the loss of the distal loxP site, it has been suggested to flank the short exon 
4 with loxP sites to minimize the region of internal homology. Furthermore, the ES cell 
screening strategy could be reconsidered. Either a long-range PCR over the long arm of 
homology or a Southern Blot may complement the current ES cell screening strategy to 
affirm the integration of the distal loxP site at the Smpd1 locus. By means of the suggested 
adoptions, it may be feasible to generate the conditional knockout mouse model in the 
future and selectively deplete the Smpd1 gene. 
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7. SUMMARY 
 
Ceramide self-association in cell membranes gives rise to formation of ceramide-rich 
domains, which in turn reorganize membrane proteins and affect reaction yields of signal 
transduction pathways. Deregulated ceramide metabolism and membrane organization has 
been shown in many disease pathologies. The present study aimed to generate transgenic 
mouse models for the enzymes acid ceramidase and acid sphingomyelinase which both 
modulate ceramide levels. Genetic mouse models are valuable scientific tools for studying 
physiological and pathological processes in vivo. 
 
In a “gain of function” model, acid ceramidase expression cassettes were introduced into the 
murine genome. The expression cassette comprised a CAG-promoter driving the 
transcription of acid ceramidase complementary DNA. Genetic components of the CAG-
Asah1 expression cassette were assembled by DNA cloning techniques. Functionality of the 
construct was tested in vitro proving CAG-Asah1 dependent enhancement of acid 
ceramidase protein levels and activity. The transgene cassette was delivered to the murine 
genome by pronuclear injections into fertilized eggs. Transgenic offspring was identified by 
PCRs and three founder lines were established. The gene dosage of transgene copies in 
distinct founder lines was determined by quantitative PCR methods. Sphingosine levels of 
liver, kidney and spleen tissue homogenates were determined by mass spectrometry. The 
data revealed that tissues of CAG-Asah1 transgenic animals displayed significantly higher 
levels of the acid ceramidase reaction product in comparison to wild type tissues. The results 
can be explained by an enhanced catalytic activity of acid ceramidase in CAG-Asah1 animals. 
In conclusion, my research generated a CAG-Asah1 transgenic mouse model which may 
reveal important scientific findings with regard to the biological effects resulting from 
ceramide consumption by acid ceramidase. 
 
In an attempt to develop a conditional knockout model, the acid sphingomyelinase gene was 
targeted with a replacement vector. The design of pPS-Smpd1/KO vector aimed to enable 
the insertion of loxP recombination sites to the acid sphingomyelinase gene via homologous 
recombination in embryonic stem cells. The genetic sequences of pPS-Smpd1/KO were 
assembled by DNA cloning techniques and the completed plasmid reexamined by PCRs and 
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restriction enzyme digests. Recombination competence of the Cre/loxP system was 
confirmed in E. coli. Subsequently, murine ES cells were transfected with the pPS-Smpd1/KO 
plasmid DNA. Individual ES cell clones were screened by PCR for homologous recombination 
events and integration of the targeting construct at the acid sphingomyelinase gene locus. 
Three ES cell clones were assumed to hold a recombined acid sphingomyelinase gene and 
were utilized for injection into murine blastocysts. Examination of transgenic animals, 
however, revealed random and partial integration events of the targeting construct. In this 
study, knowledge was acquired which allows adapting the targeting construct and/or ES cell 
screening method to facilitate the generation of the conditional knockout model for the acid 
sphingomyelinase in the future. 
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9. APPENDIX 
9.1 Oxidation and β-elimination step of the AC activity assay 
Conversion of RBM14-12 by AC was stopped by the addition of methanol. Subsequently, 
NaIO4 fresh solution in an alkaline buffer, pH 10.6, was added. The enzyme reaction product 
undergoes oxidation and β-elimination and the fluorophore, umbelliferone, is generated. 
The umbelliferone production by β-elemination of the oxidized product was investigated. To 
this end, kidney (high AC activity, (Li et al. 1998)), liver (intermediate AC activity, (Li et al. 
1998)), and testicle (low AC activity, (Li et al. 1998)) tissue of wild type animals was lysed. 
Protein samples (10, 30, and 50 µg protein of each tissue) were incubated with RBM14-12 at 
pH 4.5 for 2 hours. After the addition of methanol, the samples were immidiately put into 
the fluorescence microplate reader and fluorescence (excitation 360 nm, emission 446 nm) 
quantified every 2 minutes for 1 hour (see figure 9.1). 
Fluorescence production during the oxidation and β-elimination step reaches a plateau after 
1 hour. When performing the AC activity assay, reaction plates were left in the dark for 2 
hours to ensure that the total of enzyme reaction product undergoes oxidation and β-
elimination.   
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Figure 9.1: Oxidation and β-elimination of RBM14-12. Acid ceramidase cleaves the RBM14-12 
substrate. The enzyme reactions were stopped by addition of methanol after 2 hours. The 
remaining aminodiol of the sphingoid base is oxidized in an alkaline buffer containing NaIO4 
and the fluorophore, umbelliferone, is generated by β-elemination of the oxidized product. 
Protein samples (10, 30, and 50 µg) of kidney, liver and testicle were incubated with RBM14-
12 for 2 hours at pH 4.5 and 37°C. After the addition of methanol, the samples were 
immidiately put into the fluorescence microplate reader and fluorescence (excitation 360 nm, 
emission 446 nm) quantified every 2 minutes for 1 hour. Fluorescence was quantified with a 
fluorescence microplate reader using an excitation of 360 nm and an emission of 446 nm. 
The RBM14-12 conversion scheme was adapted from (Bedia et al. 2007), copyright 2007, 
with permission from WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. 
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9.2 Sequence of the CAG-Asah1 transgene cassette   
 
Legend: The DNA sequence is colored analogous to the following DNA features 
bGH-polyA  
SCS insulator 
CAG-promoter 
Asah1 cDNA 
hGH-polyA 
other 
 
> CAG-Asah1, 281 bp (AscI) – 7554 bp (PmeI), direct, 7274 bp total 
cgcgccggatcagcctcgactgtgccttctagttgccagccatctgttgtttgcccctcccccgtgccttccttgaccctggaaggtgcc
actcccactgtcctttcctaataaaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctggggggtggggtggggca
ggacagcaagggggaggattgggaagacaatagcaggcatgctggggatgcggtgggctctatggcttctgaggcggaaagaacc
agctggggctcgactgtttggtcgccatgttgtccagtccatggacgtgggcatgcttgttgtagcccaaatcggcgtttccgtttccac
caggaaacatctctgcttgtagttcgaatatgctctttaaatcccagctgtattcctcagttatcgaggttttcttcacgagtgaaacga
attttcgtcgccttctacgccattttcttgctcagcccgttttgtcattcgcagcgaagcggtaacagcgggtcgctcatatgacggtatt
tttttaatacacttcagctatactgttatttcaaaaacatatttcttttgttactttttatgcagttcatttgccaccaaaaagtagtctttt
ggattgatttatttctaaaaatggtgtaattcaagaaattcagagggccaagtaatatacttaatgaccgttatttaaaacacactca
aggagatttatttaaacggctacaatggttttccaaataacttatttactgttgacttctataaaacataggtgtatatattattatttctt
attgatttgagataattttaatttccacaatattttttcttgtgattaacagagaaagtcaaactcataacatttatcgggtaaaagtctc
tatgaagtagcggttaacagtgaagtcacaaaagtgtggccgtacgccaatcgagcgagtatccctaacctgcaatatttttagttgg
ttttttcagcaatagccccacttttctcaaagagtgcaacaagtgattctgtttatgttttcaacaacttctctctgcggaacttgacgtg
agcggacgtatgcggacgcgtcgctgccggaaaaataagttgcgtcggcgttgcggcgttgttgtttacgtgttataataaatttgtgt
gcgtgcgagaagggcgcgctcctgtctgtgttggtgttattgtcggtcgttctcagcgcgagttttgaaataccgcattgtttaattaca
gccgccgcgactaatttcaatacaaacaaaagctggtgtgtgaatgaaattatgctaaaatagataatagttaaaggtaaaagaaa
ttaaaagatgaagaaggagaagaggaagagaagttctgcagcgcagttgcgtcggcgcagcagcgtttctatcggtgtgtgtctga
gtctgtctgtagtggtttgtctagttttttttcgggctgtgtgtgttcgtgtttgccaagcaacaatttaattgctattcaattttaaaagca
gttcaattgcaaaccattacaaatatgtaatttgctgtcgattgcttttgcactggaggactctagagcttaaggtgcacggcccacga
cattgattattgactagttattaatagtaatcaattacggggtcattagttcatagcccatatatggagttccgcgttacataacttacg
gtaaatggcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataatgacgtatgttcccatagtaacgccaataggg
actttccattgacgtcaatgggtggactatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaagtacgccccc
tattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgaccttatgggactttcctacttggcagtacatctacg
tattagtcatcgctattaccatgggtcgaggtgagccccacgttctgcttcactctccccatctcccccccctccccacccccaattttgt
atttatttattttttaattattttgtgcagcgatgggggcggggggggggggggcgcgcgccaggcggggcggggcggggcgagggg
cggggcggggcgaggcggagaggtgcggcggcagccaatcagagcggcgcgctccgaaagtttccttttatggcgaggcggcggc
ggcggcggccctataaaaagcgaagcgcgcggcgggcgggagtcgctgcgttgccttcgccccgtgccccgctccgcgccgcctcg
cgccgcccgccccggctctgactgaccgcgttactcccacaggtgagcgggcgggacggcccttctcctccgggctgtaattagcgct
tggtttaatgacggctcgtttcttttctgtggctgcgtgaaagccttaaagggctccgggagggccctttgtgcgggggggagcggctc
ggggggtgcgtgcgtgtgtgtgtgcgtggggagcgccgcgtgcggcccgcgctgcccggcggctgtgagcgctgcgggcgcggcgc
ggggctttgtgcgctccgcgtgtgcgcgaggggagcgcggccgggggcggtgccccgcggtgcgggggggctgcgaggggaacaa
aggctgcgtgcggggtgtgtgcgtgggggggtgagcagggggtgtgggcgcggcggtcgggctgtaacccccccctgcacccccct
ccccgagttgctgagcacggcccggcttcgggtgcggggctccgtgcggggcgtggcgcggggctcgccgtgccgggcggggggtg
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gcggcaggtgggggtgccgggcggggcggggccgcctcgggccggggagggctcgggggaggggcgcggcggccccggagcgc
cggcggctgtcgaggcgcggcgagccgcagccattgccttttatggtaatcgtgcgagagggcgcagggacttcctttgtcccaaatc
tggcggagccgaaatctgggaggcgccgccgcaccccctctagcgggcgcgggcgaagcggtgcggcgccggcaggaaggaaat
gggcggggagggccttcgtgcgtcgccgcgccgccgtccccttctccatctccagcctcggggctgtccgcgggggacggctgccttc
gggggggacggggcagggcggggttcggcttctggcgtgtgaccggcggctctagagcctctgctaaccatgttcatgccttcttcttt
ttcctacagctcctgggcaacgtgctggttattgtgctgtctcatcattttggcaaagaattagcttggccggccgccaccatgcgggg
ccaaagtcttctcacctgggtcctagccgcggcagtcacctgcgcccaggcacaggatgtgccgccgtggacagaagattgcagaa
aatcaacttatcctccttctggaccaacctatagaggaccagttccgtggcacaccataaatcttgatttaccaccctacaaaagatg
gcatgaattattggctcaaaaggcaccagcgttgaggattttagtgaattccataacgagtttagtgaatacatttgtgccaagtgga
aaactaatgaagatggtggatcaaaagctgcctggtatgattggcagccttcctgacccttttggagaggaaatgaggggaattgca
gatgttactgggattcctctaggagagattatttcattcaacattttctatgaattgtttaccatgtgtacatcaatcataactgaagatg
agaaaggtcatttactacatgggagaaacatggattttggaatatttcttgggtggaatataaataataacacttgggttgtcacaga
agaattaaagcccttaacagtgaatttggacttccaaagaaacaataagactgttttcaaggctacaagttttgttggatatgtgggc
atgttgacaggattcaaaccaggactgttcagtctttcactaaatgaacgtttcagtataaatggtggttatctgggtatcctagaatg
gatgttcggaaggaaagatgcccagtgggtagggtttatcactcgatcagttctggaaaacaccacaagttatgaagaagccaaga
acacactgaccaagaccaagataatggcgccagtatattttatcctgggaggcaagaagtctggagagggttgtgtgatcacacgg
gaaagaaaagagtctttggatgtctatgaacttgatcctaagcatggcagatggtatgtggtacaaaccaattatgacaggtggaaa
aacaccttgtttattgatgaccgcagaacaccggccaagaagtgtctaaatcacaccacacagaagaatctctcctttgctaccatct
atgatgtcctatcaacaaaacctgtcctcaacaagctgactgtattcacaaccttgatggatgttaccaaaggtcaatttgaaagtca
ccttcgagattgcccagacccttgtataggctggtgagcacacgttgggatcccaaggcccaactccccgaaccactcagggtcctgt
ggacagctcacctagcggcaatggctacaggtaagcgcccctaaaatccctttgggcacaatgtgtcctgaggggagaggcagcga
cctgtagatgggacgggggcactaaccctcaggtttggggcttctgaatgtgagtatcgccatgtaagcccagtatttggccaatctc
agaaagctcctggtccctggagggatggagagagaaaaacaaacagctcctggagcagggagagtgctggcctcttgctctccggc
tccctctgttgccctctggtttctccccaggctcccggacgtccctgctcctggcttttggcctgctctgcctgccctggcttcaagaggg
cagtgccttcccaaccattcccttatccaggctttttgacaacgctatgctccgcgcccatcgtctgcaccagctggcctttgacaccta
ccaggagtttgtaagctcttggggaatgggtgcgcatcaggggtggcaggaaggggtgactttcccccgctgggaaataagaggag
gagactaaggagctcagggtttttcccgaagcgaaaatgcaggcagatgagcacacgctgagtgaggttcccagaaaagtaacaa
tgggagctggtctccagcgtagaccttggtgggcggtccttctcctaggaagaagcctatatcccaaaggaacagaagtattcattcc
tgcagaacccccagacctccctctgtttctcagagtctattccgacaccctccaacagggaggaaacacaacagaaatccgtgagtg
gatgccttctccccaggcggggatgggggagacctgtagtcagagcccccgggcagcacagccaatgcccgtccttcccctgcaga
acctagagctgctccgcatctccctgctgctcatccagtcgtggctggagcccgtgcagttcctcaggagtgtcttcgccaacagcctg
gtgtacggcgcctctgacagcaacgtctatgacctcctaaaggacctagaggaaggcatccaaacgctgatgggggtgagggtggc
gccaggggtccccaatcctggagccccactgactttgagagctgtgttagagaaacactgctgccctctttttagcagtcaggccctg
acccaagagaactcaccttattcttcatttcccctcgtgaatcctccaggcctttctctacaccctgaaggggagggaggaaaatgaa
tgaatgagaaagggagggaacagtacccaagcgcttggcctctccttctcttccttcactttgcagaggctggaagatggcagcccc
cggactgggcagatcttcaagcagacctacagcaagttcgacacaaactcacacaacgatgacgcactactcaagaactacgggct
gctctactgcttcaggaaggacatggacaaggtcgagacattcctgcgcatcgtgcagtgccgctctgtggagggcagctgtggcttc
tagctgcccgggtggcatccctgtgacccctccccagtgcctctcctggccctggaagttgccactccagtgcccaccagccttgtcct
aataaaattaagttgcatcattttgtctgactaggtgtccttctataatattatggggtggaggggggtggtatggagcaaggggcaa
gttgggaagacaacctgtagggcctgcggggtctattgggaaccaagctggagtgcagtggcacaatcttggctcactgcaatctcc
gcctcctgggttcaagcgattctcctgcctcagcctcccgagttgttgggattccaggcatgcatgaccaggctcagctaatttttgtttt
tttggtagagacggggtttcaccatattggccaggctggtctccaactcctaatctcaggtgatctacccaccttggcctcccaaattg
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ctgggattacaggcgtgaaccactgctcccttccctgtccttctgattttaaaataactataccagcaggaggacgtccagacacagc
ataggctacctggccatgcccaaccggtgggacatttgagttgcttgcttggcactgtcctctcatgcgttgggtccactcagtagatg
cctgttgaattcctcgacctgcagcggccccccctcgacgaagttcctatactttctagagaataggaacttcggccgccaccggccg
ccatatgcatcctaggatcgatcgcgcgcagatcctgtgaaaataaaatgccgttcgtttgaattgtgaagcgggcgtgtgcgtgatg
aggcgaatggcaagtgtgcgatactatcggttggtggaagaatatcgtgactttgtagtgttagaaaatgttatattgtgtattatttc
aatttgaaatcaagagaattattgaatagtgctctaaactttggcatttatgttattttaaccttaatttctatctctatacaaatacatct
atcaaagcgtcttaattttgaaaatatgttaattcgtcgcactttattttgattaaccggacgatagactatcggaagatatttataaat
atcgttaattgtgtacatctcaattccaatattttttatttctggtgactgtgaaccagaacagctgtgattttatcgggcatctctgaac
atcaggtgttatcaacaagcaaagtttttattgaattcgactgttt 
 
 
9.3 Sequence of the pPS-Smpd1/KO plasmid in the vicinity of exon 2 
 
Legend: The DNA sequence is colored analogous to the following DNA features 
Exons 
loxP sites 
FRT sites 
RNA polymerase II promoter 
Neomycin resistance gene 
PGK-polyA 
other 
 
>pPS-Smpd1/KO, 3008 bp – 7256 bp, direct, 4249 bp total 
ataagaggaacaggaaggggaggagctgttttgtggctggctgctgagctatcagtcaaccacaacgaagggtaatcaggtgtctc
cagcgttacccgggccccgagggccagccagggcttcggcctgtggggcctggaggggcaagccagtcctgtctacgagcctggca
atgccccaccacagagcatcatccggccaggaccacctcagagccggctgggagcagagactggagaggtccttaccggcaccca
gagtgggactcctttggatggggctgggcttggcgctggttctggctctgtttgactccacggttctttgggttcctgccagagcttatcc
tcttccttctgaaggccattctgtcaaattcagtgccatagcgccgccgctccagagtgcctttgggtggcagaacctcacttgccccg
cctgcaaagtcttattcactgctctcaaccatgggctgaaggtgagtgcgtgaagggctgttgtggaatgctgggggcaggatgaag
tgcactggtatgcccgggggagggggcaatatatttctggtagagggtgcttcctatgcagtttgggctgcaggaattctctagaata
acttcgtataatgtatgctatacgaagttataagctctcaccgcggtggcggccgaagttcctattctctagaaagtataggaacttcg
cggccaattctaccgggtaggggaggcgcttttcccaaggcagtctggagcatgcgctttagcagccccgctggcacttggcgctac
acaagtggcctctggcctcgcacacattccacatccaccggtagcgccaaccggctcccttctttggtggccccttcgcgccaccttct
actcctcccctagtcaggaagttcccccccgccccgcagctcgcgtcgtgcaggacgtgacaaatggaagtagcacgtctcactagt
ctcgtgcagatggacagcaccgctgagcaatggaagcgggtaggcctttggggcagcggccaatagcagcttggctccttcgctttc
tgggctcagaggctgggaaggggtgggtccgggggcgggctcaggggcgggctcaggggcggggcgggcgcgaaggtcctccgg
agcccggcattctgcacgcttcaaaagcgcacgtctgccgcgctgttctcctcttcctcatctccgggcctttcgacctgcaggtcataa
tgggatcggccattgaacaagatggattgcacgcaggttctccggccgccttgggagaggctattcggctatgactgggcacaacag
acaatcggctgctctgatgccgccgtgttccggctgtcagcgcaggggcgcccggttctttttgtcaagaccgacctgtccggtgccct
gaatgaactgcaggacgaggcagcgcggctatcgtggctggccacgacgggcgttccttgcgcagctgtgctcgacgttgtcactga
agcgggaagggactggctgctattgggcgaagtgccggggcaggatctcctgtcatctcaccttgctcctgccgagaaagtatccat
catggctgatgcaatgcggcggctgcatacgcttgatccggctacctgcccattcgaccaccaagcgaaacatcgcatcgagcgagc
Exon 1 
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acgtactcggatggaagccggtcttgtcgatcaggatgatctggacgaagagcatcaggggctcgcgccagccgaactgttcgcca
ggctcaaggcgcgcatgcccgacggcgaggatctcgtcgtgacccatggcgatgcctgcttgccgaatatcatggtggaaaatggcc
gcttttctggattcatcgactgtggccggctgggtgtggcggaccgctatcaggacatagcgttggctacccgtgatattgctgaaga
gcttggcggcgaatgggctgaccgcttcctcgtgctttacggtatcgccgctcccgattcgcagcgcatcgccttctatcgccttcttga
cgagttcttctgaggggatcgatccgctgtaagtctgcagaaattgatgatctattaaacaataaagatgtccactaaaatggaagtt
tttcctgtcatactttgttaagaagggtgagaacagagtacctacattttgaatggaaggattggagctacgggggtgggggtggggt
gggattagataaatgcctgctctttactgaaggctctttactattgctttatgataatgtttcatagttggatatcataatttaaacaagc
aaaaccaaattaagggccagctcattcctcccactcatgatctatagatctatagatctctcgtgggatcattgtttttctcttgattccc
actttgtggttctaagtagcttatcgataccgtcgaggaagttcctattctctagaaagtataggaacttcgtcgagggggggcccggt
acactgcatccatgttaccactaccccactgtgacctttataaagttagggagagtaaagtcagctggctaattgtgggcttgaaatg
gtagcacaccctgagctagagtaggtagctagaggcctggtgctgaactgctgggcagtgtgtgggagatactgatgtctctttatca
tggtgacagagttatcctagctccgatttagacatggaagcctgtggagtggtggccagggttcacttgttctgtctctgacctaacttc
attggttccttccaccacagaaggagcccaatgtggcacgggtaggctctgtggccatcaagatatgcaagatgctgaacatagcac
cactagatgtgtgccagtcagccgtccatctctttgaggacgatgtggtggaggtgtggacacgttcagttctgagcccatcagaggc
ttgtggcttgcttctgggctcctcttgtggacactgggacatcttttcgacttggaacatctctttgccatcagtgccgaagccaccccc
aaagccaccgagcccaccagcccccggtgcccctgtcagccgtgtcctcttccttactgatctacactgggaccatgagtacctggag
ggcacagacccttactgtgcagatccactttgctgccgccgggggtccggatggccacccaactcccagaagggggctgggttctgg
ggcgagtacagcaagtgtgacctgcccttgcgaacgctagaaagcctgttgaaaggactgggccctgccggcccttttgaaatggtg
tactggacgggagatatccctgcccatgatgtctggcaacagtctcgccaagatcagctgagggccctgaccaccatcacagacctc
gtgaggaagttcttgggcccagtgccagtgtaccctgctgtgggcaaccatgagagcactcctgtcaatggcttccctcctcccttcat
aaagggaaaccaatcttcacaatggctctatgaagccatggccaaggcatgggaaccctggttaccagctgatgcccttcacaccct
aaggtacttactgtcggtggaaacccaggaaggaagaagaaagatggatgagggagaaaggaggagggaactgggtagactact
ccagcaggtgtcctcagcactctctactgccctccctaacctgaccctgccttccctttaattatctccagccaccctcttttcagagcta
gaataacttcgtataatgtatgctatacgaagttataagctctagcagtacatccccactccctagcttgtgtctttgcctacagtagct
ctctttgtaaaatgaattctccctccctctttaatatctcccatttttttctcaacgtggccaggcctataacatctcccgacagaaaggc
ctttgctttctgactcacctcactctttgtcctgaattcatgaagctctcaaccctctgaggcttctttactgtcagaggagccctataatt
actgctgttggtcttcagctagggtgggagctcctgggggtgggagatgacatcatgtgtacctctgcctgatgtgcaggactattgac
atctcggttacttttgtttcagaattgggggcttctatgccctcaccccacgccctggcctccgcctcatctctctcaatatgaatttttgt
tcccgtgagaacttttggctcttgatcaactccacagatcctgctggacaactccagtggctggtggaggagcttcaggctgctgaga
atcgaggagacaaagt 
 
  
Exon 2 
Exon 3 
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9.4 Real-time PCR data analysis using the 2-∆∆Ct method 
Calculations were done according to Livak et al. (Livak and Schmittgen 2001). 
 
Table 9.1: nAsah1 determination by 2-∆∆Ct calculation  
Primer pair
Asah1.3 + Asah1.4 Ragf + Ragr
Mouse Founder Ct Mean Ct Ct Mean Ct ∆Ct Calibrator ∆∆Ct 2-∆∆Ct nAsah1 Mean nAsah1 SD
1 wild type 17.36 17.24 18.32 18.45 -1.21 -1.24 0.00 1.00 2.00 2.00
1 wild type 17.27 18.43
1 wild type 17.09 18.61
2 wild type 17.04 17.13 18.91 18.39 -1.26
2 wild type 17.16 17.95
2 wild type 17.18 18.31
3 Founder 1 15.46 15.30 19.56 19.94 -4.64 -3.40 10.54 21.09 22.09 1.22
3 Founder 1 15.14 19.94
3 Founder 1 15.30 20.31
4 Founder 1 15.04 15.10 20.76 19.89 -4.79 -3.55 11.73 23.45
4 Founder 1 15.19 19.65
4 Founder 1 15.07 19.26
5 Founder 1 15.65 15.83 20.84 20.51 -4.68 -3.44 10.87 21.73
5 Founder 1 15.93 21.04
5 Founder 1 15.90 19.64
6 founder 2 12.14 12.36 18.26 18.01 -5.65 -4.41 21.28 42.57 46.09 5.18
6 founder 2 12.41 17.83
6 founder 2 12.54 17.95
7 founder 2 11.74 11.58 17.69 17.52 -5.94 -4.70 26.02 52.04
7 founder 2 11.51 17.54
7 founder 2 11.48 17.32
8 founder 2 12.23 12.25 18.74 17.94 -5.69 -4.45 21.83 43.66
8 founder 2 12.32 17.33
8 founder 2 12.21 17.75
9 founder 3 16.07 16.14 20.28 20.59 -4.45 -3.21 9.23 18.46 16.72 1.98
9 founder 3 16.24 20.89
9 founder 3 16.11 30.33
10 founder 3 14.66 14.97 19.67 19.08 -4.10 -2.87 7.29 14.57
10 founder 3 15.19 19.10
10 founder 3 15.07 18.46
11 founder 3 14.82 15.01 19.04 19.34 -4.34 -3.10 8.56 17.13
11 founder 3 15.42 19.43
11 founder 3 14.78 19.56
Wasser P1 24.07 29.65
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